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Abstract 
 
Childhood acute lymphoblastic leukaemia (ALL) does not possess a 
propagating cell hierarchy, at least as defined by B-cell precursor 
immunophenotype.  Indeed, many, or even all, leukaemic blasts may have the 
potential to propagate the disease.  This unusual characteristic mirrors the 
substantial capacity for clonal expansion demonstrated by fully differentiated 
normal lymphoid cells.  This Fellowship aimed to investigate the genetic 
programmes underlying the propagation of acute lymphoblastic leukaemia. 
An initial candidate approach confirmed the expression of PIWIL2, a gene 
critical to the maintenance of germline stem cells, in both cell line and primary 
ALL.  Knockdown of PIWIL2 resulted in reduced cellular proliferation and 
significant prolongation of doubling time in two ALL cell lines, SEM (MLL/AF4) 
and 697 (E2A/PBX1).  Unexpectedly, PIWIL2 was also found to be expressed in 
peripheral lymphoid cells from healthy donors, but not terminally differentiated 
cells of myeloid origin, suggesting that PIWIL2 may have a previously 
unidentified function in both normal and malignant lymphoid cells. 
A second project has developed an in vitro genome-wide RNAi screen to 
identify candidate genes involved in the clonal propagation of ALL.  This project 
has assessed a serial re-plating assay using feeder cell co-culture to provide a 
surrogate niche environment.  Initial results have demonstrated the feasibility of 
such an approach.  The benefit of using a co-culture re-plating assay, as 
compared to a standard suspension culture approach, remains under 
investigation. 
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Finally, this Fellowship developed a protocol for the lentiviral transduction of 
patient-derived leukaemic blasts and cloned and validated a novel lentiviral 
vector capable of in vitro analysis, in vivo disease monitoring and RNAi.  With 
these, it will now be possible to validate candidate leukaemic propagation genes 
in vivo, using primary leukaemic material.  The results of these studies will 
provide candidates for the development of novel therapeutic agents for children 
with ALL. 
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1.1 Childhood B precursor acute lymphoblastic leukaemia 
1.1.1 Introduction 
Acute lymphoblastic leukaemia (ALL) is the single most common malignancy of 
childhood, representing approximately 25% of malignant diagnoses between 
birth and 15 years of age (CRUK 2011).  It provides a paradigm for the 
improvement in children’s cancer therapies with survival improving from less 
than 30% fifty years ago, to 80% 5 year event free survival and 85% 5 year 
overall survival with current intensive, multi-agent chemotherapy regimens 
combined with improvements in supportive care (Pui, Relling et al. 2004).  
Despite these advances, the relatively high incidence means that it is still one of 
the most frequent causes of death from malignancy in childhood.  In addition, 
intensive therapies carry a burden of both acute and, particularly, long-term 
toxicity, which result in a significant increase in mortality for survivors of 
childhood leukaemia compared to age-matched controls, (see 1.1.6).  
Furthermore, despite the good overall survival, substantial difficulties remain in 
identifying and managing those children who have an increased risk of relapse 
and who have a much poorer chance of cure. 
Within childhood acute lymphoblastic leukaemia, leukaemias derived from the B 
lineage represent over 90% of diagnoses (O'Neill, Bunch et al. 2012).  This 
lineage has quite distinct biology from T lineage disease and so for the 
remainder of this thesis only B lineage leukaemia will be considered. 
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1.1.2 Epidemiology 
In Caucasian populations the incidence of childhood ALL is approximately 35 
cases per million children per year.  In the United Kingdom this equates to 
approximately 370 new diagnoses per year.  Boys are slightly more frequently 
affected than girls with a sex ratio of 1.2:1 (CCRG 2010). 
The only established causative exposure for childhood ALL is ionizing radiation, 
either in the form of in utero exposure to diagnostic radiation (Doll and 
Wakeford 1997; Pearce, Salotti et al. 2012) or environmental exposure, such as 
following the atomic bombing of Japan in 1945 (Preston, Kusumi et al. 1994).  
Many other environmental risk factors have been investigated with regard to the 
risk of developing ALL, mostly without identifying good evidence of association.  
In particular, despite substantial public anxiety surrounding exposure to 
environmental radon (UKCCSInvestigators 2002) or neonatal vitamin K 
injections (Fear, Roman et al. 2003), no evidence of an association between 
these factors and development of ALL has been found.  Another area of 
concern, exposure to electromagnetic fields from overhead or domestic power 
cables (Coghill, Steward et al. 1996; Ahlbom, Day et al. 2000), is supported by 
data which may indicate a moderate excess risk in exposed children 
(UKCCSInvestigators 1999), but has not been supported by a plausible 
biological explanation to date. 
In contrast, substantial epidemiological evidence exists to support the theory 
that a delayed exposure or abnormal response to childhood infection may 
facilitate malignant transformation of a pre-malignant clone, (see 1.1.3).  
Notably, studies of large UK and US cohorts identified regular attendance at 
day-care before the age of 1 year, a proxy for early exposure to infections, to be 
the only factor associated with a decreased risk of developing ALL (Ma, Buffler 
et al. 2002; Gilham, Peto et al. 2005). 
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A number of genetic syndromes are well recognised to predispose to the 
development of ALL.  Most of these are rare, with the exception of trisomy 21, 
Down syndrome, which carries an approximately 20 fold increased risk of ALL 
(Hasle, Clemmensen et al. 2000).  The underlying genetic properties of Down 
syndrome associated ALL (DS-ALL) are not the same as non DS-ALL, with low 
incidence of MLL rearrangements and t(9;22) (Pui, Raimondi et al. 1993; 
Forestier, Izraeli et al. 2008; Maloney, Carroll et al. 2010) and an excess 
representation in the group of patients with deregulation of CRLF2 (Mullighan, 
Collins-Underwood et al. 2009; Russell, Capasso et al. 2009).  Outcome for 
children treated for DS-ALL has been seen to vary between different trial 
groups.  However, there is a general consensus that children with Down 
syndrome experience greater treatment related toxicity, benefiting from more 
intensive supportive care and possibly from certain dose modifications (Maloney 
2011).  However, some groups have identified poorer outcome following dose 
modifications (Bohnstedt, Taskinen et al. 2009; Goto, Inukai et al. 2011) and the 
optimal balance between dose intensity and treatment toxicity remains to be 
determined. 
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1.1.3 Origins of the disease 
The origin of ALL has been a subject of intense research over many years.  
Pioneering work by Mel Greaves has demonstrated the development of a pre-
malignant clone in utero.  Clonal populations harbouring the most common 
genetic aberrations, high hyperdiploidy and the ETV6/RUNX1 translocation, as 
well as translocations involving the MLL gene, have been identified in 
monozygotic twins concordant for ALL, implying a common fetal origin to their 
disease (Mahmoud, Ridge et al. 1995; Ford, Bennett et al. 1998; Maia, van der 
Velden et al. 2003).   Furthermore, analysis of Guthrie blood spots has 
demonstrated the presence of ETV6/RUNX1 translocations as frequently as in 
1% of newborn blood samples (Mori, Colman et al. 2002).  This frequency is 
100 fold that of the development of overt ETV6/RUNX1 positive ALL, implying 
that the additional genetic changes required for full malignant transformation are 
relatively rare.  Furthermore, in a fascinating recent study of a single pair of 
monozygotic twins discordant for ALL, Hong et al demonstrated the presence of 
a persistent ETV6/RUNX1 positive pre-malignant clone in the unaffected twin 
(Hong, Gupta et al. 2008).  Whilst the translocation resulted in an abnormal 
immunophenotype, believed to represent a “pre-malignant stem cell”, it lacked 
the additional copy number changes seen in the ALL of the affected twin and 
failed to undergo malignant transformation over an eighteen month period of 
monitoring. 
The nature of the additional genetic changes required to convert a pre-
malignant cell into overt leukaemia has attracted a substantial amount of 
attention, particularly in recent studies.  Some secondary mutations are well 
recognised, such as the deletion of the second, un-translocated ETV6 gene in 
ETV6/RUNX1 positive ALL (Golub, Barker et al. 1995; Raynaud, Cave et al. 
1996), deletion of CDKN2A (Okuda, Shurtleff et al. 1995; Zhou, Gu et al. 1995), 
CCNC (Li, Lahti et al. 1996; van Delft, Horsley et al. 2011) or ATM (Raimondi, 
Frestedt et al. 1995).  Another group of mutations are found within the pathways 
determining B precursor development.  Recent studies have identified frequent 
mutations of the transcription factors which govern the process of normal B 
precursor development, with 40% of B precursor leukaemias harbouring a 
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mutation of one or more of these genes.  Most frequent are the largely 
monoallelic loss of function mutations within PAX5, a master regulator of B 
lineage commitment and development, and IKZF1 which encodes the 
transcription factor IKAROS (Mullighan, Goorha et al. 2007).  A final group of 
common mutations are those which result in activation of key proliferative 
pathways such as the RAS/RAF/MAPK/ERK pathway (Case, Matheson et al. 
2008; Nicholson, Knight et al. 2012). 
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1.1.4 Cytogenetic subgroups 
Childhood acute lymphoblastic leukaemia is characterised by the recurrent 
finding of a relatively small number of well-defined cytogenetic abnormalities, 
reviewed in (Moorman 2012).  These subgroups are found to correlate strongly 
with age, white count at diagnosis and immunophenotype, as well as with 
prognosis.  In particular they identify a number of patients with substantially 
worse prognosis and consequently allow escalation in their treatment.  Broadly 
the abnormalities can be grouped into: translocations - which result in the 
creation of a fusion oncogene which codes for an abnormal fusion protein with 
leukaemogenic potential; abnormal ploidy - both hyperdiploid and hypodiploid 
subgroups exist and carry good and poor risk respectively; other – this group 
contains a variety of biological subtypes which carry a range of prognoses. 
Two aberrations, high hyperdiploidy (defined as 51-65 chromosomes) and 
t(12;21)(p13;q22) which results in the fusion oncogene ETV6/RUNX1 
(previously known as TEL/AML1) are identified in approximately 38% and 25% 
of B precursor ALL respectively (Moorman, Ensor et al. 2010).  They carry a 
good overall prognosis although, given their relatively high prevalence, still 
represent a substantial proportion of cases which go on to relapse.  Other well 
defined abnormalities are much less frequent, the most common amongst which 
are (Moorman, Ensor et al. 2010): t(1;19)(q23;p13) - TCF3/PBX1 (previously 
E2A/PBX1) present in 4% and carries an intermediate to good prognosis on 
modern protocols; t(9;22)(q34;q11) – BCR/ABL present in 3% and carrying a 
very poor prognosis with standard chemotherapy but recently greatly improved 
with the increasing use of tyrosine kinase inhibitors with early results showing 3 
year event free survival of approximately 80%, even without allogeneic bone 
marrow transplantation (Schultz, Bowman et al. 2009; Rives, Estella et al. 
2011); intrachromasomal amplification of chromosome 21 – iAMP21 a relatively 
newly identified abnormality in which multiple complex processes result in the 
amplification of a common region of 5Mb which includes the AML1 gene 
(Harewood, Robinson et al. 2003; Strefford, van Delft et al. 2006).  This 
abnormality affects 2% of cases and whilst it originally held an extremely poor 
prognosis (Moorman, Richards et al. 2007), identification of these cases and 
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subsequent escalation to intensive chemotherapy appears to have resulted in 
improvement in outcome (Heerema, Raetz et al. 2011; Moorman 2012); 
rearrangements of the MLL gene are uncommon outside of infancy but continue 
to carry a poor prognosis, especially in younger children.  Overall they are 
present in 2% of cases but each individual rearrangement is rather rarer, 
making sub-classification by translocation partner difficult. 
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1.1.5 Current management strategies 
Current management of childhood B precursor acute lymphoblastic leukaemia 
in highly developed countries is based on intensive multi-agent chemotherapy 
regimens, which are applied in a stratified and response adjusted manner.  
Stratification within the UK is based on the NCI risk criteria whereby a child will 
receive more intensive chemotherapy if they are greater than 10 years old or if 
their white blood cell count is greater than 50 x 109/L at any point prior to 
starting treatment.  Within the current UK treatment guidelines, this would 
involve escalation from regimen A to regimen B.  Having started treatment, 
further escalation in therapy to regimen C would be applied either if cytogenetic 
analysis demonstrated a high risk abnormality, namely hypodiploidy, t(17;19), 
MLL rearrangement or iAMP21, or if there was a poor response to treatment 
judged by either failure to achieve morphological remission or high risk minimal 
residual disease (MRD) monitoring.  Patients identified as having t(9;22) 
Philadelphia chromosome would move to a separate, BCR/ABL specific 
protocol.  
Therapy is divided in individual courses, namely remission induction, 
consolidation and delayed intensification interspersed with and followed by 
maintenance therapy (Figure 1-1).  The initial courses are intensive and aimed 
at achieving a molecular remission, as determined by PCR based analysis of 
clonal B/T cell receptor rearrangements.  Subsequent maintenance therapy 
consists principally of oral chemotherapy aimed at prolonged suppression of 
residual leukaemic cells.  Central nervous system prophylaxis is delivered 
throughout therapy with repeated intrathecal administration of methotrexate. 
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Figure 1-1. UK therapy for B precursor ALL.  Each regimen contains the same courses, 
delivered in the same order.  The number and delivery of drugs differs between regimens.  
Maintenance phase is timed to give two years of therapy for girls and three years for boys, 
taken from the beginning of interim maintenance (not shown, delivered between consolidation 
and delayed intensification). 
 
 
 
 
Further modifications to therapy are limited, but include the use of tyrosine 
kinase inhibitors for patients whose leukaemia has t(9;22), or haematopoietic 
stem cell transplantation in first complete remission for patients with high risk 
cytogenetic features and poor response to therapy, as determined by analysis 
of MRD.  This strategy is otherwise withheld for relapsed disease. 
Recent modifications to UK therapy have aimed at using the improved risk 
stratification offered by MRD analysis to reduce treatment in patients showing a 
good response to therapy, thereby reducing toxicity.  This step is based on the 
extremely good survival seen in both of these groups of patients - >95% overall 
survival in the recent UKALL2003 trial.  The current UK trial, UKALL2011, is 
aimed at further reducing the treatment related morbidity and mortality, 
especially that related to dexamethasone use, see 1.1.6. 
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1.1.6 Long term effects of treatment 
As the overall survival from childhood B precursor ALL has improved to beyond 
80%, so the treatment related toxicity has become an increasing concern.  As 
longitudinal studies mature, we are developing a clearer idea of the impact that 
intensive multi-agent chemotherapy has on long-term health and well-being.  
Young adults treated for childhood malignancy, including leukaemias, have a 
significant excess mortality compared to age matched controls (Figure 1-2) 
(Armstrong, Liu et al. 2009).  The risk of death from relapse has dropped as 
treatment intensity increases, instead, death from second malignancy and 
cardiac disease now dominates.  Not only is this important for the individual 
survivor, but with one in 640 young adults in the US a survivor of childhood 
malignancy, it also represents an important strategic healthcare concern.  
Current clinical trials continue to attempt to reduce toxicity, focusing on further 
stratifying patients and reducing treatment intensity to the best risk groups.  In 
addition, it is hoped that altered dosing schedules may provide a degree of 
protection from toxicity.  An example of this is the modification of 
dexamethasone administration in UKALL 2011, where shorter course of 
dexamethasone, albeit at a higher dose, are being compared with the current 
continuous administration during remission induction. 
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Figure 1-2.  Late mortality amongst 5-year survivors of childhood malignancy in the US 
Childhood Cancer Survivor Study (Armstrong, Liu et al. 2009). 
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1.2 Cancer stem cell theory 
1.2.1 Introduction 
That both solid and haematological tumours demonstrate extensive 
heterogeneity has been known for many years.  More recently, knowledge of 
this physical heterogeneity has been complemented by an increasing 
understanding of variation in biological and functional characteristics.  Much of 
this work has been aimed at identifying the cell population within a malignancy 
which is able to maintain the disease and potentially initiate relapse.  This cell 
population was believed to sit at the apex of a hierarchy, where its capacity for 
indefinite divisions allowed it to populate a tumour.  The heterogeneity of that 
tumour was derived from the differentiation occurring as cells expanded and 
differentiated.  As this situation mirrored normal adult stem cells, in particular 
the well characterised haematopoietic stem cell, the term cancer stem cell was 
adopted to describe this population.  The identification of cancer stem cells 
(CSCs) in a broad range of malignancies followed, as it was hoped that 
targeting this population specifically might offer a novel therapeutic approach.  
As our understanding of the CSC has developed, this goal seems increasingly 
difficult to achieve.  Nevertheless, understanding the principle of self-renewal 
within a malignancy may improve the understanding of a tumour’s biology.   
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1.2.2 Definition 
As the concept of the cancer stem cell developed, it became important to 
ensure that a common understanding existed as to what this new term meant.  
This was particularly true as the term itself led to confusion, with some believing 
that it implied the cell must have arisen from a normal adult stem cell.  Similarly, 
as in vivo engraftment assays were frequently used to define these cells, the 
alternative name of tumour-initiating cell led some to believe that the CSC was 
synonymous with the cell of origin of a malignancy.  Neither of these 
assumptions is true, although either may hold for a particular malignancy.  In 
response to the growing interest in CSCs and in an attempt to avoid these 
confusions, the American Association of Cancer Researchers convened a 
workshop at which they discussed the need for a definition of the CSC (Clarke, 
Dick et al. 2006).  Whilst their report includes discussion of the relatively 
infrequency of CSCs and how they may sit within a hierarchy analogous to 
normal adult stem cells, the definition at which they arrived was: 
“a cell within a tumor that possess (sic) the capacity to self-renew and 
to cause the heterogeneous lineages of cancer cells that comprise the 
tumor.” 
A recent review of the state of CSC understanding, performed by a 2011 
Working Conference on CSC, has further sought to develop a unified approach 
to the definition, experimental isolation and functional investigation of CSCs 
(Valent, Bonnet et al. 2012).  In particular, this Conference promoted the 
detailed reporting of experimental parameters to aid the development of 
understanding of CSC biology.   
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1.2.3 Identification of cancer stem cells 
Much of the pioneering work on cancer stem cells was performed by John 
Dick’s laboratory in Toronto.  His work identifying stem cells in acute myeloid 
leukaemia provided the first evidence of a rare stem cell with a defined 
immunophenotype.  Using fluorescence activated cell sorting (FACS) and 
xenotransplantation studies in NOD/scid mice, Dick’s laboratory demonstrated 
enrichment of blasts with engraftment potential in the CD34++CD38- 
population.  The frequency of stem cells in rose from 0.2-200 per million cells up 
to 10-50,000 per million cells in this population, but not in CD34+CD38+ or 
CD34- cells (Lapidot, Sirard et al. 1994; Bonnet and Dick 1997).  Subsequent 
studies by this group and others have confirmed the presence of a defined and 
rare Leukaemia Propagating Cell (LPC) (Hope, Jin et al. 2004; Goardon, Marchi 
et al. 2011).  However, experimental limitations may mean that this population is 
not as rare as was once believed (Taussig, Vargaftig et al. 2010). 
In addition to the identification of the AML stem cell, the techniques developed 
in Dick’s laboratory came to define the gold standard for functional assessment 
of “stemness”.  These and similar techniques were used to enrich for tumour-
initiating capacity in a range of malignancies, including breast cancer (Al-Hajj, 
Wicha et al. 2003), colon cancer (Dalerba, Dylla et al. 2007; O'Brien, Pollett et 
al. 2007; Ricci-Vitiani, Lombardi et al. 2007), brain tumours (Hemmati, Nakano 
et al. 2003; Singh, Clarke et al. 2003), pancreatic cancer (Hermann, Huber et al. 
2007; Li, Heidt et al. 2007), ovarian cancer (Zhang, Balch et al. 2008; Alvero, 
Chen et al. 2009; Curley, Therrien et al. 2009), prostate cancer (Collins, Berry 
et al. 2005), hepatic cancer (Ma, Chan et al. 2007), lung cancer (Ho, Ng et al. 
2007; Eramo, Lotti et al. 2008) and gastric cancer (Fukuda, Saikawa et al. 2009; 
Takaishi, Okumura et al. 2009).   
The importance of the experimental conditions has become increasingly well 
recognised, even within highly immunocompromised species.  Syngeneic 
transplantation studies of murine leukaemia and lymphoma suggested that 
inter-species barriers may result in a falsely low CSC frequency (Kelly, Dakic et 
al. 2007).  Key amongst the conditions to be optimised are use of the most 
immunocompromised mouse strains, particularly NSG mice (McDermott, Eppert 
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et al. 2010; Taussig, Vargaftig et al. 2010), and direct/orthotopic injection to 
avoid clearance of transplanted cells from peripheral blood, an important factor 
even in NSG mice (Taussig, Vargaftig et al. 2010). In addition, the gender of 
recipient mice can affect engraftment and so must be considered when 
allocating recipient groups (McDermott, Eppert et al. 2010).   
Optimising these conditions can dramatically alter the frequency of tumour-
initiating cells.  A number of studies have questioned the degree to which the 
immunophenotype of cancer stem cells is restricted, particularly with regard to 
expression of CD133 (Joo, Kim et al. 2008; Ogden, Waziri et al. 2008; Wang, 
Sakariassen et al. 2008). In human melanoma, early studies using less 
developed xenotransplantation strategies identified a rare stem cell, enriched 
for by expression of ABCB5 (Schatton, Murphy et al. 2008) or CD271 (Boiko, 
Razorenova et al. 2010).  However, by optimising the assay conditions, 
tumorigenic cells can be demonstrated at a frequency of 1 in 4 cells, 
irrespective of their immunophenotype (Quintana, Shackleton et al. 2008; 
Quintana, Shackleton et al. 2010). 
Consequently, whilst the cancer stem cell model seems likely to hold true for a 
number of conditions, it will not describe the mechanism of tumour maintenance 
and initiation of relapse in all malignancies.  Instead, other models of tumour 
heterogeneity may be more relevant for particular diseases. 
Most recently, three studies have used lineage tracing techniques to 
demonstrate the presence of distinct populations responsible for populating 
both benign/pre-malignant (Driessens, Beck et al. 2012; Schepers, Snippert et 
al. 2012) and malignant (Chen, Li et al. 2012; Driessens, Beck et al. 2012) 
tumours.  These three studies provide the first identification of a cancer stem 
cell in situ, rather than relying on xeno-transplantation studies.  Chen et al were 
further able to demonstrate that the glioma CSC compartment was responsible 
for disease re-growth following tumour de-bulking with standard cytotoxic drug 
therapy (Chen, Li et al. 2012).  Regrowth was reduced by combining cytotoxic 
drug therapy and “suicide gene” targeting of the CSC compartment, offering 
initial validity to the concept of targeting the CSC to prevent relapse. 
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1.2.4 Models of heterogeneity 
1.2.4.1 Hierarchical versus Stochastic heterogeneity 
For many, the existence of a cancer stem cell has come to imply the existence 
of a hierarchy.  However, the mutually exclusive “hierarchical” and “stochastic” 
models are intended to describe possible origins of tumour heterogeneity, not 
stemness.  As described in 1.2.1, the hierarchical model mirrors the normal 
tissue architecture, with a rare stem cell, such as the haematopoietic stem cell, 
sat at the apex of a hierarchy.  Division and maturation of that stem cell results 
in progenitor/precursor cells with increasing degrees of differentiation but a loss 
of capacity for self-renewal/clonal expansion.  It should be possible to identify 
and isolate the stem cell in this situation, whilst other populations would lack 
self-renewal.  The stochastic model, however, describes a situation where all 
populations have an equal potential to self-renew, although most cells will not 
be capable of doing so at any one time.  Instead, randomly applied factors, both 
intrinsic (genetic, epigenetic, transcriptional) and extrinsic (niche factors, 
immune response) result in stemness being a functional phenotype, rather than 
an innate one.  As such, tumour-initiating capacity cannot be enriched for. 
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1.2.4.2 Clonal evolution 
The acquisition of increasing numbers of genetic abnormalities throughout 
tumour initiation and progression has been known about for many years.  
Furthermore, the capacity for clonal evolution to underlie the development of 
therapy resistance has long been predicted: 
“With variants being continually produced, and even increasing in 
frequency with tumor progression, the neoplasm possesses a 
marked capacity for generating mutant sublines, resistant to 
whatever therapeutic modality the physician introduces.”(Nowell 
1976) 
However, there has been increasing interest in this model recently, as modern 
techniques such as fluorescence in situ hybridisation (FISH) and next 
generation sequencing permit mutational analysis either at the single cell level 
or quantitatively within a mixed population.  Such approaches have been used 
to develop phylogenetic trees, which in turn can predict the order in which 
mutations were accrued.  These data may yield the answers to questions such 
as: 1) what is the cell of origin; 2) which are driver and which passenger 
mutations; 3) which mutations are key to therapy resistance. 
Two recent studies have used differing approaches to dissecting the clonal 
evolution of ALL.  Using multiplexed FISH analysis of diagnostic, relapsed and 
xenografted leukaemias, Mel Greaves’ and Tariq Enver’s laboratories have 
been able to analyse clonal complexity at a single cell level (Anderson, Lutz et 
al. 2011).  They have shown not only simple linear evolution of clones, but 
much more complex branching patterns, with complex clonality at diagnosis.  
Relapse was initiated by either major or minor clones from diagnosis, and on 
occasion, by more than one (potentially unrelated) clone.  In the absence of 
therapeutic pressure, serial engraftment in NSG mice largely recapitulated the 
clonal complexity of the diagnostic specimen. 
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The groups of John Dick and Jim Downing used an unbiased SNP array 
approach (Notta, Mullighan et al. 2011).  They too demonstrated both linear and 
more complex patterns of clonal evolution, but their evidence suggested, at 
least for Philadelphia chromosome positive ALL, that a proportion of transplants 
are populated largely by minor diagnostic clones.  
The common essential finding of both of these papers, however, was that 
leukaemia-propagating cells share in the genetic diversity displayed by the bulk 
leukaemia.  This finding allows both the cancer stem cell and clonal evolution 
hypotheses to co-exist and interact.  Whilst the hypothesis of clonal evolution 
does not dictate the presence or absence of a hierarchy, the greater diversity 
found in the absence of a hierarchy would provide a larger genetic pool for 
clonal evolution in ALL. 
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1.2.5 The genetics of leukaemia stem cells 
The vast majority of work looking at the genetic determinants of leukaemic stem 
cell biology has been conducted in myeloid malignancy.  In part this is due to 
the much clearer definition of the LSC in AML as compared to ALL, but also, the 
phenotypic similarity between normal haematopoietic stem cells (HSC) and 
AML stem cells (CD34+CD38-).  One hypothesis is that the AML stem cell is 
directly derived from an HSC and as such, it is reasonable to consider that they 
may share a common stemness programme.  Whilst this sounds straightforward 
it is worth noting that the determinants of HSC stemness are only beginning to 
be clearly defined.  Furthermore, much of the underpinning work, as well as a 
number of studies modelling AML, have been conducted in mice and 
increasingly we are aware of substantial differences between the control of 
murine and human haematopoiesis, for review see (Doulatov, Notta et al. 
2012). 
Nevertheless, there is a substantial body of evidence demonstrating the 
importance of several pathways in HSC biology, including Wnt which acts in 
many different ways in what appears to be a highly dose dependent fashion 
(Luis, Ichii et al. 2012), TGFβ/Smad acting to maintain stem cell quiescence 
(Blank and Karlsson 2011) and Hedgehog (Mar, Amakye et al. 2011).  
However, to look at these pathways in isolation undoubtedly misses the detail 
provided by the interplay between them.  A recent study grouped a large 
number of pathways involved in all stages of haematopoiesis into modules 
(Novershtern, Subramanian et al. 2011).  Interestingly, this study showed that a 
number of modules were important in multiple and quite diverse branches of the 
haematopoietic hierarchy.  This argues in favour of the importance of 
interactions, not only between pathways but probably also with the 
niche/cytokine milieu etc, in providing an overall environment which has been 
artificially compartmentalised into modules by the approach taken. 
  
Chapter 1:  Introduction – Cancer stem cells 
21 
Despite the apparent difficulties, a number of candidate leukaemic stem cell 
programmes have recently been described.  In a murine model of MLL induced 
leukaemia, stem cells expressed a genetic signature which was more similar to 
normal myeloid precursors and embryonic stem cells than to HSCs 
(Somervaille, Matheny et al. 2009).  More recently, Goardon et al have 
examined LSC populations in primary human CD34+ AML (Goardon, Marchi et 
al. 2011).  This study demonstrated hierarchically organised LSC potential in 
both lymphoid-primed multipotential progenitor-like (LMPP-like, CD38-
CD45RA+) and granulocyte-macrophage progenitor-like (GMP-like) 
populations.  Global expression profiles derived from these populations most 
closely matched the expression profiles derived from the equivalent populations 
in normal bone marrow, rather than normal HSC populations.  However, these 
populations were enriched for the LSC “self-renewal” expression profile which 
has previously been determined in a murine model of MLL-AF9 induced AML 
(Krivtsov, Twomey et al. 2006).  In this setting, global expression profiles most 
closely matched that of normal GMP cells, but a 363 gene “self-renewal 
associated” signature was enriched in populations with self-renewal potential, 
namely HSCs and leukaemic GMPs .   
A study contemporaneous to Goardon et al and again using primary human 
AML, found a negative correlation between the expression profile of functionally 
determined LSCs and that of comparable normal lineage committed populations 
(Eppert, Takenaka et al. 2011).  Instead, Eppert et al found that the LSC profile 
correlated with that of normal cord blood HSCs.  The differences in findings 
between these two studies may derive from the different immunophenotypic 
definitions used, or the alternative source of normal comparator material (bone 
marrow v cord blood).  However, this study was also able to determine a limited 
(44 gene) expression signature which was common to both leukaemic and 
normal haematopoietic stem cells and was highly enriched for genes functioning 
in stem cell regulation or oncogenesis.  Furthermore, they demonstrated a 
correlation between expression of this signature and clinical outcome, providing 
evidence of the relevance of the LSC to patients.   
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Whilst no comparable study has yet been published in ALL, our laboratory has 
recently performed an analysis of data from sorted CD34+ and CD34- 
lymphoblastic leukaemic populations, using the Eppert signature (Rehe, Wilson 
et al. 2012)(Appendix D).  We have found that neither CD34+ nor CD34- ALL 
populations cluster with the CD34+CD38- AML cells or HSCs from Eppert et al 
using Principle Component Analysis.  These data are consistent with our 
current model of ALL propagation which predicts that propagation is mediated 
by a lymphoid “self-renewal” programme rather than an HSC programme, see 
1.2.6.  
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1.2.6 Leukaemia stem cells in acute lymphoblastic leukaemia 
Unlike the clear demonstration of a hierarchy in AML, the nature of the 
leukaemia propagating cell (LPC) in ALL has been rather more controversial.  
Initial studies showed that in both high and standard risk leukaemias, 
populations with an immature CD34+CD19- immunophenotype provided the only 
source of LPCs (Cobaleda, Gutierrez-Cianca et al. 2000; Cox, Evely et al. 
2004).  Subsequent studies, however, have failed to confirm these findings.  
Indeed, two groups have demonstrated in both high risk Philadelphia positive 
and standard risk ETV6/RUNX1 positive leukaemia, the population expressing 
the B lymphoid differentiation marker CD19, is the only one to harbour LPCs 
(Castor, Nilsson et al. 2005; Hong, Gupta et al. 2008).  In the study conducted 
by Tariq Enver’s laboratory, leukaemia propagating potential was restricted to 
an abnormal leukaemia associated immunophenotype, CD34+CD38-/lowCD19+ 
(Hong, Gupta et al. 2008). 
More recently it has been demonstrated that a number of assay variables can 
have significant effects on the likelihood of transplantation.  In particular, human 
cells which have been antibody labelled and sorted can be removed by the 
residual immune system of even the most immunocompromised strains 
currently available (Taussig, Vargaftig et al. 2010).  This constraint may be 
bypassed to some extent by direct injection into the bone marrow, thereby 
avoiding peripheral immune effector cells (Taussig, Vargaftig et al. 2010).  
Additional factors which may reduce rates of engraftment include the strain of 
mice and specific antibodies used for sorting (Taussig, Vargaftig et al. 2010) 
and male gender (McDermott, Eppert et al. 2010).  Failure to engraft may 
therefore have explanations other than an inherent lack of leukaemia 
propagating potential. 
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We have previously shown that using NSG mice, the most 
immunocompromised strain currently available, combined with direct 
intrafemoral injection, leukaemia propagation is not limited to CD34+CD19-, 
CD34+CD19+ or CD34-CD19+ populations (le Viseur, Hotfilder et al. 2008).  This 
has been confirmed in a separate study by Kong et al, who again used NSG 
mice but transplanted via facial vein injection (Kong, Yoshida et al. 2008).  We 
have also demonstrated that cells from the more mature CD34-CD19+ 
population were able to repopulate the entire leukaemia in recipient mice, 
including the “immature” haematopoietic stem cell like phenotype, CD34+CD19-.  
We called this phenomenon malleability in order to differentiate it from the 
“plasticity” associated with changes in lineage specificity. 
Using a murine model of BCR/ABL1 positive Arf-/- ALL, Williams et al 
demonstrated the leukaemia propagating potential of (perhaps) every 
transformed pre-B cell (Williams, den Besten et al. 2007).  These findings have 
been supported by studies of human leukaemias which have again shown a 
high frequency of LPCs in unsorted primary (Morisot, Wayne et al. 2010) and 
primografted (Schmitz, Breithaupt et al. 2011) leukaemia specimens.  The high 
frequency of LPCs, combined with the presence of leukaemia propagation in a 
range of immunophenotypes argues against the presence of a stem cell 
hierarchy in ALL.  However, the studies published to date have left a number of 
factors still to be addressed.  In particular, the lack of evidence of sorted primary 
populations transplanted at limiting dilution leaves the possibility of a rare but 
potent hierarchical stem cell in ALL.  Furthermore, studies have focused on high 
risk cytogenetic subgroups and therefore not determined whether these findings 
may apply more widely in B precursor ALL. 
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We have recently studied sorted patient derived blasts, both primary and 
passaged (primografted), from 13 patients with a variety of standard and high 
risk cytogenetic backgrounds (Rehe, Wilson et al. 2012)(Appendix D).  
Transplantation of cells at limiting dilution has demonstrated frequent LPCs, 
present in primary material between 1:40-1:2,900, increasing to as frequent as 
1:6 in primografted samples.  Furthermore, there was no difference in the LPC 
frequency or engraftment kinetics of blast populations sorted for CD10, CD20 or 
CD34. 
In addition to studying patterns of engraftment, expression microarray analysis 
and quantitative reverse transcriptase PCR of sorted CD34+ and CD34- blasts 
populations have demonstrated different transcriptomic patterns which mirror 
the corresponding normal B-precursor population including expression of IRF4, 
MS4A1/CD20, IgH constant locus, IgL  and  loci (le Viseur, Hotfilder et al. 
2008).  More recent analysis of the same data has applied putative leukaemia 
stem cell signatures derived from AML.  If, as recent data suggest, there is no 
hierarchy in ALL and blasts from all populations have equal leukaemia 
propagating potential then such signatures should not be able to differentiate 
between these populations.  Indeed, we found that whilst the signatures 
accurately separate immature CD34+CD38- AML blasts from more mature 
populations, CD34+ and CD34- ALL blasts clustered together, demonstrating 
an uncoupling of leukaemia propagating potential from differentiation in ALL 
(Rehe, Wilson et al. 2012)(Appendix D). 
The results of the most recent studies, using more highly immunocompromised 
xenograft assays, strongly suggest that there is no hierarchy in acute 
lymphoblastic leukaemia.  As discussed in 1.2.4.2, clonal evolution is not 
dependent on either the presence or absence of a hierarchy.  Indeed, a 
situation in which new clones evolve across all immunophenotypes, each of 
which possesses leukaemia propagating capacity (Anderson, Lutz et al. 2011), 
argues in favour of a disease which lacks a hierarchy and in which LPCs are 
not-infrequent.  This would provide an ideal milieu for the development of 
therapy resistant clones and so it is surprising perhaps that ALL, at least in 
childhood, is remarkably treatable.  
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1.2.7 The therapeutic relevance of cancer stem cells 
Just as the cancer stem cell (hierarchical versus stochastic) and clonal 
evolution models are not mutually exclusive, so other biological properties add 
further levels of complexity into the behaviour of a cancer/leukaemia 
propagating cell, as recently reviewed in (Magee, Piskounova et al. 2012).  
Lineage plasticity, epithelial-mesenchymal/mesenchymal to epithelial transition, 
bidirectional interconvertibility (Gupta, Chaffer et al. 2009), malleability (le 
Viseur, Hotfilder et al. 2008), differences in cell of origin and differing kinetics to 
each of these factors make the number of potential disease, and even patient, 
specific cancer propagating properties so large, that for many cancers it seems 
unlikely that the original hope of specifically targeting the CSC therapeutically 
will ever be realised.  Nevertheless, ensuring that novel therapies do effectively 
include CSCs in their target profiles, when such a population is present, will be 
an essential component of developing novel therapies. 
The exception to this may be in malignancies where the maintenance of the 
disease relies upon a programme innate to the parent lineage, and not derived 
from a particular combination of genetic/epigenetic mutations.  Lymphoid 
malignancy may present such a scenario, as lymphoid maturation is not 
accompanied by an obligate loss of self-renewal potential.  In contrast to most 
other tissues, both progenitor and fully differentiated lymphoid cells retain the 
ability to clonally expand: progenitors following successful expression of the 
pre-B receptor at the cell surface; differentiated lymphocytes following 
exposure, and re-exposure, to antigen.  It may therefore be possible to identify 
novel therapeutic targets from amongst the pathways governing lymphoid clonal 
expansion and its counterpart, clonal deletion.  Furthermore, it might be hoped 
that these targets may hold more generalizable therapeutic potential for other 
diseases involving the lymphoid system, notably chronic lymphocytic leukaemia, 
myeloma and lymphoma. 
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One approach to identifying important elements of the clonal expansion 
programme in malignant lymphoid populations is to apply loss of function 
analyses.  Experimentally, these can be performed by manipulating the 
endogenous post-transcriptional control mechanism known as RNA 
interference.  This approach, described in 1.3, can either be used to investigate 
a candidate target or applied in a screening format, described in 1.4.
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1.3 Small RNAs and RNA interference 
1.3.1 Introduction to small RNAs 
A substantial proportion of the non-protein coding genome is transcribed, 
resulting in an increasingly complex variety of small, and long, non-coding RNA 
species.  Many of these species are expressed across a wide range of 
organisms and mediate diverse functions in a sequence-directed manner, for 
review see (Farazi, Juranek et al. 2008).  The most well understood function of 
small, non-coding RNAs is to act as guide strands for RNA-mediated post-
transcriptional gene silencing, also known as RNA interference (RNAi).  This 
endogenous process, in mammals exemplified by microRNAs (miRNAs), allows 
the post-transcriptional control of gene expression by targeting complementary 
mRNA for translational repression or degradation (depending on the degree of 
complementarity between guide strand and target mRNA). 
Just two endogenous RNA species have been identified in mammals - miRNAs 
and, more recently, PIWI-interacting RNAs (piRNAs).  These two non-coding 
RNAs have distinct structures, see Table 1-1, and associate with different 
members of the Argonaute family of proteins which are also highly-conserved 
across species.   
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Table 1-1.  Characteristics of miRNA and piRNA (adapted from (Farazi, Juranek et al. 2008) 
 miRNAs piRNAs 
Expression Ubiquitous Germline 
Precursor 
structure 
Hairpin structure ?single stranded 
Length 20-23 28-33 
Modification Unmodified 2’-O-methylation at 3’ terminus 
Function 
mRNA degradation 
Translational repression 
mRNA cleavage 
Control of methylation 
?Histone modifications 
Effector 
protein 
partners 
Argonaute proteins PIWI proteins 
 
The Argonaute family comprises proteins with highly conserved domains known 
as PIWI/PAZ Domain (PPD) proteins, see Figure 1-3.  The family is divided into 
two distinct clades, based on sequence homology: Argonaute clade proteins 
associate with miRNAs and represent core effectors within the well-studied 
classical RNA interference pathways; PIWI clade proteins associate with 
piRNAs and function via alternative pathways which are still not well 
understood. 
 
 
Figure 1-3.  The structure of PIWI/PAZ Domain (PPD) proteins.  PAZ domain – single 
stranded RNA binding pocket (Lingel, Simon et al. 2004; Ma, Ye et al. 2004); Mid domain – 5’-
phosphate binding; PIWI – RNase H endonuclease domain (Song, Smith et al. 2004).  The 34 
amino acid PIWI Box (PB) is the most highly conserved region (Cox, Chao et al. 1998). 
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1.3.2 Argonaute clade proteins and microRNAs 
The single stranded RNA guides which associate with Argonaute proteins in 
mammals are predominantly derived from miRNAs.  The human genome 
contains approaching 500 miRNA encoding genes which are transcribed to give 
a primary miRNA (pri-miRNA) containing hairpin loops which will be processed 
to give between 1 and 6 mature miRNAs (Landgraf, Rusu et al. 2007) (Figure 
1-4). 
The pri-miRNA is bound by the double stranded RNA binding domain of the 
nuclear protein DGCR8, which subsequently associates with the RNase III 
protein DROSHA to form the nuclear Microprocessor complex (Gregory, Yan et 
al. 2004).  DROSHA cleaves the pri-miRNA to produce a hairpin with a 2 
nucleotide 3’ overhang and 5’ phosphorylation known as a precursor miRNA 
(pre-miRNA) (Lee, Jeon et al. 2002; Basyuk, Suavet et al. 2003; Lee, Ahn et al. 
2003).  The cleaved pre-miRNA is shuttled into the cytoplasm by the GTP 
dependent nucleocytoplasmic transporter, EXPORTIN 5 (Yi, Qin et al. 2003).  In 
the cytoplasm the hairpin loop is cleaved by another RNase III protein, DICER 
(Hutvagner, McLachlan et al. 2001), again resulting in a 2 nucleotide 3’ 
overhang and 5’ phosphorylation (Elbashir, Lendeckel et al. 2001).  These 
modifications allow binding to the PAZ and Mid domains of Argonaute proteins 
(see 1.3.1).  One strand of the resultant mature miRNA, now 21-23 nucleotides 
in length, is loaded into a protein complex which includes an Argonaute protein, 
called the RNA-induced silencing complex, RISC (Hammond, Bernstein et al. 
2000).  Here, it acts as a guide strand for the binding of single stranded target 
mRNA.   
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Figure 1-4.  Schema of miRNA processing.  1) Primary miRNA transcripts are generated from 
genomic regions and processed in the nucleus by the RNase III enzyme DROSHA to give 
precursor miRNAs (2).  Precursor miRNAs are transported into the cytoplasm by EXPORTIN 5 
where the loop is removed by another RNase III, DICER (3), to give a mature miRNA.  The 
miRNA is loaded into the RNA Induced Silencing Complex (RISC, 4) where it acts as a guide 
strand for an Argonaute protein.  Depending on the degree of complementarity, this may result 
in transcript cleavage (as shown) or sequestration and prevention of translation. 
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In humans, each miRNA may target as many as 100 transcripts (Brennecke, 
Stark et al. 2005; Lim, Lau et al. 2005), with a 6-8 nucleotide sequence at the 5’ 
end of an miRNA, known as the seed region, targeting the 3’ untranslated 
region of their respective mRNAs by (Lewis, Burge et al. 2005).  Only rarely 
would an endogenous human miRNA have full complementarity to its target.  
The predominant method of miRNA modulation in humans is therefore inhibition 
of translation, rather than mRNA degradation, which relies on near 
complementarity and is seen more frequently in plants.  mRNA bound into RISC 
is then prevented from being translated, or transported to mRNA processing 
bodies – P bodies, where it can either be degraded or returned for cytoplasmic 
translation (Parker and Sheth 2007). 
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1.3.3 PIWI clade proteins and PIWI-interacting RNAs 
The second clade of PPD proteins consists of homologues of the Drosophila P-
element induced wimpy testis protein - Piwi.  First identified in 1997, 
constitutional knockout studies showed that Piwi mutants had reduced numbers 
of adult germ cells, despite normal numbers of embryonic germline stem cells 
(Lin and Spradling 1997).  It has subsequently been shown that this protein is 
essential for the maintenance of germline stem cells (Cox, Chao et al. 1998), 
and that this function is likely to be reliant on their role in suppressing the 
expression of retrotransposons, thereby protecting from integration associated 
mutational events (Aravin, Hannon et al. 2007). 
1.3.3.1 PIWI clade proteins in mammals 
Piwi homology has been described in a number of mammals.  Amongst these 
are the murine Miwi (mouse Piwi), Mili (Miwi like) (Kuramochi-Miyagawa, 
Kimura et al. 2001; Deng and Lin 2002) and Miwi2 (Carmell, Girard et al. 2007), 
and their human homologues PIWIL1 (PIWI-Like 1, HIWI) , PIWIL2 (HILI), 
PIWIL4 (HIWI2) and the additional PIWIL3 (Sharma, Nelson et al. 2001; Sasaki, 
Shiohama et al. 2003).  The most extensively studied amongst these are the 
murine homologues which, as in flies, are expressed in a developmentally 
controlled manner in testes (but not in ovaries) (Aravin, Sachidanandam et al. 
2007).  Knockout models again show varying blocks in spermatogenesis without 
an effect on testicular primordial germ cell numbers or ovarian gametogenesis 
(Deng and Lin 2002; Kuramochi-Miyagawa, Kimura et al. 2004; Carmell, Girard 
et al. 2007). 
Analysis of the expression of PIWI-Like genes in humans is less thorough.  
Expression of PIWIL4 seems to be ubiquitous (Sugimoto, Kage et al. 2007), 
whilst expression of PIWIL2 and 3 is largely restricted to the testis (Sasaki, 
Shiohama et al. 2003).  The best studied family member, at least in health, is 
PIWIL1.  Within the testis, expression is restricted to germline cells, 
spermatocytes and spermatids (Qiao, Zeeman et al. 2002), but expression has 
also been demonstrated in heart, brain, kidney, pancreas, prostate, skeletal 
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muscle and CD34+ haematopoietic precursors, where expression is lost during 
in vitro differentiation culture (Sharma, Nelson et al. 2001). 
1.3.3.2 Mammalian PIWI interacting RNAs - piRNAs 
In 2006, a novel class of small RNAs was found to associate with PIWI clade 
proteins in both flies (Saito, Nishida et al. 2006; Vagin, Sigova et al. 2006) and 
mammals (Aravin, Gaidatzis et al. 2006; Girard, Sachidanandam et al. 2006; 
Grivna, Beyret et al. 2006; Lau, Seto et al. 2006; Watanabe, Takeda et al. 
2006), the Piwi-interacting RNA (piRNA).  Whilst in flies a heavy bias towards 
sequences derived from repeat elements supported a primary role in control of 
retrotransposons, mammalian piRNAs showed less specificity for repeat 
elements, suggesting more diverse mechanisms of action in mammals.  
Interestingly, the balance of sequences derived from repeat elements versus 
exonic elements varies during murine embryogenesis, suggesting also a 
dynamic function for these complexes (Aravin, Sachidanandam et al. 2007; 
Gan, Lin et al. 2011). 
Tens of thousands of piRNA sequences are transcribed from a relatively limited 
number (50-100) of piRNA clusters (Aravin, Gaidatzis et al. 2006; Girard, 
Sachidanandam et al. 2006; Grivna, Beyret et al. 2006; Lau, Seto et al. 2006; 
Watanabe, Takeda et al. 2006).  They are believed to be processed from long 
(25-35 kilobases) single stranded RNA precursors (Betel, Sheridan et al. 2007) 
by an unidentified endonuclease and 2’-O-methylated at the 3’ end by HEN1 
(Kirino and Mourelatos 2007).  This methylation both stabilises piRNAs and 
contributes to their PIWI protein binding specificity (Tian, Simanshu et al. 2011).   
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1.3.4 Non-canonical RNAi pathways – PIWI/piRNAs functions 
The original view of Piwi function in Drosophila germline stem cells was that of 
retrotransposon control.  Whilst a novel mechanism is thought to underlie 
piRNA generation, known as the Ping-Pong cycle, the subsequent effector 
function is believed to be similar to canonical RNAi mediated by miRNAs, 
namely post-transcriptional mRNA degradation.  As PIWI clade proteins have 
conserved RNase III domains it seems likely that this remains an important 
function in mammalian homologues of Piwi, but increasing evidence points 
towards additional functions of the PIWI/piRNA complex in mammals. 
The most work on non-canonical PIWI/piRNA function exists in the field of 
methylation.  Mammalian PIWI proteins are expressed during embryogenesis, 
and in particular during the period of de novo DNA methylation of embryonic 
germ cells (day 14.5 post coitum – day 2/3 after birth).  This is a critical period 
for establishing methylation of transposons in the male germline, preventing the 
subsequent expression of these genes. Both Mili and Miwi knockout mice have 
reduced testis specific CpG methylation of retrotransposons and an associated 
increase in retrotransposon expression, a phenotype similar to that of DNA 
methylation deficient dnmt3L knockout animals (Aravin, Sachidanandam et al. 
2007; Carmell, Girard et al. 2007; Kuramochi-Miyagawa, Watanabe et al. 2008).  
Furthermore, a role for piRNAs in the maintenance of paternal imprinting has 
been described (Watanabe, Tomizawa et al. 2011). 
Whilst the vast majority of studies have concentrated on the function of PIWI 
proteins in the control of retrotransposons in germline specific stem cells, a 
recent study in Aplysia, the sea hare, has demonstrated a quite different 
function for PIWI/piRNA complexes.  Thomas Tuschl’s and Eric Kandel’s 
laboratories identified piRNAs in small RNA libraries produced from Aplysia 
neurones (Rajasethupathy, Antonov et al. 2012).  PIWI/piRNA complexes 
modulated the expression of the transcriptional repressor CREB2 in response to 
the neuromodulatory agent serotonin, known to be involved in learning and 
memory.  This effect was mediated by a sequence specific methylation of the 
CREB2 promoter.  This study provides the first example of the effect of 
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PIWI/piRNA directed CpG methylation on gene function, in addition to which it is 
an extragonadal effect. 
A small number of less comprehensive studies have also suggested possible 
roles for PIWI proteins in maintaining histone modifications, both in mice (Wang, 
Han et al. 2011) and humans (Sugimoto, Kage et al. 2007). 
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1.3.5 PIWI/piRNAs in malignancy 
Whilst the study of PIWI/piRNA function in humans has been limited by the 
apparent gonadal specificity of this system, there have been a number of 
studies looking at the expression of PIWI genes in human malignancy.  The 
recent interest in cancer stem cells, combined with the germline stem cell 
specificity of PIWI proteins has raised the possibility that PIWI/piRNA 
complexes may be involved in modulating a stem cell programme in 
malignancy.   
The expression of PIWIL1 has been demonstrated in seminoma (Qiao, Zeeman 
et al. 2002), pancreatic adenocarcinoma (Grochola, Greither et al. 2008), and 
endometrial adenocarcinoma (Liu, Jiang et al. 2010).  Furthermore, single 
studies have found expression of PIWIL1 to be associated with poorer outcome 
in gastric carcinoma (Liu, Sun et al. 2006; Wang, Liu et al. 2012), glioma (Sun, 
Wang et al. 2011), low stage/non-metastatic colorectal carcinoma (Zeng, Qu et 
al. 2011), hepatocellular carcinoma (Zhao, Zhou et al. 2012), oesophageal 
carcinoma (He, Wang et al. 2009) and soft-tissue sarcoma (Taubert, Greither et 
al. 2007) whilst expression has been associated with tumour invasion in 
squamous cell carcinoma of the cervix (Liu, Jiang et al. 2010). 
Whilst these studies have not looked at other members of the PIWI-Like 
proteins, additional studies have examined the expression of PIWIL2 in 
malignancy.  Similar to PIWIL1, expression of PIWIL2 has been demonstrated 
in cervical carcinoma (Lee, Schutte et al. 2006; Feng, Peng et al. 2009; He, 
Chen et al. 2010), breast carcinoma (Lee, Jung et al. 2010) and most recently 
papillary thyroid carcinoma (Yin, Li et al. 2011). 
These studies, however, have almost exclusively looked at the correlation 
between malignancy/stage and expression of PIWI-Like genes, often in a non-
quantitative fashion.  Consequently, little is known about the mechanism of 
action of PIWI-Like genes in malignancy.  A small number of studies have, 
however, started to examine two potential mechanisms.  Firstly is a proposed 
anti-apoptotic effect of PIWIL2.  One of the initial papers demonstrating 
expression of PIWIL2 in malignancy demonstrated a correlation between 
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expression of PIWIL2 and expression of the anti-apoptotic pathway genes 
STAT3 and Bcl-XL (Lee, Schutte et al. 2006).  This study did not, however, 
demonstrate the mechanism by which PIWIL2 might influence expression of 
these anti-apoptotic genes.  A more recent study has demonstrated the 
association of PIWIL2 with STAT3 and c-src in a complex which appears to 
phosphorylate STAT3 (Lu, Zhang et al. 2012).  This results in increased binding 
to the promoter of, and subsequent down-regulation of expression of, p53.   
The second mechanism which has been investigated is the role of PIWIL2 in 
the control of methylation.   Siddiqi et al demonstrated a directly tumorigenic 
effect of a PIWIL2 expression vector in mesenchymal stem cells, resulting in the 
production of soft tissue sarcomas (Siddiqi, Terry et al. 2012).  This study also 
found that clones expressing PIWIL2 showed global hypermethylation, whilst 
PIWIL2 knockdown resulted in decreased growth and reduced DNA 
methylation.  Interestingly, this study found no evidence of methylation changes 
specific to promoter CpG islands, although this may relate to the relatively short 
period of culture following transfection.  Instead they postulate that the function 
of PIWIL2 directed methylation in sarcoma continues to be the suppression of 
retrotransposon expression. 
To date, however, no studies have attempted to identify the expression of 
piRNAs in malignancy, and none have suggested a plausible link between the 
sequence specific role of PIWI/piRNA complexes and their function in 
malignancy.
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1.4 Functional screening by shRNA library 
1.4.1 Introduction to shRNA screens 
High throughput RNAi screens have proved a powerful tool in identifying genes 
involved in diverse biological processes.  The original screen structure tended 
to involve individual construct transfection of siRNAs in a 96-well format.  Such 
screens have been enormously informative in Drosophila and other lower 
organisms, as well as mammalian systems.  More recently, virally delivered, 
shRNA based libraries have allowed the development of massively parallel 
functional RNAi screens.  This approach has identified existing and novel genes 
important to embryonic (Hu, Kim et al. 2009; Chia, Chan et al. 2010; 
Westerman, Braat et al. 2011) and haematopoietic (Ali, Karlsson et al. 2009; 
Hope, Cellot et al. 2010; Baudet, Karlsson et al. 2012) stem cell maintenance, 
neuronal synaptic development (Valakh, Naylor et al. 2012) and circadian clock 
modification (Zhang, Liu et al. 2009). 
shRNA based functional screens are most obviously suited to identification of 
genes involved in cell proliferation and survival, and have therefore become an 
important tool in cancer research.   
The general procedure for lentiviral based screening involves:  
1. Transduction of target cells with lentiviral pools to give one construct 
per cell;  
2. Harvesting of sample to provide a baseline for construct prevalence;  
3. Period of culture to determine effect of gene knockdown, combined 
with antibiotic selection to remove untransduced cells;  
4. Harvesting second sample for comparison with baseline.   
The effect of knockdown of individual genes can be assessed by analysing the 
variation in construct prevalence between the baseline sample taken prior to 
knockdown and the second sample taken after a period of culture with 
knockdown.    
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1.4.2 Screening approaches – Positive and Negative screening 
In broad terms, screens can be conducted to produce either positive selection 
or negative selection outputs.  The former involves an assay in which the output 
is colonies which have been positively selected following exposure to an 
environmental pressure (e.g. irradiation, drug treatment, immunophenotypic 
selection etc) (Westbrook, Martin et al. 2005; Brummelkamp, Fabius et al. 2006; 
Gazin, Wajapeyee et al. 2007).  This approach requires sequencing of 
individual clones and provides information only on genes deleterious to survival 
under selective pressure (constructs targeting these genes will be identified 
from proliferating clones).  Negative selection involves analysis of the whole 
population at the end of the assay and therefore provides information on the 
prevalence of constructs relative to each other, including those which have 
become more, and those which have become less, prevalent (Schlabach, Luo 
et al. 2008; Silva, Marran et al. 2008).  Information is therefore gathered on 
genes which are beneficial to cell growth and survival (in this instance, hairpin 
construct prevalence will decrease) as well as those which are deleterious. 
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1.4.3 The development of shRNA libraries 
In order to identify the causative construct of a phenotype generated by a 
pooled/parallel RNAi screen, it is essential that: 1) each cell should receive only 
a single construct; 2) individual constructs can be identified at the end of the 
experiment. 
The first constraint was addressed by development of microRNA adapted 
hairpins by the laboratories of Greg Hannon, Cold Spring Harbour Laboratories, 
and Stephen Elledge, Harvard University (Dickins, Hemann et al. 2005; Silva, Li 
et al. 2005; Stegmeier, Hu et al. 2005).  By cloning the hairpin into the middle of 
a sequence derived from miRNA-30 (mir30), the construct is believed to follow a 
more natural pathway from transcription to RISC via processing by DROSHA 
and DICER.  This results in more efficient processing, active export from the 
nucleus and active loading into RISC, see Figure 1-4.  A substantially greater 
knockdown is achieved, making just a single lentiviral integration effective. 
The second of these requirements has been satisfied by sequencing or array 
based analysis of a specific construct.  The two principle approaches available 
are the analysis of either a barcode, unique to an individual shRNA construct, or 
analysis of the unique construct itself.  Modern iterations of the second option 
tend to rely on analysis of a “half-hairpin” to avoid probe self-annealing during 
array analysis (Schlabach, Luo et al. 2008; Silva, Marran et al. 2008). 
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1.4.4 Limitations of shRNA screens 
Genome-wide screens are so complex, that is to say they require accurate 
transduction of a very large number of constructs with a high degree of 
coverage, that to perform them in primary material is unfeasible.  This presents 
a difficulty, as hits identified by the in vitro analysis may not remain valid in an in 
vivo situation.  In a head-to-head comparison of in vitro and in vivo screening, 
Meacham et al found less than 10% of differentially represented hairpin 
constructs to be shared between the two situations (Meacham, Ho et al. 2009).   
Another difficulty with the complexity of whole-genome screens is that 
constructs have not been prospectively validated.  Instead, hairpin sequences 
are derived from algorithms which are designed to maximise knockdown whilst 
minimising off-target effects, especially those derived from the critical seed-
region, see 1.3.2.  Despite this, it is presumed that a proportion of hairpins will 
not achieve substantial levels of knockdown, and it has been demonstrated that 
at least 1% of hits in an siRNA screen is an off-target effect (Schultz, 
Marenstein et al. 2011).  Recently, an analysis tool for predicting off-target 
effects from the seed-region has been described (Sigoillot, Lyman et al. 2012).  
Such approaches may help to limit false positive hits generated by off-target 
effects, although it may still be prudent to confirm that potential therapeutic 
targets are indeed false hits. 
Finally, a small number of studies have demonstrated an innate toxicity to virally 
delivered shRNAs in the setting of murine models of disease.  This effect can 
be modulated by expressing shRNAs from a miRNA context (McBride, 
Boudreau et al. 2008).  Use of miRNA adapted hairpins is not without 
complications however.  Two studies have shown the potential for shRNAmir 
constructs, which produce much higher levels of shRNA precursors than do 
native shRNAs, to saturate the endogenous RNAi machinery, probably at the 
level of nuclear export by Exportin 5, resulting in disturbed endogenous miRNA 
function (Grimm, Streetz et al. 2006; Pan, de Ruiter et al. 2011).  
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1.4.5 shRNA screening in cancer 
The unbiased nature of genome-wide functional screening has allowed the 
identification of novel tumour-suppressor genes (Westbrook, Martin et al. 2005; 
Zender, Xue et al. 2008; Iorns, Ward et al. 2012) as well as potential therapeutic 
targets (Cole, Huggins et al. 2011; Zuber, Shi et al. 2011).  RNAi screens can 
also be adapted to more complex assays.  Within cancer research this includes 
synthetic lethality screens used to look for factors potentiating the effect either 
of an existing therapy (Azorsa, Gonzales et al. 2009), or of a commonly mutated 
gene such as RAS (Luo, Emanuele et al. 2009) or BRCA2 (Hattori, Skoulidis et 
al. 2011).  The standard cellular survival screen can also be adapted to look at 
specific cell populations and has been applied to candidate brain tumour stem 
cell populations to identify genes essential for cancer stem cell survival and 
maintenance (Wurdak, Zhu et al. 2010; Goidts, Bageritz et al. 2012).
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1.5 Hypothesis and objectives of the study 
As has been discussed (see 1.2.5 and 1.2.6), lymphoblastic leukaemic blasts 
with propagating potential are frequent and are not arranged in a hierarchy.  
This frequency of propagating potential argues in favour of self-renewal being 
an intrinsic feature of all lymphoblasts which they are able to activate 
stochastically in response to intrinsic, or more probably extrinsic, cues such as 
niche availability.  However, the genetic determinants of this biological 
characteristic are unknown.   
 
The hypothesis underpinning this study is that: 
Acute lymphoblastic leukaemic blasts derive an intrinsic 
propagating potential from their lymphoid cell of origin 
 
The objectives of this study were: 
1) To investigate the role of the candidate stemness gene PIWIL2 in the 
propagation of childhood acute lymphoblastic leukaemia 
2) To perform an unbiased functional RNAi screen to identify genes 
involved in the propagation of childhood acute lymphoblastic leukaemia  
3) To develop techniques to allow the validation of candidate regulators of 
lymphoblastic leukaemic propagation using patient-derived leukaemic 
blasts in an in vivo model of leukaemic propagation
  
Chapter 2 
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2.1 Approvals 
2.1.1 Ethical approval for studies using patient-derived leukaemic 
material 
Bone marrow and peripheral blood samples were collected at presentation, as 
part of the initial diagnostic investigations. Written informed consent was 
obtained from patients and/or legal guardians according to protocols approved 
by the corresponding review boards. Patient samples from the UK that were 
stored before September 2006 were exempt from specific consent for research 
by the Human Tissue Act.  Samples were retrieved from Newcastle 
Haematological BioBank under the generic BioBank approval given by the 
Newcastle & North Tyneside Ethics Committee (REC reference number: 
07/H0906/109). 
Anonymised umbilical cord blood specimens, stored with consent for research, 
were obtained from the Newcastle Umbilical Cord Blood Bank, Department of 
Academic Haematology, Newcastle University. 
Healthy peripheral blood samples were collected from volunteer donors working 
within Newcastle University. 
2.1.2 Home Office approval for animal research 
Animal experiments were performed by trained researchers who had all 
completed approved Home Office training at Newcastle University and held 
current Personal Licences under the Animals (Scientific Procedures) Act 1986.  
Intrafemoral injection and sampling was performed by one of three trained 
researchers from within the research group.  All work was conducted in 
accordance with the Home Office Project Licence PPL60/3846. 
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2.2 Materials 
2.2.1 Laboratory equipment 
ABI Prism 7000 Sequence Detection System  Applied Biosystems 
Avanti J-26 XP centrifuge     Beckman Coulter 
Chromato-Vue UV trans-illuminator   Ultra-Violet Products Ltd 
DMR Fluorescence microscope    Leica 
E-410 digital SLR camera     Olympus 
EPI2500 Electroporator     RL Fischer, Heidelberg 
FACS Calibur      Beckton Dickinson 
FACS Canto II      Becton Dickinson 
Fluostar Omega plate reader    BMG Labtech 
GelDoc Imager      BioRad 
GeneAmp PCR System 9700    Applied Biosystems 
IMT-2 phase contrast microscope    Olympus 
LSM 700 confocal scanning microscope   Carl Zeiss Ltd 
Mediphot937 X-ray film developer    Colenta Labortechnik 
Model 680 microplate reader    BioRad 
Nanodrop 1000 spectrophotometer   Labtech International 
Optima L-100 XP ultracentrifuge    Beckman Coulter 
RS320 X Ray System     Gulmay Ltd 
SPOT RT digital CCD camera    SPOT Imaging 
Spectrum IVIS bioluminescent camera   Caliper Life Sciences  
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2.2.2 Software 
FACSDiva       Becton Dickinson 
Graphpad Prism 4      Graphpad Software Inc. 
Living Image 4.0      Caliper Life Sciences 
Modfit LT       Verity Software House 
Primer express 2.0      Applied Biosystems 
SDS 2.0       Applied Biosystems 
SPOT Advanced 4.0     SPOT Imaging Solutions 
ZEN 2009       Carl Zeiss Ltd 
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2.2.3 Chemicals and reagents 
2.2.3.1 General chemicals 
General chemicals were purchased from Sigma unless otherwise stated. 
2.2.3.2 Specific chemicals and reagents 
Ampicillin       Sigma 
Betaine 5 M solution     Sigma 
Bovine pancreatic DNase I     Sigma 
Carprofen       Pfizer 
ccdB Survival™ 2 T1R competent cells   Invitrogen 
Chloramphenicol      Sigma 
Coomasie Brilliant Blue G-250    Thermo Scientific 
DH5α competent cells     Invitrogen 
Dimethylsulphoxide      Sigma 
DNA loading buffer      Fermentas 
dNTP set 100 mM      Fermentas 
Ethidium bromide      Sigma 
Ficoll-Paque       GE Life Sciences 
Gateway pENTR1A dual selection vector  Invitrogen 
GelRed       VWR International 
IPTG        Sigma 
JM109 competent cells     Promega 
Kanamycin       Sigma 
Lipofectamine LTX Plus     Invitrogen 
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Lymphoprep       Axis-Shield 
Phosphate buffered saline (PBS)    GIBCO 
Polybrene       Sigma 
Propidium Iodide      Sigma 
Protamine       Sigma 
Protein Assay Reagent     BioRad 
Puromycin       Sigma 
RNase A       QIAGEN 
Trypan blue       Sigma 
XenoLight™ D-Luciferin     Caliper Life Sciences 
X-Gal        Sigma 
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2.2.3.3 Experimental kits 
Decode shRNAmir library     Thermo Scientific 
DNA blood mini kit      QIAGEN 
Endofree Plasmid Maxi Kit     QIAGEN  
Gateway Vector Conversion System   Invitrogen 
Gateway LR Clonase II enzyme kit   Invitrogen 
miScript Reverse Transcription Kit   QIAGEN 
miScript Primer Assay     QIAGEN 
miScript SYBR Green PCR Kit    QIAGEN 
Nucleospin miRNA kit     Macherey-Nagel 
pGEM-T Easy Vector cloning kit    Promega 
Platinum® SYBR® Green SuperMix UDG  Applied Biosystems 
QIAquick PCR purification kit    QIAGEN 
QIAprep Spin Miniprep Kit     QIAGEN  
RevertAid™ H Minus cDNA Synthesis Kit  Fermentas 
RNeasy Micro kit      QIAGEN 
RNeasy Mini Kit      QIAGEN 
SuperSignal West Dura     ThermoScientific 
Wizard SV Gel and PCR clean-up kit   Promega 
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2.2.3.4 Enzymes 
All restriction enzymes were purchased from Fermentas.  Additional enzymes 
were purchased as follows: 
Calf Intestinal Alkaline Phosphatase   Invitrogen 
Klenow fragment      Fermentas 
KOD Hot Start DNA polymerase    Novagen/Merck 
Shrimp Alkaline Phosphatase    Fermentas 
Vent polymerase      New England Biolabs 
2.2.3.5 Cell culture media and supplements 
Fetal calf serum      Sigma 
Fetal calf serum      Gibco 
Recombinant human IL-3     R & D Systems 
Recombinant human IL-7     R & D Systems 
Recombinant human stem cell factor   R & D Systems 
RPMI1640       Sigma 
RPMI1640       PAA  
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2.2.4 Buffers and media 
2.2.4.1 DNA electrophoresis buffers 
DNA loading buffer (6x)   0.25% w/v bromophenol blue 
       0.25% w/v xylene cyanol 
       20 mM EDTA 
       30% w/v glycerine 
 
TAE      40 mM Tris 
       0.114% v/v acetic acid 
       1 mM EDTA 
       pH 8 
 
TBE      90 mM Tris 
       90 mM H3BO3 
       2 mM EDTA 
       pH8 
 
TE buffer     10 mM Tris.Cl, pH 8.0 
       1 mM EDTA 
2.2.4.2 Western immunoblotting buffers 
Urea buffer     9 M urea 
       4% w/v CHAPS 
       1% w/v DTT 
 
Stacking gel buffer (4x)   500 mM Tris 
       0.4% w/v SDS 
       pH 6.8 
 
Separating gel buffer (4x)   1.5 M Tris 
       0.4% w/v SDS 
       pH 8.8 
 
Protein loading buffer (6x)   350 mM Tris, pH 6.8 
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       12 mM EDTA 
       500 mM DTT 
       0.012% w/v bromophenol blue 
       30% w/v glycerol 
 
Electrophoresis buffer   25 mM Tris 
       190 mM glycine 
       0.1% w/v SDS 
 
Transfer buffer     25 mM Tris 
       10% v/v methanol 
       190 mM glycine 
 
TST      10 mM Tris 
       150 mM NaCl 
       0.1% v/v Tween 20 
 
Coomassie blue stain    Coomassie G-250 0.1% w/v 
       Acetic acid 10% v/v 
       Methanol 40% v/v 
 
Ponceau stain     Ponceau S 0.1% w/v 
       Acetic acid 5% v/v 
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2.2.4.3 Bacterial culture buffers 
LB medium     1% w/v tryptone 
       0.5% w/v yeast extract 
       1% w/v NaCl 
       pH 7.5 
 
LB agar plates     LB medium 
       1.5% w/v agar 
 
SOC medium     2% w/v tryptone 
       0.5% w/v yeast extract 
       10 mM NaCl 
       2.5 mM KCl 
       20 mM Mg2+ 
       20 mM glucose 
 
Calcium Chloride/Magnesium Chloride 80 mM Magnesium chloride 
       20 mM calcium chloride  
       0.2 µm filtered 
 
Calcium chloride     0.1 M calcium chloride 
       0.2 µm filtered 
 
X-Gal-solution    0.4% w/v NN-dimethylformamide 
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2.2.4.4 Cell culture media 
Cells Medium Supplements 
HS-5, Kasumi-1, M2-
10B4, SEM, 833K 
RPMI 1640, HEPES 
modification 
2 mM L-Glutamine 
10% v/v fetal calf serum 
REH, 697 RPMI 1640 2 mM L-Glutamine 
10% v/v fetal calf serum 
293T Dulbecco’s Modified 
Eagle’s Medium 
4 mM L-Glutamine 
1 mM sodium pyruvate 
10% v/v fetal calf serum 
 
2.2.4.5 Lentiviral transfection buffers 
Calcium chloride 0.5 M   0.5 M CaCl 
       0.2 µm filtered 
 
HeBS, 2x     0.28 M NaCl 
       0.05 M HEPES 
       1.5 mM NaOH 
       pH 7.0 (critical 6.95<pH>7.05) 
       0.2 µm filtered 
 
2.5 mM HEPES, pH 7.3   0.25% v/v 1 M HEPES 
       pH 7.3 
       0.2 µm filtered 
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2.2.4.6 Cell purification and flow cytometry buffers 
Citrate buffer     0.25 M Sucrose 
       40 mM sodium citrate  
       pH 7.6 
 
DNA staining and lysis buffer  20 µg/ml propidium iodide 
       0.5% v/v NP-40 
       0.5 mM EDTA  
       PBS 
 
Dilution buffer     2 mM EDTA 
       PBS 
       pH 7.2 
 
Red cell lysis buffer     150 mM ammonium chloride 
       10 mM potassium bicarbonate 
       1 mM EDTA 
 
DNase digest buffer    0.5 mM MgCl 
       1 mM CaCl 
       PBS 
 
MACS buffer     0.5% w/v bovine albumin 
       2 mM EDTA 
       PBS 
       pH 7.2 
       degassed in vacuum chamber 
 
2.2.4.7 RNAi buffers 
siRNA hybridisation buffer   100 mM NaCl 
       25 mM Tris 
       pH 7.5 
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2.2.5 Oligonucleotide sequences 
2.2.5.1 Quantitative Reverse Transcriptase PCR primers - mRNA 
AML1/ETO Fw: 5’ - AAT CAC AGT GGA TGG GCC C - 3' 
Re: 5' - TGC GTC TTC ACA TCC ACA GG - 3' 
ANGPT1 Fw: 5’ - TCT CTT CCC AGA AAC TTC AAC ATC T - 3’ 
Re: 5’ - TCA TGT TTT CCA CAA TGT AAT TCT CA - 3’ 
BMI1  Fw: 5’ - AAT CCC CAC CTG ATG TGT GT - 3’ 
Re: 5’ - GCT GGT CTC CAG GTA ACG AA - 3’ 
CD34  Fw: 5’ - AAA GCA CCA ATC TGA CCT GAA AA - 3’ 
Re: 5’ - CGA GGT GAC CAG TGC AAT CA - 3’ 
EZH2  Fw: 5’ - GGG CTC CAA AAA GCA TCT ATT G - 3’ 
Re: 5’ - TGC ACA GGA TCT TTG ATA AAA ATC C - 3’ 
GAPDH  Fw: 5’ - GAA GGT GAA GGT CGG AGT C - 3’ 
Re: 5’ - GAA GAT GGT GAT GGG ATT TC - 3’ 
HMGA2 Fw: 5’ - CCC AAA GGC AGC AAA AAC AA - 3’ 
Re: 5’ - GCC TCT TGG CCG TTT TTC TC - 3’ 
MEIS1 Fw: 5’ - GCA TGC AGC CAG GTC CAT - 3’ 
Re: 5’ - TAA AGC GTC ATT GAC CGA G - 3´ 
MLL/AF4 Fw:  5´ - CAG AAG CCC ACG GCT TAT GT - 3’  
Re:  5´ - GCA AAC CAC CCT GGG TGT TA - 3’  
PIWIL1 Fw: 5’ - GGA TTT GTT GCC AGC ATC AAT - 3’ 
Re: 5’ - AGG CAG ACT TTG AGC CCA TCT - 3’ 
PIWIL2 Fw:  5’ - AGG CAG AGG CCA TGT ATT TGG - 3’ 
Re: 5’ - AAG CAT TTC CCG TTT CAG - 3’ 
PIWIL3 Fw: 5’ - GGA AAT TTG GAG AGC GCC ATA - 3’ 
Re: 5’ - CCA TTC CAC TCT CCG CTC TTT - 3’ 
PIWIL4 Fw: 5’ - TGC TGG AAG TAC CTT CAT GGA - 3’ 
Re: 5’ - GCT GCC AGT CTT GGG GAA AA - 3’ 
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TBP  Fw: 5’ - CCT AAA GAC CAT TGC ACT TCG T - 3’ 
Re: 5’ - GTT CGT GGC TCT CTT ATC CTC A - 3’ 
TERT  Fw: 5’ - GGA GAA CAA GCT GTT TGC GG - 3’ 
Re: 5’ - AGG TTT TCG CGT GGG TGA G - 3’ 
2.2.5.2 Quantitative Reverse Transcriptase PCR primers - shRNA 
shAGF1  5’ - TTC TCA GTA CGA TTT CGA GG - 3’ 
shANGPT1  5’ - TTA GTG CAA AGA TTG ACA AGG T - 3’ 
shMA6  5’ - TGG AGT AGG TCT GCT TTT CTT TT - 3’ 
2.2.5.3 siRNA sequences 
siAGF1 sense  5’ - CCU CGA AAU CGU ACU GAG AAG - 3' 
  antisense  3’ - UUG GAG CUU UAG CAU GAC UCU - 5’ 
siMA6  sense  5’ - AAG AAA AGC AGA CCU ACU CCA - 3' 
  antisense 3' - UUU UCU UUU CGU CUG GAU GAG GU - 5' 
siPIWIL2_5 sense  5’ - CUG CUA AUC UGG UAC GCA AUU - 3’ 
  antisense 3’ - UUG ACG AUU AGA CCA UGC GUU - 5’ 
siPIWIL2_e sense  5’ - GGA UGA GUG UAC UAA GCU U - 3’ 
  antisense 3’ - AAG CUU AGU ACA CUC AUC C - 5’ 
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2.2.5.4 Gateway cloning primers 
pTRIPZ shRNAmir30 restriction cloning primers 
 Fw: 5’ - GAG AGA GTC GAC CGA CCT CCC TAG CAA ACT GGG - 3’  
GTC GAC – SalI restriction site 
 Re: 5’ - GAG AGA GAT ATC GAC TCA CTA TAG GGC CCG CC - 3’  
GAT ATC – EcoRV restriction site 
Entry vector sequencing reverse primer 
 5’ - GTA ACA TCA GAG ATT TTG AGA CAC - 3’ 
Destination vector sequencing primer 1 
 5’ - CAC ATT ATA CGA GCC GGA AGC AT - 3’ 
Destination vector sequencing primer 2 
 5’ - CAG TGT GCC GGT CTC CGT TAT CG - 3’  
Chapter 2:  Materials & methods 
61 
 
2.2.6 Mammalian cell lines 
The following derived mammalian cell lines were used either for cell culture 
experiments, for production of recombinant lentivirus, to condition medium or as 
a source of RNA for qRT PCR. 
Table 2-1.  Mammalian cell lines 
Cell line Origin Cytogenetics 
SEM Relapsed childhood ALL t(4;11)(q21;q23) – MLL/AF4 
REH Relapsed childhood ALL t(12;21)(p13;q22) – TEL/AML1 
697 Relapsed childhood ALL t(1;19)(q23;p13) – E2A/PBX1 
Kasumi-1 Relapsed childhood AML t(8;21)(q22;q22) – RUNX1/RUNX1T1 
SKNO-1 Relapsed young adult AML t(8;21)(q22;q22) – RUNX1/RUNX1T1 
833K Metastatic testicular 
seminoma 
 
293T Human embryonic kidney Transformed by adenovirus 5 
transfection 
M2-10B4 Murine bone marrow 
stroma 
Derived from a C57BL/6J X C3H/HeJ 
F1 mouse 
HS-5 Human bone marrow 
stroma 
Transformed by HPV-16 E6/E7 
transfection 
NALM6 Relapsed young adult ALL t(5;12)(q33.2;p13.2) – ETV6/PDGFRβ 
RS4;11 Relapsed adult ALL t(4;11)(q21;q23) – MLL/AF4 
MV4;11 Diagnosis childhood AML t(4;11)(q21;q23) – MLL/AF4 
THP-1 Relapsed childhood AML t(9;11)(p22;q23) – MLL/AF9 
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2.2.7 Bacterial strains 
The following bacterial strains were used either for the maintenance of lentiviral 
plasmids (2.3.7), during the TA cloning of qRT PCR amplicons prior to 
sequencing (2.3.8) or during the Gateway cloning project (2.3.12). 
Table 2-2.  Bacterial strains 
Strain Experimental 
use 
Genetics 
JM109 Maintenance of 
lentivectors 
TA cloning 
endA1, recA1, gyrA96, thi, hsdR17 
(rk–, mk+), relA1, 
supE44, Δ(lac-proAB), [F′, 
traD36, proAB, laqIqZΔM15] 
DH5α Gateway cloning  F- φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rk-, 
mk+) phoA supE44 λ- thi-1 gyrA96 
relA1 
ccdB Survival 
2T1R 
Gateway cloning  F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 
araΔ139 Δ(ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
fhuA::IS2  
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2.2.8 Antibodies 
2.2.8.1 Fluorochrome labelled antibodies for flow cytometry 
All antibodies were purchased from Becton Dickinson 
Specificity Clone Fluorochrome 
CD3 SK7 Fluorescein isothiocyanate (FITC) 
CD14 M5E2 Phycoerythrin (PE) 
CD15 MMA FITC 
CD19 SJ25C1 PE 
CD19 SJ25C1 Allophycocyanin (APC) 
CD20 L27 PerCP Cy5.5 
CD34 8G12 APC 
CD45 (murine) 30-F11 PE-Cy7 
TER-119/Erythroid 
(murine) 
TER-119 PE-Cy7 
2.2.8.2 Primary antibodies for Western immunoblotting 
Specificity Species Dilution Manufacturer 
PIWIL2 Mouse 1:500 Abnova 
PIWIL2 Goat 1:100-1:25000 Santa Cruz 
PIWIL2 Rabbit 1:200-1:2000 Abcam 
GAPDH Mouse 1:50000 HyTest 
2.2.8.3 Secondary antibodies for Western immunoblotting 
Specificity Species Dilution Manufacturer 
Anti-goat Donkey 1:5000 Santa Cruz 
Anti-mouse Rabbit 1:2500-1:5000 GE Healthcare 
Anti-rabbit Goat 1:5000 Dako 
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2.3 Methods 
2.3.1 General cell culture methods 
2.3.1.1 Thawing viable cells 
Viable cells were retrieved from liquid nitrogen and thawed rapidly using a water 
bath at 37oC.  Cells were carefully transferred to a 20 ml universal container.  
Nine volumes of the appropriate medium at 4oC was added drop wise.  Cells 
were centrifuged 300 x g, 10 minutes and the supernatant aspirated.  Cells 
were resuspended in the appropriate medium, at the desired concentration and 
transferred to a culture flask or dish. 
2.3.1.2 Cell counting using a Haemocytometer 
An estimate of the cell concentration was made using an Improved Neubauer 
Counting Chamber.  Cells in suspension were diluted 1:1 with trypan blue, or in 
the case of homogenised splenic samples, methylene blue to lyse red blood 
cells, and 8-10 μl placed into the chamber.  Viable cells, being those which did 
not take-up trypan blue, within a quadrant etched on the chamber, were 
counted using an inverted phase contrast microscope.  As the quadrant has a 
volume of 0.1 mm3 the number of cells in 2 quadrants (allowing for a 1:1 
dilution) multiplied by 10000, is the concentration of cells per millilitre.  
2.3.1.3 Routine cell culture – suspension cells 
Leukaemic cell lines SEM, REH, pre-B 697 and Kasumi-1 were cultured in 
upright culture flasks in an incubator set to 37oC, 5% CO2, fully humidified.  
Cells were counted every 2-3 days, see 2.3.1.2, and resuspended in fresh 
medium at a concentration between 5 and 8 x 105 cells/ml. 
2.3.1.4 Routine cell culture – adherent cells 
The adherent cell lines 293T, 833K, HS-5, and M2-10B4 were grown in treated 
culture dishes or flasks in an incubator set to 37oC, 5% CO2, fully humidified.  
Cells were split at confluence or for 293T, whilst still sub-confluent.  To split 
cells, medium was aspirated, the plate washed with a volume of warmed PBS 
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equal to the initial volume of medium and then cultured at 37oC with 1x trypsin 
(10x trypsin, Sigma, diluted with PBS) for 1-10 minutes, depending on the cell 
line.  The volume of trypsin used was 2.5 ml for 100mm dishes and 5 ml for 
larger dishes and flasks.  Following incubation, cells were released by gentle 
tapping and then the trypsin activity neutralised by addition of 7.5 ml or 20 ml 
culture medium containing 10% v/v fetal calf serum (FCS).  The cells were 
resuspended by pipetting, diluted further with fresh medium and transferred to 
fresh dishes. 
2.3.1.5 Production of conditioned medium 
HS-5 cells were grown to near confluence in 100 mm culture dishes.  The 
medium was aspirated and replaced with fresh alpha modified minimum 
essential medium (αMEM) supplemented with 10% v/v FCS.  This medium was 
harvested after 48 hours and 0.45 μm sterile filtered.  The conditioned medium 
was aliquoted and stored at -20oC. 
2.3.1.6 Freezing cells 
Cell stocks were made by resuspending cells at 1 x 107 cells/ml in ice-cold FCS 
with 10% v/v dimethylsulphoxide.  Between 250 and 1000 μl of suspension was 
transferred to a cryovial and placed in an insulated freezing box.  Cells were 
immediately transferred to a -80oC freezer for 48-72 hours before being moved 
for long-term storage in a liquid nitrogen tank. 
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2.3.2 Specific cell culture methods 
2.3.2.1 Expansion and growth arrest of M2-10B4 feeder cells 
The murine bone marrow stromal cell derived cell line M2-10B4 was used for 
co-culture experiments with SEM cells.  This cell line was chosen as the 
laboratory had experience of growth arresting these cells using irradiation. 
M2-10B4 feeder cells were cultured in either 150 mm culture dishes or 175 cm2 
culture flasks in RPMI, 2 mM L-Glutamine and 10% v/v FCS.  Cells were grown 
to confluence, trypsinised and reseeded at a 1:5 dilution, as described in 
2.3.1.4. 
To growth arrest cells, five dishes or flasks were trypsinised as described in 
2.3.1.4.  The cell suspension was centrifuged 300 x g, 10 minutes, the cells 
resuspended in 7.5 ml complete medium and carefully pipetted into a 75 cm2 
flask.  This produced a suspension of 1 mm depth when the flask was laid 
down.  Cells were irradiated for 24 minutes at 310 kV, 10mA to give a dose of 
80 Gy.  Initially, cells were incubated for 2 hours to allow recovery before being 
re-trypsinised.  For later experiments, cells were immediately resuspended with 
fresh medium, without the need for trypsinisation.  Resuspended cells were 
either seeded out immediately or frozen down for later use, see 2.3.1.6. 
Thawed or freshly irradiated feeder cells were seeded into fresh 150 mm dishes 
or 175 cm2 flasks at 5 x 106 cells per flask.  This cell density provided a 
confluent/sub-confluent cell layer for co-culture. 
2.3.2.2 Production of puromycin resistant feeder cells 
To produce feeder cells which could be co-cultured in the presence of 
puromycin, M2-10B4 cells were stably transfected with a plasmid encoding the 
puromycin N-acetyl-transferase gene (PAC).  Transfection was performed using 
Lipofectamine™ LTX, a cationic lipid preparation which complexes with DNA to 
form liposomes.  Liposomes are endocytosed and the plasmid is subsequently 
released into the cytoplasm where it can be transcribed. 
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M2-10B4 cells were seeded at 30% confluence in a six well plate.  The following 
day, Lipofectamine/DNA complexes were prepared as follows.  Serum free 
Optimem medium, 500 µl, was mixed with 2.5 µg PAC plasmid, 2.5 µl Plus 
Reagent (supplied with Lipofectamine) and incubated at room temperature for 5 
minutes.  Between 3.5 – 15 µl Lipofectamine was added and the mixture 
shaken vigorously for 3 minutes and incubated at room temperature for 40 
minutes.  Each of the wells containing M2-10B4 cells was aspirated of medium 
and washed with 5 ml Optimem to remove FCS.  The Lipofectamine/DNA 
mixture was then added, 500 µl per well, and the plate incubated for 5 hours at 
37oC, 5% CO2. After 5 hours the Lipofectamine was aspirated off and replaced 
with 4 ml complete medium. 
On day 3 post transfection, 1 µg/ml puromycin was added to the wells.  This 
was increased to 2 µg on day 4 and maintained like this thereafter.  A small 
number of colonies grew and were expanded by trypsinisation, initially into a 12 
well plate and subsequently into larger dishes.  These cells were maintained in 
2 µg/ml puromycin thereafter.  
2.3.2.3 Density gradient centrifugation 
Density centrifugation was used to separate mononuclear cells from mixed cell 
populations in peripheral blood or to isolate viable cells from apoptotic 
cells/debris during the puromycin selection step of the RNAi screen, section 
2.3.10.4.  This process uses an iso-osmotic medium with a known density 
(1.077 g/ml) to separate viable mononuclear cells, which have a lower density, 
from erythrocytes, granulocytes and apoptotic cells which all have a higher 
density and thus pass through the separation medium during centrifugation.  
The mononuclear cell layer is then recovered from the interface between 
centrifugation medium and the original cell suspension medium and washed to 
provide purified, viable mononuclear cells. 
Cells were used either as whole blood diluted 3:1 with dilution buffer (phosphate 
buffered saline (PBS) supplemented with 2 mM EDTA, pH 7.4), or as cultured 
cell lines resuspended in PBS.  Peripheral blood, 35 ml, was carefully layered 
onto 15 ml Ficoll-Paque in a 50 ml polypropylene tube.  Alternatively, 10 ml 
cultured cells were layered onto 8 ml Lymphoprep in a 20 ml Universal tube.  
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The layered cells were carefully transferred to a centrifuge to avoid mixing at 
the interface and centrifuged at 400 x g for 40 minutes (peripheral blood) or 20 
minutes (cultured cells), ambient temperature with no brake applied.  Viable 
cultured cells were then recovered by pipette and washed once in 20 ml PBS, 
300 x g, 10 minutes and resuspended in culture medium.  Peripheral 
mononuclear cells were recovered and washed three times in 50 ml dilution 
buffer: 300 x g, 10 minutes, 200 x g, 15 minutes, 200 x g 15 minutes.  This 
wash step removed both retained Ficoll-Paque and platelets. 
Granulocytes were isolated from the fraction which passed through Ficoll-Paque 
by resuspending the erythrocyte/granulocyte pellet in 2 ml dilution buffer and 
addition of 50 ml red cell lysis buffer (150 mM ammonium chloride, 10 mM 
potassium bicarbonate, 1 mM EDTA).  After incubation for 10 minutes at room 
temperature, granulocytes were washed as described above for peripheral 
blood mononuclear cells.   
Peripheral blood mononuclear cells and granulocytes were further purified by 
MACS immunomagnetic bead sorting as described in 2.3.2.5. 
2.3.2.4 Thawing of umbilical cord blood specimens 
Stored viable umbilical cord blood specimens in 10% v/v DMSO were kindly 
donated by the Newcastle Cord Blood Bank, Department of Academic 
Haematology, Newcastle University.  Specimens were retrieved from liquid 
nitrogen and thawed in a water bath, 37oC, until just a few ice crystals 
remained.  One volume of RPMI, 10% v/v FCS, 1% v/v L-glutamine, 4oC was 
added to the cord blood over 2 minutes to allow equilibration of DMSO, followed 
by a further 4 minutes of equilibration.  The specimen was then transferred to a 
sterile 500 ml bottle and made up to 600 ml with medium RPMI medium 
supplemented as above, 4oC, to dilute DMSO to 1% v/v.  The cell suspension 
was then aliquoted into 50 ml polypropylene tubes and centrifuged at 100 x g, 
15 minutes, 4oC.   
Cell pellets showed significant degree of clumping due to DNA released from 
lysed granulocytes which comprise a substantial proportion of a cord blood 
specimen.  The pellets were therefore resuspended in 50 ml PBS, 0.5 mM 
MgCl2, 1 mM CaCl and 0.5% w/v bovine serum albumin and 5000 units bovine 
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DNase1 added.  Cells were incubated for 45 minutes at room temperature.  
Residual solid particles were allowed to settle over 2 minutes before the 
suspension was filtered through a 40 μm cell strainer.  The solid particles were 
then washed once with 50 ml PBS which was also passed through the same 
cell strainer.  Cells were then centrifuged at 200 x g, 15 minutes and 
resuspended in dilution buffer.  If there was heavy red cell contamination, an 
ammonium chloride red cell lysis was performed as described in 2.3.2.3. 
2.3.2.5 MACS microbead purification of cell populations 
Immunomagnetic cell sorting using MACS microbeads, Miltenyi Biotec, was 
used to isolate CD3, CD14, CD15, CD19 and CD34 positive populations from 
peripheral blood or umbilical cord blood (CD34).  CD133 labelling was also 
used to isolate SEM cells from M2-10B4 feeder co-cultures during the Decode 
RNAi screening experiments.  This technique uses antibody conjugated 
microbeads to label cells expressing the desired antigen.  Cells are then passed 
down a column containing ferrous spheres, held within a magnet.  Microbead 
labelled cells are held within the column whilst non-labelled cells are washed 
away.  Labelled cells were then recovered and can be used for on-going cell 
culture or nucleotide extraction. 
Cell suspensions were prepared by density gradient centrifugation as described 
in 2.3.2.3 and 2.3.2.4, or by trypsinisation of SEM-GIPZ/M2-10B4 co-cultures, 
as described for adherent cells in 2.3.1.4.  Cells were resuspended in MACS 
buffer (PBS, 2 mM EDTA, 0.5% w/v bovine serum albumin, degassed, 4oC) at 
107 cells in 80 μl buffer (CD3/14/15/19) or 108 cells in 300 μl buffer (CD34/133).  
FcR blocking agent was added to umbilical cord blood and SEM-GIPZ cells, 
100 μl per 108 cells. Peripheral blood mononuclear cells from each donor were 
divided into aliquots, one for each of CD3/14/19 labelling.  CD15 labelling was 
performed in cells isolated from the granulocyte population.  Microbeads were 
then added to each aliquot, 20 μl per 107 cells (CD3/14/15/19) or 100 μl per 108 
cells (CD34/133).  Cells were incubated at 4oC for 20 (CD3/14/15/19) or 30 
minutes (CD34/133), and vortexed after ten minutes.  Following incubation, 
cells were washed twice with 4 or 10 ml MACS buffer and centrifuged: 
peripheral leukocytes and SEM-GIPZ cells 300 x g, 5 minutes, 4oC; umbilical 
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cord blood 200 x g, 10 minutes, 4oC.  Cells were resuspended in 500-1000 μl 
MACS buffer. 
Selection columns were primed with 500 μl (MS column) or 3 ml (LS column) 
MACS buffer.  Cells suspended in MACS buffer were added to the columns and 
the flow through collected.  In the case of umbilical cord blood specimens, this 
unlabelled, CD34-, flow-through specimen was collected to provide a control 
population.  The column was washed three times with 500 μl (MS) or 3 ml (LS) 
MACS buffer to remove unlabelled cells.  The column was then removed from 
the magnet and cells eluted with either 1 ml (MS) or 5 ml (LS) MACS buffer.  
For CD34 labelled cord blood specimens, cells were passed down a second, 
primed LS column to further purify the CD34+ population. 
Following isolation, cells were counted.  In the case of umbilical cord blood an 
aliquot was labelled with anti-CD34 APC antibody as described in 2.3.9.6 and 
analysed using the FACS Calibur.  Remaining cells were lysed with buffer RLT 
for extraction of RNA according to 2.3.5.1.  In the case of isolated SEM-GIPZ 
cells, a pellet was frozen at -20oC for subsequent DNA extraction according to 
2.3.3.1. 
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2.3.3 Isolation and purification of DNA 
2.3.3.1 Isolation of genomic DNA – Qiagen spin preparations 
Genomic DNA was isolated from either cultured cell lines or patient derived 
leukaemic blasts using the QIAamp DNA Blood Mini kit, QIAGEN.  The lysis 
step is followed by adsorption of DNA onto the silica membrane of the QIAamp 
spin column and subsequent washing steps to remove protein and other 
contaminants.  Eluted DNA is predominantly 20-30 kilobases in length. 
Cells were either taken fresh from in vitro culture, harvested fresh from a 
xenografted mouse or stored as a cell pellet at -20oC.  Protease K, 20 μl, and 
RNase A, 4 μl, were added to a 1.5 ml microfuge tube.  Cells were resuspended 
in 200 μl PBS and added to the tube.  Two hundred microliters buffer AL was 
added to the cell suspension and pulse mixed by vortex for 15 seconds.  The 
sample was then incubated at 56oC for 10 minutes.  The microfuge tube was 
centrifuged and 200 μl ethanol added.  The tube was again pulse mixed by 
vortex for 15 seconds.  Having again centrifuged the microfuge tube, the lysate 
was applied to a QIAamp mini spin column and centrifuged at 6000 x g for 1 
minute.  The column was transferred to a clean collection tube.  The column 
was washed with 500 μl buffer AW1, 6000 x g 1 minute, followed by 500 μl 
buffer AW2, 20000 x g, 3 minutes.  The column was again transferred to a clean 
collection tube and centrifuged at 20000 x g, 1 minute.  The collection tube was 
transferred to a 1.5ml microfuge tube and 200 μl of either nuclease free water 
(Sigma) or buffer AE was pipetted onto the membrane.  The column was 
incubated at room temperature for between 1 and 5 minutes before being 
centrifuged at 6000 x g, for 1 minute.  DNA concentration and purity were 
assessed by spectrophotometry using a Nanodrop 2000, following which the 
DNA was stored at -80oC.   
2.3.3.2 Purification of PCR products – Qiagen spin preparations 
QIAquick PCR purification kit, QIAGEN, was used to purify PCR amplification 
products, removing residual primers, nucleotides, enzymes and salts.  The 
resultant amplicons were suitable for subsequent cloning.   
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Five volumes of buffer PB were added to 1 volume of PCR sample, pipette 
mixed and transferred to the QIAquick spin column.  The column was 
centrifuged 20000 x g, 1 minute and the flow-through discarded.  The 
membrane was washed with 750 μl buffer PE, centrifuged 20000 x g, 1 minute 
and the flow-through discarded.  The column was placed in a fresh collection 
tube and centrifuged again at 20000 x g, 1 minute.  The spin column was 
transferred to a clean 1.5 ml microfuge tube, 50 μl buffer EB added to the 
membrane and incubated at room temperature for 1 minute.  The column was 
centrifuged 20000 x g, 1 minute.  DNA concentration and purity were assessed 
by spectrophotometry using a Nanodrop 2000 and stored at -80oC, or the DNA 
was used directly for TA cloning, see 2.3.8. 
2.3.3.3 Purification of PCR/restriction digest products for cloning 
During the cloning of the shRNAmir30 constructs into the Gateway Entry vector, 
restriction digestion of shRNAmir30 amplicons and the pENTR1a dual selection 
vector was followed by separation of the residual vector by gel electrophoresis, 
see 2.3.12.3.  The desired bands were visualised using a Chromato-Vue UV 
trans-illuminator, cut out into a weighed 2 ml microfuge tube, reweighed and the 
DNA isolated using the QIAquick gel extraction kit.  For DNA extraction all 
centrifuge steps were carried out at 18000 x g for 1 minute.   
Three volumes of buffer QG were added to 1 volume of gel (volume to weight) 
and incubated at 50oC until the gel slice was completely dissolved.  Isopropanol 
equivalent to the volume of the initial gel was added and pipette mixed.  The 
sample was then added to the QIAquick column, centrifuged and the flow-
through discarded.  Five hundred microliters buffer QG was added to the 
column, centrifuged and the flow-through discarded.  The membrane was 
washed by adding 750 μl buffer PE, centrifuging and discarding the flow-
through.  The spin column was centrifuged again to remove residual ethanol 
and the column transferred to a fresh 1.5 ml microfuge tube.  DNA was eluted 
by addition of 30-50 μl buffer EB directly to the membrane, incubation at room 
temperature for 1 minute and centrifugation.  DNA concentration and purity 
were assessed by spectrophotometry using a Nanodrop 2000 and stored at 4oC 
prior to use for cloning, see 2.3.12.3. 
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2.3.3.4 Purification of amplified Decode RNAi screen barcode region 
Decode RNAi library barcode regions, amplified by hot start PCR, were purified 
by gel electrophoresis.  PCR product (100 μl) was mixed with 25 μl 5x DNA 
loading dye (Fermentas) and run in multiple wells of a 1.25% w/v agarose/TBE 
gel with 1:10000 GelRed DNA stain.  The desired band at 250 bp was 
visualised using a Chromato-Vue UV trans-illuminator, cut out into a weighed 2 
ml microfuge tube, reweighed and the DNA isolated using the Wizard SV gel 
and PCR clean-up kit.  For DNA extraction all centrifuge steps were carried out 
at 16000 x g for 1 minute. 
One volume of Membrane Binding Solution was added to 1 volume of gel 
(volume to weight) and incubated at 56oC until the gel slice was completely 
dissolved.  This process was aided by intermittent vortexing.  Seven hundred 
microliters of dissolved gel were added to an SV Mini column, incubated at 
room temperature for 1 minute and centrifuged.  The flow-through was 
discarded.  Further aliquots of dissolved gel from the same time-point were 
added to the column up to a total of 7 ml.  Having loaded all the dissolved gel 
onto the column, the membrane was washed with 700 μl Membrane Wash 
Solution and centrifuged.  The column was transferred to a clean collection tube 
and centrifuged to remove any residual ethanol.  The column was transferred a 
clean 1.5 ml microfuge tube and 50 μl nuclease free water was added directly to 
the membrane.  The column was incubated for 1 minute and centrifuged.  DNA 
concentration and purity were assessed by spectrophotometry using a 
Nanodrop 2000 and stored at 4oC prior to shipping for microarray analysis. 
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2.3.4 Transient RNA interference using siRNA 
2.3.4.1 Introductory principles 
The normal cellular RNA interference (RNAi) machinery comprises of short non-
coding RNA sequences, principally microRNAs in mammals, and effector 
proteins.  These effectors proteins include the endoribonucleases, Drosha and 
Dicer, which process microRNAs and load them into the RNA Induced Silencing 
Complex, RISC.  One of the two strands of a processed non-coding RNA is 
bound to the RNA binding domain and acts as a guide for RISC to bind target 
mRNA sequences and either degrade them or prevent translation, depending 
on the degree of complementarity.   
For the current experiments, synthesised siRNAs were delivered by 
electroporation of suspension cells.  This method offers efficient delivery with 
minimal toxicity to the cell lines studied.  siRNAs are taken up by the 
endogenous RNAi machinery which then degrades complementary mRNA, 
providing a mechanism for experimental post-transcriptional modulation of 
target genes. 
2.3.4.2 Electroporation 
Cells were counted and resuspended at 1 x 107 cells/ml.  The desired number 
of cells was transferred to an electroporation cuvette with a 4 mm electrode gap 
(Eurogentec or Peqlab).  The desired volume of siRNA was added, the cuvette 
gently shaken and then locked into the electroporator.  A square wave electrical 
impulse was delivered over 10 ms, ranging from 330 – 350 V.  The cuvette was 
incubated at ambient temperature for a minimum of 15 minutes before the cells 
were resuspended at 0.5 x 106/ml and transferred back to the incubator for on-
going culture.   
For serial electroporation experiments, cells were counted after 48-72 hours, 
aliquots taken for RNA isolation or analysis as described in 2.3.4.3 and 2.3.4.4, 
whilst the required number of cells was resuspended at 1 x 107 cells/ml and re-
electroporated as described above.  
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2.3.4.3 Analysis of cell proliferation 
To analyse cell proliferation, cells were counted prior to each electroporation.  
The total proliferation was then adjusted according to the number of cells 
carried forward to the subsequent electroporation, using the equation: 
 ( )           ( )  { ( )  (      )} 
Where: N(B) = Number of cells counted at time point B 
  N(A) = Number of cells counted at time point A (pre first  
   electroporation) 
  N(A elec) = Number of cells electroporated at time point A 
This same equation was applied to each time point to create a corrected 
running cell count, from which the kinetics of cell proliferation could be 
calculated. 
2.3.4.4 Analysis of cell cycle 
Cell cycle analysis was performed using propidium iodide staining of DNA.  This 
technique uses the variation of cellular DNA content during the cell cycle to 
attribute cells to: G0/G1 – diploid cells; S phase intermediate ploidy; G2 – 
tetraploid cells.  The degree of propidium iodide staining was assessed by flow 
cytometry and the data analysed using ModFit LT software. 
Between 2.5-5 x 105 cells were washed with 3 ml PBS, 300 x g, 4 minutes.  The 
supernatant was aspirated and the cells resuspended in 100 μl citrate buffer.  
To this, 400 μl DNA staining/lysis buffer and 1 μl RNase A were added and 
incubated at 4oC, in the dark, for a minimum of 30 minutes.  Cells were 
analysed using a FACS Calibur flow cytometer, with 20000 events recorded. 
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2.3.5 Gene expression analysis using quantitative reverse transcribed 
polymerase chain reaction 
2.3.5.1 Isolation of RNA – RNeasy method 
Isolation of mRNA was performed using the RNeasy kit from QIAGEN which 
binds RNA to a silica membrane.  This is followed by washing steps to remove 
protein and buffer constituents and subsequent elution of purified RNA.  For 
small samples, <5 x 105 cells, the RNeasy micro kit was used, see 2.3.5.2, as 
this allows elution into very small volumes, maximising RNA concentration.   
Between 0.5-5 x 106 cells were washed in PBS and lysed with 350 μl buffer 
RLT.  The lysate was loaded into a QIAshredder column and centrifuged 20000 
x g, 2 minutes.  Homogenised lysate was either stored at -20oC or used 
immediately.  One volume (350 μl) of 70% ethanol was added to the lysate, the 
sample loaded into an RNeasy spin column and centrifuged 10000 x g, 30 
seconds.  For isolation of cellular protein, the flow-through from this step was 
retained and made up to 2 ml with ice-cold acetone and stored at -20oC.  
Protein was isolated according to 2.3.6.1. The membrane was then washed in 
three steps: 700 μl buffer RW1, centrifugation 10000 x g, 30 seconds; 500 μl 
buffer RPE, centrifugation 10000 x g, 30 seconds; 500 μl buffer RPE, 
centrifugation 10000 x g, 2 minutes.  The column was then transferred to a 
fresh collection tube and centrifuged 20000 x g, 1 minute to remove residual 
ethanol.  The column was transferred to a fresh collection tube and the RNA 
eluted in 25 - 50 μl nuclease free water.  RNA purity and concentration were 
assessed by spectrophotometry using a Nanodrop 2000, following which the 
RNA was stored at -20oC. 
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2.3.5.2 Isolation of RNA – RNeasy micro method 
Less than 5 x 105 cells were resuspended in 350 μl buffer RLT Plus, loaded into 
a QIAshredder column and centrifuged 20000 x g, 2 minutes.  One volume (350 
μl) of 70% ethanol was added to the homogenised lysate, the sample loaded 
into an RNeasy micro column and centrifuged 10000 x g, 30 seconds.  The 
membrane was then washed in three steps: 700 μl buffer RW1, centrifugation 
10000 x g, 30 seconds; 500 μl buffer RPE, centrifugation 10000 x g, 30 
seconds; 500 μl 80% ethanol, centrifugation 10000 x g, 2 minutes.  The column 
was then transferred to a fresh collection tube and centrifuged with the lid open 
at 20000 x g, 5 minutes to remove residual ethanol.  The column was 
transferred to a fresh collection tube and the RNA eluted in 14 μl nuclease free 
water.  RNA purity and concentration were assessed by spectrophotometry 
using a Nanodrop 2000, following which the RNA was stored at -20oC.  
2.3.5.3 Isolation of small RNA – NucleoSpin method 
For analysis of shRNA expression an alternative method was required to isolate 
RNA fragments of less than 200 nucleotides.  The NucleoSpin kit again uses a 
similar principle of binding nucleic acids to a silica membrane with an additional 
on column DNA digest step to remove residual DNA.  Depletion of proteins and 
alteration of buffer conditions then allows binding of short RNA (18-200 
nucleotides) to the silica membrane.  Whilst the two RNA fractions (<200 and 
>200 nucleotides) can be isolated using separate columns, for the present 
study they were bound to the same membrane and eluted as a single fraction. 
Between 1-5 x 106 cells were washed once in PBS and lysed by addition of 300 
μl buffer ML.  Lysate was loaded into NucleoSpin Filter column and centrifuged 
11000 x g, 1 minute.  The lysate was either stored at -20oC until subsequent 
RNA isolation or used immediately. 
Room temperature lysate was mixed with 150 μl ethanol and vortex mixed for 5 
seconds.  The sample was incubated at room temperature for 5 minutes before 
being loaded into a NucleoSpin RNA column and centrifuged 14000 x g, 1 
minute.  The flow-through, containing protein and small RNA, was retained.  
The RNA column, with bound large RNA, was washed once with 350 μl buffer 
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MDB, 11000 x g, 1 minute.  An on column DNA digest was performed by 
addition of 150 μl recombinant RNase free DNase (provided with the kit), for 15 
minutes at room temperature. 
During the DNA digest step, the flow-through containing short RNA was cleared 
of protein by addition of 300 μl buffer MP and vortexing for 5 seconds.  The 
sample was loaded into a Nucleospin Protein Removal Column and 
centrifugation 11000 x g, 1 minute.  The binding conditions of the flow-through 
were adjusted by addition of 800 μl buffer MX and vortexing 5 seconds.  The 
sample was added in 600 μl aliquots to the RNA column containing bound long 
RNA and centrifugation 11000 x g, 30 seconds. 
The RNA column with bound long and short fragment RNA was washed in three 
steps: 600 μl buffer MW1, centrifugation 11000 x g, 30 seconds; 700 μl buffer 
MW2, 11000 x g, 30 seconds; 250 μl buffer MW2, centrifugation 11000 x g, 2 
minutes.  The column was transferred to a fresh collection tube and centrifuged 
11000 x g, 1 minute.  RNA was then eluted into a fresh collection tube in 30-50 
μl nuclease free water.  RNA purity and concentration were assessed by 
spectrophotometry using a Nanodrop 2000, following which the RNA was stored 
at -20oC. 
2.3.5.4 Preparation of cDNA from mRNA by reverse transcription 
RNA was reverse transcribed to produce cDNA using the RevertAid™H Minus 
First Strand cDNA Synthesis Kit.  Up to 1 µg RNA was added to each reaction 
along with 1 µl random hexamer primers and DEPC treated water to a total of 
12 µl.  This initial reaction was incubated at 70oC for 5 minutes to disrupt the 
secondary structure of the RNA.  After cooling to 4oC, 8 µl of master mix was 
added to each reaction as follows: 5x reaction buffer, 4 µl; 10 mM dNTPs, 2 µl; 
Ribolock RNase inhibitor, 1 µl; RevertAid H minus reverse transcriptase, 1 µl.  
The total 20 µl reaction was the reverse transcribed under the following 
conditions: 25oC, 10 minutes; 42oC, 60 minutes; 70oC, 10 minutes; held at 4oC.  
cDNA was diluted for use using 30 µl DEPC treated water. 
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2.3.5.5 Plating of RT PCR for mRNA quantitation 
Quantitative reverse transcribed polymerase chain reaction (qRT PCR) was 
performed in a 384 well format using an ABI Prism 7000 Sequence Detection 
System.  Each well was pipetted with 8 µl of PCR mastermix as follows: 5 µl 2x 
Platinum® SYBR® Green SuperMix UDG; 0.3 µl 10 µM primer mix; 2.7 µl 
sterilised deionised water.  One exception was the qRT PCR analysis of the 
MLL/AF4 fusion transcript in SEM cells for which the mastermix contained 0.1 µl 
5 µM primer mix; 2.9 µl sterilised deionised water.  This lower primer 
concentration was used to avoid the formation of primer dimers.  For each 
primer pair, 2 µl cDNA was pipetted into triplicate wells.  The plate was sealed 
with an adhesive cover and centrifuged 2000 x g, 30 seconds.  The reaction 
was performed as follows: 50oC, 2 minutes; 95oC, 10 minutes; 60oC, 15 
seconds; followed by 40 cycles of 95oC, 15 seconds; 60oC, 1 minute; followed 
by a single cycle of 95oC, 15 seconds; 60oC 15 seconds; 95oC 15 seconds.  
The completed plate was either discarded or stored at -20oC prior to analysis of 
the product by gel electrophoresis or TA cloning, see 2.3.8. 
2.3.5.6 Preparation of cDNA from shRNA by reverse transcription 
cDNA for analysis of shRNA expression was reverse transcribed using miScript 
reverse transcription kit.  This kit uses a mixture of poly(A) polymerase and a 
reverse transcriptase so that miRNAs, which are not polyadenylated, are both 
polyadenylated and reverse transcribed in parallel.  Reverse transcription can 
then by primed by oligo-dT primers which also have a universal tag sequence 
which allows binding of a universal primer during the PCR step, see 2.3.5.7.   
Each reaction contained 4 µl reaction buffer (5x), 1 µl reverse transcriptase mix, 
1 µg RNA and DEPC treated water to a total volume of 20 µl.  The reaction was 
incubated at 37oC for 60 minutes followed by 95oC for 5 minutes.  The reaction 
was made up to 50 µl with DEPC treated water and stored at -20oC prior to qRT 
PCR. 
2.3.5.7 Plating of qRT PCR for shRNA quantitation 
qRT PCR for analysis of shRNA expression was performed in a 384 well format 
using an ABI Prism 7000 Sequence Detection System.  Each well was pipetted 
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with 8 µl of PCR mastermix as follows: 5 µl 2x QuantiTect SYBR Green PCR 
mastermix; 1 µl miScript Universal primer (10x); 0.3 µl specific primer (10 µM), 
see 2.2.5.2; 1.7 µl sterilised deionised water.  cDNA produced according to 
2.3.5.6 was diluted further 1:10.  For each primer pair 2 µl of cDNA was pipetted 
into triplicate wells.  The plate was sealed with an adhesive cover and 
centrifuged 2000 x g, 30 seconds.  The reaction was performed as follows: 
95oC, 15 minutes; followed by 40 cycles of: 94oC, 15 seconds; 55oC, 30 
seconds. 
2.3.5.8 Analysis of data 
qRT PCR data was analysed using SDS 2.0 software to produce the cycle 
threshold (Ct) value for each replicate.  The mean Ct value was calculated for 
each set of triplicates, with an acceptable standard deviation of 0.3 cycles.  A 
ΔCt value was generated by subtracting the Ct of the reference gene (Ref), 
commonly GAPDH, from the Ct of the gene of interest (GOI) to provide an 
internally controlled value for gene expression.  This ΔCt value could then be 
compared between control and experimental samples to provide a comparison 
of the level of expression of the gene of interest expressed as the number of 
PCR cycles, the ΔΔCt. 
    (           ) 
     (                        ) 
A ratio of the expression of the gene of interest in the experimental sample 
compared to the control sample was derived as follows, assuming that each 
cycle of the reaction resulted in a doubling of the DNA content of the well: 
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2.3.6 Western immunoblotting 
2.3.6.1 Isolation of cellular protein 
Protein was precipitated by addition of at least two volumes of acetone at -20oC 
to the flow through recovered from RNA isolation as detailed in 2.3.5.1 and 
2.3.5.2.  Precipitate was centrifuged at 16000 x g, 4oC for 15 minutes.  Acetone 
was aspirated and the precipitate centrifuged further for 1 minute to allow 
removal of residual acetone.  The protein pellet was air dried for 5-10 minutes 
before being resuspended in 30 µl of 9 M urea buffer.  Protein suspensions 
were stored at -20oC for quantification and Western Blot analysis. 
2.3.6.2 Polyacrylamide gel electrophoresis 
Polyacrylamide gels were cast with a thin stacking gel poured on top of a 8% 
separating gel, as follows.  Separating gel buffer was diluted to 1x with 
deionised water and acrylamide-bis-acrylamide, final concentration 8% w/v.  
This was thoroughly mixed.  To this were added 0.1% w/v ammonium 
persulphate and 0.01% w/v TEMED and the gel poured into a 0.75 mm casting 
chamber (BioRad).  Two hundred microliters isopropanol was pipetted onto the 
surface of the separating gel to give a uniform surface against which to pour the 
stacking gel. 
Once the separating gel was set, the isopropanol was poured off and the 4x 
stacking gel buffer was diluted with deionised water and acrylamide-bis-
acrylamide, final concentration 4% w/v.  After mixing, 0.1% w/v ammonium 
persulphate and 0.01% w/v TEMED were added and the gel poured onto the 
separating gel. 
Gels were loaded into an electrophoresis tank which was filled with 
electrophoresis buffer.  Either marker or a protein sample, 10 µg, was loaded 
into each well.  Electrophoresis was performed at 50 V until the samples had 
passed into the separating gel.  The voltage was then increased to 150 V and 
the sample run until sufficient separation of the marker bands was achieved. 
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2.3.6.3 Blotting procedure 
Protein samples were transferred from the electrophoresis gel onto a PVDF 
membrane as follows.  The membrane was wetted in methanol and then placed 
into transfer buffer (10% v/v methanol).  The separating gel was placed against 
the membrane and clamped in a transfer cassette with filter paper and sponges 
to ensure close apposition.  The assembly was performed in transfer buffer to 
minimise the risk of air bubbles being trapped between gel and membrane. 
The transfer cassette was placed in a transfer chamber in transfer buffer with an 
ice block to minimise heating of the buffer.  The transfer was performed at 150 
V for 1 hour. 
2.3.6.4 Immunolabelling 
Following transfer, the membrane was cut along the 70 kDa markers.  The 
membrane with proteins greater than 70 kDa was then cut to allow labelling with 
different primary antibody concentrations.  All sections of the membrane were 
incubated in 5-10% w/v milk in TST for 1 hour to block non-specific protein 
binding sites.  The membrane sections were then incubated in primary 
antibodies diluted in 5-10% milk in TST as detailed in 2.2.8.2, 4oC, overnight, 
with the lower, <70 kDa, membrane being labelled with anti GAPDH antibody. 
Following overnight incubation, membranes were washed three times in TST for 
5-10 minutes.  Washed membranes were then incubated in secondary 
antibodies, detailed in 2.2.8.3, diluted in 5-10% milk in TST, at room 
temperature for 1 hour.  Membranes were again washed three times in TST for 
5-10 minutes. 
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2.3.6.5 Membrane development 
Development of horseradish peroxidase conjugated secondary antibodies was 
performed using SuperSignal West Dura chemiluminescence substrate kit.  This 
kit contains two components, a peroxidase solution and a luminol solution.  
These were mixed 1:1 and pipetted onto a smoothed piece of clingfilm.  Blots 
were placed protein side down onto the mixture and incubated at room 
temperature for 5 minutes, except for GAPDH which was incubated for 1 
minute.  Excess solution was blotted away at the end of the incubation and the 
membrane wrapped in clingfilm and taped into a film cassette. 
The membranes were then exposed to x-ray film in a dark room for between 1 
second and 30 minutes.  The x-ray film was processed using a Mediphot937 
developer. 
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2.3.7 General cloning techniques 
2.3.7.1 Production of competent bacteria 
Competent cells were produced using a magnesium chloride/calcium chloride 
method(Sambrook and Russel 2001).  Non-competent E.coli, strain JM109 
(Promega), were subcultured in 4 ml Luria Bertani (LB) medium overnight, 
37oC.  Four millilitres of the overnight culture was inoculated into 400 ml LB 
medium, which was incubated with regular measurements made of the optical 
density using a SmartSpec™ Plus spectrophotometer (BioRad).  When the 
OD600 reached 0.4, cells were split into eight, 50 ml polypropylene tubes and 
cooled on ice for 10 minutes.  The cultures were centrifuged at 2700 x g, 10 
minutes, 4oC and the supernatant removed.  Each cell pellet was resuspended 
by swirling with 30 ml MgCl-CaCl solution, 4oC, before being centrifuged as 
above.  Each cell pellet was resuspended in 2 ml CaCl solution at 4oC, following 
which all eight suspensions were pooled.  Five hundred and sixty microlitres of 
dimethyl sulfoxide (DMSO) was added to the 16 ml of suspension, which was 
incubated on ice for 15 minutes.  A further 560 µl of DMSO was added and 100 
µl aliquoted into pre chilled polypropylene tubes.  Cells were stored at -80oC. 
2.3.7.2 Transformation of competent bacteria 
Competent E. coli were thawed on ice.  Twenty five to fifty microliters of thawed 
bacteria were transferred to polypropylene tubes containing 1 µl (1-3 µg) of 
plasmid and incubated on ice for 30 minutes.  Cells were then heat shocked in a 
water bath at 42oC for 45 seconds before being returned to ice for 2 minutes.  
Each culture received 850 µl SOC medium and was then incubated at 37oC on 
a horizontal rotator shaker for 1 hour. 
Following incubation, cells were plated out at different concentrations onto 1.5% 
w/v LB/agar culture plates containing the appropriate selection antibiotic.  Cell 
suspensions were allowed to absorb into the agar before the plates were placed 
in an incubator at 37oC for overnight culture. 
Following overnight culture, individual colonies were picked using a pipette tip, 
and transferred to a sterile universal container containing 5 ml of LB medium 
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supplemented with selective antibiotic.  This culture was again incubated 
overnight at 37oC in a rotatory shaker at 180 rpm.  Plasmid DNA was isolated 
using the Miniprep technique described in 2.3.7.3 and analysed by restriction 
digestion. 
2.3.7.3 Plasmid purification – Qiagen Miniprep 
The QIAprep miniprep kit, Qiagen, was used for the isolation of small quantities 
of plasmid DNA for analysis or to take forward to further cloning steps.  This kit 
uses a modified alkaline lysis protocol followed by binding of DNA to a silica 
membrane under low salt and pH conditions.  Centrifuge wash steps remove 
endonucleases (buffer PB) and salts (buffer PE).  DNA is then eluted in a small 
volume of buffer EB. 
 A culture of 5 ml LB medium with appropriate selection antibiotic was 
inoculated with a scraping from a glycerol stock or with 100 μl from a previous 
culture.  This pre-culture was incubated overnight in a rotatory shaker at 37oC. 
Two millilitres of culture was centrifuged at 8000 x g, 2 minutes and the 
supernatant discarded.  The pellet was resuspended in 250 μl buffer P1 
supplemented with 100 μg/ml and Lyse Blue 0.1% v/v.  Cell lysis was performed 
by addition of 250 μl buffer P2 followed by vigorous mixing and incubation at 
room temperature for 5 minutes.  The lysis step was terminated by addition of 
350 μl buffer N3 and immediate vigorous mixing.  The resultant precipitate was 
centrifuged out at 18000 x g, 10 minutes.  The supernatant was then transferred 
to a QIAprep spin column and centrifuged at 18000 x g, 1 minute.  The flow-
through was discarded.  The spin column was then washed with 500 μl buffer 
PB followed 750 μl buffer PE, being centrifuged at 18000 x g, 1 minute for each 
wash.  The spin column was centrifuged at 18000 x g, 1 minute to dry the 
membrane.  DNA was eluted by addition of 30-50 μl buffer EB or nuclease free 
water to the membrane, incubation for 1 minute and subsequent centrifugation 
at 18000 x g, 1 minute.  DNA concentration and purity were assessed by 
spectrophotometry using a Nanodrop 2000, following which the plasmid was 
stored at 4oC. 
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2.3.7.4 Plasmid purification – Qiagen Maxiprep 
The Endofree Plasmid Maxiprep kit, Qiagen, was used for the large scale 
purification of plasmids.  This kit uses a modified alkaline lysis protocol, followed 
by removal of endotoxin and subsequent binding of supercoiled DNA to Qiagen 
Anion-Exchange Resin in the Qiagen-tip 500, under low salt and pH conditions.  
After wash steps, the purified DNA is eluted in a high salt buffer and then 
precipitated using isopropanol. 
A pre-culture of 5 ml LB medium with appropriate selection antibiotic was 
inoculated with a scraping from a glycerol stock or with 100 μl from a previous 
culture used for Plasmid Miniprep and analytical restriction digest.  This pre-
culture was incubated overnight in a rotatory shaker at 37oC.  The following day, 
4 ml of the pre-culture was inoculated into 400 ml of LB medium with 
appropriate selection antibiotic and cultured overnight in a rotatory shaker at 
37oC. 
The bacterial culture was centrifuged at 6000 x g, 15 minutes, 4oC.  The 
bacterial pellet was resuspended in 10 ml buffer P1 supplemented with RNase 
100 μg/ml and Lyse Blue 0.1% v/v to demonstrate homogeneous mixing.  Cell 
lysis was performed by addition of 10 ml buffer P2 followed by vigorous mixing 
and incubation at room temperature for 5 minutes.  The lysis step was 
terminated by addition of 10 ml buffer P3 at 4oC and vigorous mixing.  The 
resultant lysate was immediately poured into the QIAfilter cartridge and 
incubated at room temperature for 10 minutes to allow the precipitate, 
containing proteins, genomic DNA and detergent to rise to the top.  The lysate 
was then eluted from the cartridge into a fresh 50 ml container.  Endotoxin was 
removed by addition of 2.5 ml buffer ER, mixing and incubation on ice for 30 
minutes. 
The Qiagen-tip 500 was equilibrated by applying 10 ml buffer QBT.  The filtered 
lysate was then applied and allowed to pass through by gravity flow.  The 
Qiagen-tip 500 was washed by two additions of 30 ml buffer QC.  Plasmid DNA 
was eluted with 15 ml buffer QN and precipitated by addition of 10.5 ml (0.7 
volumes) of room-temperature isopropanol.  The precipitated DNA was 
centrifuged at 15000 x g, 4oC, 30 minutes.  The supernatant was carefully 
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decanted leaving the pellet intact.  The pellet was washed with 5 ml 70% 
ethanol in endotoxin-free water and centrifuged 15000 x g, 4oC, 10 minutes.  
The supernatant was again carefully decanted leaving the pellet intact.  The 
pellet was air dried and then dissolved in 100-200 μl buffer TE.  DNA 
concentration and purity were assessed by spectrophotometry using a 
Nanodrop 2000, following which the plasmid was stored at 4oC. 
2.3.7.5 Plasmid analysis by restriction enzyme digestion and gel 
electrophoresis 
Restriction enzyme digests were performed to validate the identity of isolated 
plasmids.  Plasmid DNA was digested with a combination of enzymes chosen to 
provide fragments of known length, which could then be resolved by gel 
electrophoresis.  One microgram of plasmid DNA was digested with enzyme 
and the appropriate buffer (Fermentas) made up to 20 µl with sterilised 
deionised water.  Digestion was performed at 37oC for 1 hour and terminated 
either by thermal denaturation or addition of 1 μl 0.5 M EDTA.  Details of more 
complex digestions are provided in the individual methods sections. 
Digestion products were resolved using TBE or TAE/agarose gels containing 
GelRed 0.01% v/v (VWR International), or stained using 2 ng/ml ethidium 
bromide.  Gels were imaged using a GelDoc imager (BioRad). 
2.3.7.6 Storage of plasmids as glycerol stocks 
Bacterial cultures grown for plasmid isolation were frozen to allow initiation of 
future cultures.  Aliquots of 700 μl of bacterial cultures were transferred to sterile 
1.7 ml microtubes.  Sterile glycerol, 300 μl, was added to each tube and mixed 
by inversion.  These stocks were stored at -80oC. 
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2.3.8 TA cloning of PCR products 
2.3.8.1 Introduction 
Sequencing of quantitative RT PCR products was used to confirm their 
specificity.  Amplicons were TA cloned into the pGEM-T Easy vector (Promega).  
This approach uses the template independent addition of a 3’ deoxyadenosine 
by DNA polymerase as part of the PCR reaction, pairing it with 3’ terminal 
thymidine bases found at each end of the linearised vector. 
Using the pGEM-T Easy vector system, colonies can be screened for 
successful ligation by Blue-White screening.  The vector contains the β-
Galactosidase gene (LacZ) which metabolises X-Gal to give a blue colour.  
Successful ligation of PCR products normally disrupts the reading frame of the 
LacZ, resulting in white colonies.  Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
binds to the Lac repressor allowing transcription of the gene. 
2.3.8.2 Ligation into the pGEM-T Easy vector 
PCR products from quantitative RT PCR for PIWI-Like transcripts were purified 
as described in 2.3.3.2.  Ligation reactions were pipetted as described in Table 
2-3, using 1:1-1:3 insert:vector ratios and incubated at 4oC, overnight.   
Ligation reactions (2 µl) were transformed into competent JM109 cells 
according to 2.3.7.2.  Culture plates containing 100 µg/ml ampicillin were 
prepared for Blue-White screening by spreading 50 µl IPTG, 200mM, on each 
plate and incubating at room temperature for 15 minutes.  Each plate was then 
spread with 20 µl X-Gal and incubated at 37oC for 2 hours.  Transformed 
bacteria were then spread onto the culture plates and incubated at 37oC 
overnight. 
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The following day, white colonies were picked and cultured overnight in 6 ml LB 
medium containing 100 µg/ml ampicillin.  Plasmid DNA was extracted as 
described in 2.3.7.3.  Plasmids were analysed by control restriction digest using 
EcoRI and a second appropriate enzyme, as described in 2.3.7.5.  Clones with 
appropriate restriction patterns were sent for commercial sequencing, DBS 
Genomics (Durham University), using the M13 forward primer. 
Table 2-3.  Reaction mixture for ligation of qRT PCR amplicons and pGEM-T Easy vector 
Reagent Volume 
Amplicon DNA --- 
Linearised vector (50 ng/µl) 1 µl 
T4 DNA ligase (3 Weiss units/µl) 1 µl 
T4 ligase buffer (2x) 5 µl 
Sterilised deionised water --- 
Total volume 10 µl 
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2.3.9 Lentiviral vectors 
2.3.9.1 Introduction 
The use of recombinant lentiviral vector particles allows for the transduction of 
mammalian cells.  Unlike other retroviridae, which gain access to the host 
genome only following nuclear membrane breakdown during nuclear division, 
lentiviridae express a membrane associated matrix protein which is recognised 
by mammalian nuclear import proteins and results in active transport of the pre-
integration complex into the host nucleus.  Once in the host nucleus, reverse 
transcribed double stranded DNA is integrated into the host genome by the viral 
protein integrase.  These characteristics make lentiviral vectors suitable for 
transduction of slowly, or non-, dividing cells such as patient derived leukaemia 
blasts and stem cells. 
The lentiviral genome has been separated to place genes necessary for viral 
packaging (packaging vector, e.g. pCMV8.91), production of envelope proteins 
(envelope vector, e.g. pMD2.G – coding for vesiculo stomatitis virus G protein, 
VSV-G) and the gene of interest (lentiviral vector/transfer vector, e.g. pSLIEW) 
onto three separate plasmids (Appendix B).   Separation of these three critical 
components of the lentiviral genome, combined with deletion of many auxillary 
but non-essential viral genes such as vpr, vpu, nef and vif, provides a level of 
biosecurity.  The transfer vector is the only vector to contain the encapsidation 
signal, ψ, required for packaging of viral RNA within the viral particle.  
Consequently, the transfer vector is the only genetic material contained within 
the virus and subsequently transferred to the target cell.  Further security has 
been afforded by the production of self-inactivating (SIN) viruses, in which there 
is a deletion of a critical 133 base pair region in the 3’ long terminal repeat 
sequence (LTR).  Following reverse transcription, this deletion is transferred to 
the 5’ LTR, removing transcriptional capacity from the resultant provirus.  
As a consequence of these engineered security features, viral particles must be 
produced in a producer cell line.  Expression of viral genes from each of the 
three plasmids results in production of proteins able to package a complete 
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virus particle.  The use of the VSV-G pseudotype results in the ability to infect a 
broad range of mammalian cells. 
Lentiviral plasmids were transformed, isolated and their identity confirmed using 
the procedures detailed in 2.3.6.  Virus production and subsequent transduction 
of mammalian cells are detailed below. 
Lentivirus production was performed using the transformed human embryonic 
renal cell line 293T.  It represents a highly transfectable and rapidly growing cell 
line which produces large yields of recombinant lentivirus.  Co-transfection of 
lentiviral plasmids was performed by calcium phosphate precipitation of DNA.  
293T cells avidly take up calcium phosphate crystals, and therefore the 
associated plasmid DNA.  Transcription of the viral genome results in 
production of viable but replication incompetent virus, which is released into the 
culture supernatant, from where it can be harvested. 
2.3.9.2 Co-transfection of 293T cells by calcium phosphate precipitation  
293T cells were passaged at sub-confluence prior to transduction.  On the day 
prior to transduction, cells were plated at 2-3 x 106 cells per 100 mm culture 
dish to provide a monolayer with 30-40% confluence on the day of transfection.  
On the day of transfection, 0.5 M CaCl solution, 2x HeBS and 2.5 mM HEPES, 
pH 7.3 were brought to room temperature.  Lentiviral plasmids were mixed in a 
sterile, endotoxin free microtube (1.7ml): pMD2.G envelope plasmid - 5 µg; 
pCMVΔ8.91 packaging plasmid - 15 µg; pSLIEW transfer plasmid - 20 µg.  The 
volume of the plasmid mixture was adjusted to 250 µl with 2.5 mM HEPES, pH 
7.3.  To this, 250 µl 0.5 M CaCl solution was added and mixed.  The 
plasmid/CaCl solution was then added drop wise to the 2x HeBS, whilst 
bubbling air through the 2x HeBS to ensure even mixing and avoid uneven 
calcium phosphate precipitation.  The mixture was incubated at room 
temperature for 30-35 minutes before being added drop wise to 293T cells.  The 
culture dish was gently shaken, not swirled, to evenly distribute the calcium 
phosphate/DNA precipitates. 
On the morning following transfection, the medium was aspirated from the 
culture dish, cells were washed once with PBS, 37oC, and 10 ml fresh medium 
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replaced.  Cells were cultured for a further 48-96 hours prior to harvesting the 
viral supernatant. 
2.3.9.3 Viral harvesting and concentration by ultracentrifugation 
On day 3-4 following transfection, the medium was aspirated from the 293T 
cells and centrifuged at 300 x g, 10 minutes to pellet cellular debris.  The 
supernatant was then filtered using a low protein binding PVDF 0.45 µm filter 
(Millipore).  If a second harvest was required, then 8-10 ml fresh Dulbecco’s 
MEM medium was put onto the cells and harvested, as above, 24 hours later. 
Viral particles were concentrated by ultracentrifugation using a Beckman 
Optima ultracentrifuge.  Disposable conical centrifuge inserts were sterilised 
with 70% ethanol and air dried in a laminar flow hood.  Viral supernatant was 
transferred to the conical inserts.  Medium was added to bring the supernatant 
to within 10 mm of the top of the insert to prevent it collapsing under vacuum 
and to balance the centrifuge bucket to within 0.2 g of its paired bucket.  The 
ultracentrifugation step was performed 120000 x g, 4oC, 2 hours, with a 
constant vacuum applied by the centrifuge. 
Following ultracentrifugation, supernatant was carefully decanted from the 
insert.  Viral particles were then resuspended in 50 - 1000 μl of the desired 
medium, aliquoted and stored at -80oC. 
2.3.9.4 Titration of lentivirus particles 
Frozen lentivirus particle were titrated using the t(4;11)(q21;q23) B precursor 
cell line SEM and the standard spinfection protocol, see 2.3.9.5.  Lentiviral 
concentrate was added to wells at 0.5 μl – 25 μl.  The expression of EGFP was 
analysed by flow cytometry (FACS Calibur) on day 4 post transduction, as 
described in 2.3.9.6.  Lentiviral concentration was calculated using the two 
following methods. 
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For accurate calculation of titre when aiming for low multiplicity of infection, the 
volume of inoculum which produced 20 – 30% transduction was applied to the 
following formula: 
      (     )   {  (    )}    
where: F is the frequency of EGFP positive cells; Co is the total number of 
target cells infected; V is the volume of the inoculum; D is the dilution factor of 
the inoculum. 
As the rate of transduction was not linearly associated with the volume of the 
inoculum, an alternative method was used when estimating viral titres required 
for higher rates of transduction.  In this instance the percentage of transduced 
cells was plotted against volume of the inoculum and a logarithmic curve fitted 
using Excel 2010 (Microsoft).  The volume required to produce the desired 
percentage of transduction was calculated using the formula: 
                  {(   )  } 
where y is the desired proportion of transduced cells and a and b are functions 
of the equation describing the curve,       ( )  . 
2.3.9.5 Lentiviral transduction of target cells 
Transduction of suspension culture cells by lentivirus was performed using a 
spinfection technique.  This involves adding lentivirus to suspended cells and 
then centrifuging the suspension, frequently in the presence of the cationic 
polymer polybrene, to bring cells and virus into proximity on the surface of the 
plate.  Whilst the centrifuge speeds used are substantially slower than the 
ultracentrifugation step detailed in 2.3.9.3, the viral particles retain fragments of 
cell membrane from the producer cell line, 293T.  This results in viral particles 
being brought down to the surface of the plate at comparatively low centrifuge 
speeds.  Following spinfection, a period of culture allows transduced cells to 
express the transfer vector before transduction efficiency is assessed using a 
reporter gene, e.g. green fluorescent protein (GFP), or selective culture 
conditions are applied, e.g. puromycin selection. 
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Target cells were resuspended at either 1 x 106/ml or 2.5 x 106/ml, either in 
complete medium or Optimem serum free medium (Gibco/Invitrogen).  
Suspensions of patient-derived blasts were augmented with additional growth 
factors.  Standard spinfection conditions also required augmentation with 
polybrene 8 μg/ml, although this was reduced to 4 μg/ml in some experiments 
or replaced with protamine 5 μg/ml. 
Cells were plated into a 48 well plate with 0.5 x 106 cells per well.  Virus 
concentrate was added to the cells before plates were balanced and wrapped in 
Parafilm (Pechiney Plastic Packaging Co).  Spinfection was initially performed 
at 1500 x g, 32oC, 2 hours.  Later spinfections were performed at 900 x g, 34oC, 
50 minutes. A modification was made for spinfection of larger numbers of cells.  
For transduction of 5 x 106 cells, suspended in 2 ml in 6 well plates, an initial 
spin at 50 x g for 20 minutes settled cells on to the bottom of the plate before 
increasing the speed for the spinfection. 
Following spinfection, Parafilm was removed and cells were incubated either for 
6-8 hours or overnight.  Following overnight incubation, medium containing 
polybrene and virus was either replaced with fresh complete medium, or diluted 
with fresh complete medium in the case of very concentrated spinfections.  
Cells were transferred to larger wells for on-going incubation which allowed 
expression of transduced genes prior to analysis or selection. 
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2.3.9.6 Assessment of transduction efficiency by flow cytometry 
Transduction efficiency was assessed by measuring expression of a reporter 
gene encoded by the transfer vector.  In the case of pSLIEW this was enhanced 
green fluorescent protein (EGFP), whilst for pGIPZ it was turbo GFP (tGFP).  A 
non-transduced population was used to control for auto-fluorescence. 
Cells were resuspended and a small aliquot transferred to a FACS tube.  
Samples were analysed using a FACS Calibur (BD Biosciences) fitted with a 
488 nm laser and 530/30 nm filter.  Dead cells and debris were gated out using 
forward and side scatter profiles.  A threshold was set using a non-transduced 
population, so that 99.7% of non-transduced cells were below that threshold.  
Positive cells were defined as those cells in the transduced population which 
had a signal greater than the threshold. 
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2.3.10 Decode library screening methodologies 
2.3.10.1 Introduction 
To perform an unbiased functional screen for genes involved in the self-renewal 
of leukaemic cells, a genome-wide short hairpin RNA (shRNA) library, produced 
commercially by Open Biosystems, was used.  The transfer vector used in this 
library is the pGIPZ construct, which encodes a Turbo GFP (tGFP) reporter, 
shRNA construct and puromycin N-acetyl-transferase gene, PAC. 
2.3.10.2 Determining the puromycin sensitivity of experimental cell lines 
Puromycin is an antibiotic which inhibits protein synthesis and is toxic to a broad 
range of both prokaryotic and eukaryotic cells.  As such it can be used to 
positively select mammalian cells expressing the PAC gene, which is encoded 
by the pGIPZ vector. 
The minimum concentration of puromycin required was determined by WST-1 
assay, which relies on the metabolism of the tetrazolium salt of WST-1 to 
formazan by mitochondrial dehydrogenases.  The formazan dye produced by 
viable cells can be quantitated by colorimetry at 440 nm, providing an estimate 
of cell viability and therefore the cellular toxicity of puromycin. 
Candidate cell lines were seeded into 96 well plates at 5 x 104 cells/well and 
cultured overnight in the presence of increasing concentrations of puromycin, 
0.1-2 µg/ml.  After 6 days of culture, 10 μl WST1 reagent was added to each 
well and the cells incubated at 37oC.  Colorimetric measurements were made 
using a Model 680 microplate reader at 1, 2 and 4 hours during the incubation 
period. 
2.3.10.3 Transduction of cell lines with pGIPZ pools 
Multiple test transductions were performed to optimise transduction conditions 
as well as to determine the relative transduction efficiency of the experimental 
cell lines.  Initially, the functional titre of control virus (provided with the library) 
in each tested cell line was calculated as described for viral titration in 2.3.9.4.  
The functional titre was then used to calculate the relative transduction 
Chapter 2:  Materials & methods 
97 
 
efficiency (RTE) by comparison to the functional titre of the control virus stock in 
HEK293T cells (as determined by Open Biosystems), as follows: 
    
                             
                           
 
The RTE then allows an estimation of the functional viral titre in each of the 
seven experimental pools in the given cell line. 
Knowing the functional viral titre in the cell line to be tested allows the 
calculation of the volume of virus required to produce the desired rate of 
transduction in a given number of cells.  In order to minimise the number of cells 
receiving multiple viral integrations, the proportion of cells to be transduced 
should be 0.3.  This is termed the multiplicity of infection (MOI) and, at 0.3, is 
predicted to result in just 3% of cells receiving more than one integration. 
     {  }  
(                                            {     })
    
 
The number of cells to be transduced should be sufficient to provide 100 fold 
coverage of the pool, that is, each hairpin construct should be integrated into at 
least 100 cells.  This is calculated as follows: 
  
   (   )
   (   )
 
 
 
 
N is the required number of transduced cells; p the desired probability of 
representation - 0.95; and f the fractional proportion of a single shRNA in the 
library, i.e. the reciprocal of the complexity of 10,000 per pool. T represents the 
fraction of transfected cells and equals approximately the MOI. C is the 
coverage of each single shRNA, which should be 100-fold for a negative 
selection. The desired cell number, N, is therefore 1 x 107 cells per spinfection. 
Transduction of cell lines using pools of non-silencing control virus particles was 
carried out according to the standard spinfection protocol detailed in 2.3.9.5, 
with modifications to the medium designed to optimise transduction efficiency. 
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2.3.10.4 Puromycin selection and cell sampling 
Having assessed the transduction efficiency by flow cytometry on day 4 
following transduction, see 2.3.9.6, transduced cells were selected by the 
addition of 0.4-0.8 μg/ml puromycin to the culture medium.  The proportion of 
cells expressing tGFP was monitored by flow cytometry, see 2.3.9.6.   
During the test experiments with the single lentiviral pool, pool 7, low 
transduction (7.5 – 15%) on day 4 raised concerns about the proportion of 
transduced cells harvested for the baseline sample.  Cells were therefore 
cultured overnight in 1 μg/ml puromycin, followed by density gradient 
centrifugation, see 2.3.2.3, and harvesting of cells for DNA extraction.  
2.3.10.5 Seeding of transduced cells onto M2-10B4 feeder cells 
Following a period of selection in puromycin containing medium, pGIPZ 
transduced cells were seeded out onto irradiated M2-10B4-PAC cells.  To 
maintain the 5 x 106 cell coverage, ten plates/flasks of feeder cells each 
received 50 ml RPMI medium, 1% v/v FCS, 0.4 – 0.8 μg/ml puromycin and 5 x 
105 cells.  This equated to 1 x 104 cells/ml, or approximately 3 x 104 cells/cm2. 
Following a period of co-culture, when pGIPZ transduced cells had expanded 
sufficiently (aiming for 3 doublings), the medium was aspirated and saved.  The 
plates/flasks were washed once with 10ml PBS and the wash fraction saved.  
The adherent cells were then trypsinised, see 2.3.1.4.  Trypsinised cells were 
resuspended in complete medium and pooled.  All fractions were centrifuged, 
300 x g, 10 minutes, the cells resuspended in complete medium, counted and 
pooled.  An aliquot was taken for analysis by flow cytometry and, following the 
first plating, 5 x 106 cells were reseeded onto fresh irradiated M2-10B4-PAC 
cells, as above.  The remaining cells were then divided: 1-2 x 107 cells were 
taken for MACS microbead sorting, using CD133 to isolate leukaemic cells from 
feeders, whilst any remaining cells were frozen viable as back-up. 
Cells harvested for DNA extraction were positively selected using MACS CD133 
microbead kit, as described in 2.3.2.5.  Selected cells were stored as pellets of 
5 x 106 cells at -20oC for DNA extraction according to 2.3.3.1. 
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2.3.10.6 Amplification and purification of barcode regions 
pGIPZ transduced cells which had been harvested during the test experiments 
with pool 7 and stored as pellets, had their DNA extracted according to 2.3.3.1.  
The barcode region, unique to each shRNAmir30 construct, was then amplified 
by PCR and purified by gel electrophoresis.  The resultant amplicons were then 
deconvoluted by co-hybridisation of baseline and experimental samples to a 
2x105K Agilent array provided with the Decode library. 
The PCR was performed according to the Decode library manual, as follows.  A 
minimum of 4 reactions was carried out per time-point sample to ensure 
sufficient coverage.  Reactions were pipetted to a total volume of 100 μl, see 
Table 2-4.  A positive control used 1 ng of plasmid DNA, containing a barcode 
region, supplied with the library.  A negative control contained no template DNA.  
The reactions were performed using a GeneAmp PCR System 9700, 
programmes according to Table 2-5. 
Table 2-4.  Reagents for PCR amplification of Decode barcode regions 
 Volume 
(μl) 
Final 
concentration 
5 M Betaine 10 0.5M 
10x KOD hotstart polymerase buffer 10 1x 
dNTP’s (2 mM each) 10 0.2 mM (each) 
MgSO4 (25 mM) 4 1 mM 
Forward primer (5 pmol/μl) 6 0.3 μM 
Reverse primer (5 pmol/μl) 6 0.3 μM 
KOD hotstart polymerase (1 U/μl) 2 0.02 U/μl 
Template DNA – 850 ng --- --- 
Nuclease free water --- --- 
Total volume 100 μl  
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Table 2-5. Reaction conditions for PCR amplification of Decode barcode regions 
 Temperature Time Cycles 
Hot start enzyme 
activation 
94oC 3 minutes 1 
Melt 94oC 35 seconds 
30 Anneal 62oC 35 seconds 
Extension 72oC 1 minute 
The PCR reactions were then purified by electrophoresis on a 1.25% w/v 
TBE/agarose gel.  The band at approximately 250 bp was visualised using 
Chromato-Vue UV trans-illuminator, excised and extracted according to 2.3.3.4.  
Purified DNA was quantitated by spectrophotometry and sent to the Functional 
Genomics and Proteomics Facility, University of Birmingham, for commercial 
labelling, hybridisation and scanning, according to the Open Biosystems 
Decode manual. 
2.3.10.7 Analysis of data from genome-wide RNAi screen 
Data from the genome-wide screen were analysed commercially through the 
University of Birmingham using a customised version of "Agi4x44PreProcess" in 
R (R version 2.15.0).  The principle steps involved subtraction of background 
signal, removal of control probes and summarisation of the multiple probes 
present for each construct (generation of the median value).  Normalisation was 
performed using “Normalize the columns of a matrix to have the same 
quantiles, allowing for missing values”.  Constructs whose probes had a median 
fold change of >2.5 were compared between different arrays (representing 
different time point comparisons in the trial screen).  
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2.3.11 Transduction of patient-derived material with lentiviral particles 
2.3.11.1 Transduction setup and spinfection 
Aliquots of patient-derived peripheral blood or bone marrow blasts were 
retrieved from liquid nitrogen either on the day of, or the day prior to spinfection, 
thawed and counted with Trypan Blue to assess viability as described in 2.3.1.  
Cells were centrifuged at 300 x g, 5 mins and resuspended at 1 x 106 cells/ml in 
either αMEM supplemented with 10% v/v FCS, 10% v/v horse serum, 10% v/v 
HS-5 conditioned medium, see 2.3.1.5, or in serum free expansion medium 
(SFEM) supplemented with 10% v/v FCS.  Five hundred microliters (5 x 105 
cells) were pipetted into wells of a 48 well culture plate and supplemented with 
the appropriate polybrene or protamine.  For some experiments additional 
cytokines were added to specific wells to assess their effect on transduction and 
cell survival.  These included stem cell factor, 50 ng/ml, interleukin 7 (IL-7), 10 
ng/ml and IL-3, 20 ng/ml.  SLIEW/SLMIEW lentivirus was added to the wells, 
with one well left without virus to provide an untransduced control.  The plate 
was balanced to within 0.2 g and sealed with Parafilm. 
Spinfection was performed as detailed in section 2.3.9.5. 
Following overnight culture, 350 µl transduction medium was aspirated from the 
cells and replaced with 850 µl fresh medium.  For those specimens transduced 
in the presence of cytokines, the fresh medium was supplemented with the 
same cytokine concentrations.  Cells were either transplanted into NSG mice, 
see 2.3.11.4, or analysed my five-colour flow cytometry on day 3 or 4 following 
transduction, see 2.3.11.2. 
2.3.11.2 Assessment of transduction by multicolour flow cytometry 
Analysis of transduction was performed by flow cytometry using either single 
colour assessment of EGFP (FACS Calibur, 2 samples only) or four-colour 
assessment of EGFP, anti-CD19 PE, anti-CD20 PerCP Cy5.5, anti-CD34 APC.  
For samples which had been harvested following xeno-transplantation, murine 
cells were excluded by staining with anti-murine CD45/Ter119 PE Cy7. 
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Cells were resuspended and washed once in 3 ml PBS in a flow cytometry tube, 
450 x g, 4 minutes.  Cells were resuspended in 100 μl PBS and stained with 
anti-CD19, 10 μl, anti-CD20, 10 μl, anti-CD34, 2.5 μl with or without anti-murine 
CD45, 2.5 μl, anti-Ter119, 2.5 μl, at room temperature, protected from light for 
20 minutes.  Cells were then washed twice in 2.5 ml PBS, 450 x g, 4 minutes 
and resuspended in 300 μl PBS ahead of analysis using a FACS Canto II flow 
cytometer. 
2.3.11.3 Washing procedure for removal of residual lentivirus 
In order to remove residual, infectious lentivirus, transduced cells were 
stringently washed each day from day 1 post-transduction onwards.  This 
protocol was developed during the course of this project. 
On Day 1 following transduction, 350 μl supernatant was removed from the 
transduced cells.  Cells were resuspended in 850 μl medium followed by the 
addition of a further 20 ml RPMI 1640, 10% FCS.  Cells were centrifuged 300 x 
g for 10 minutes.  The supernatant was aspirated using a plastic pipette (to 
avoid the risk of sharps related injuries) and the cells resuspended to repeat the 
above wash procedure.  Following the second wash, cells were resuspended in 
1 ml SFEM supplemented as for the transduction experiment.  The wash 
procedure was repeated on subsequent days.  
2.3.11.4 Xenotransplantation studies using NSG mice 
Xenotransplantation studies were conducted using intrafemoral injection into 
NOD/scid IL-2 receptor gamma common chain knockout (NSG) mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice (Shultz, Lyons et al. 2005) (Jackson Laboratories, 
supplied by Charles River UK Ltd).  These mice, in addition to the severe 
combined immune deficiency (scid) background, have a further deletion of the 
IL-2 receptor gamma common chain.  The product of this gene is an intrinsic 
component of a number of cell surface receptors within the adaptive immune 
system and these mice therefore have profound immune deficiency.  
Functionally they lack B- and T-cells, NK cells and have disorders of 
macrophage and complement function.  In addition to currently providing the 
most sensitive model for leukaemic engraftment (McDermott, Eppert et al. 
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2010), NSG mice also have a longer lifespan than NOD/scid mice and are 
therefore well suited to transplantation studies which can take many months.  
Intrafemoral transplantation was performed by one of three trained members of 
the laboratory.  Transplants were performed in a laminar flow hood with aseptic 
technique, under general anaesthesia.  Mice received subcutaneous Carprofen 
analgesia, 5 mg/kg, whilst anaesthetised.  A suspension of patient derived 
leukaemic cells or derived cell line cells of between 20 – 30 μl was injected into 
the femur through a hole made in the distal femoral joint, as described in (le 
Viseur, Hotfilder et al. 2008). 
2.3.11.5 In vivo imaging of transduced, fLuc+ leukaemia cells 
In vivo imaging of mice transplanted with leukaemic blasts (patient-derived or 
cell line) transduced with SLIEW or SLMIEW viruses was performed using an 
IVIS Spectrum bioluminescent camera.  For standard planar imaging, mice 
received an intraperitoneal injection of 3 µg D-Luciferin.  For 3 dimensional 
imaging, mice received 4.5 µg D-Luciferin.  Mice were anaesthetised using 3% 
v/v isofluorane in an induction chamber so that imaging could begin, with on-
going 2% v/v isofluorane, 10 minutes after the D-Luciferin injection. 
2.3.11.6 Harvesting mice for engraftment leukaemic material 
At the end of an experiment, mice were killed by cervical dislocation.  Material 
was harvested from the spleen and bone marrow, and for one experiment also 
from the liver and kidney (collected as for the spleen).  The spleen was 
dissected out of the abdomen, weighed and macerated through a 40 μm cell 
strainer into PBS.  Femurs and tibias were dissected out of both legs, the end 
cut off and the marrow flushed out with PBS using a 25G needle.  Bone marrow 
was also then passed through a 40 μm cell strainer to provide a single cell 
suspension and remove any fragments of bone. 
2.3.11.7 Harvesting organs for immunohistochemistry 
For one mouse transplanted with L578-SLIEW, the brain, kidneys, liver and 
spleen were dissected out and placed into formalin for fixation.  Organs were 
then embedded in paraffin and cut into 4 μm sections and mounted on glass 
Chapter 2:  Materials & methods 
104 
 
slides.  Haematoxylin and eosin staining was performed by Dr Jennifer Jackson, 
Northern Institute for Cancer Research.  Immunohistochemical staining was 
performed commercially by the Department of Pathology, Royal Victoria 
Infirmary using a Ventana Benchmark XT or Ventana Benchmark Ultra and 
Ventana Ultraview detection system (CD10, CD79a, TdT) and University 
College London (CD19). 
Slides for fluorescent microscopy were mounted using DAPI mount by Dr J 
Jackson and viewed using a Leica DSM fluorescence microscope and captured 
with SPOT RT digital CCD camera. 
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2.3.12 Cloning of a single vector combining in vitro analysis, in vivo 
analysis and RNAi – pSLMIEW 
2.3.12.1 Introduction 
The modification of the existing pSLIEW vector to include a microRNA adapted 
sort hairpin sequence would allow patient-derived material to receive EGFP (in 
vitro analysis), fLuc (in vivo imaging) and an shRNA (gene knockdown) with a 
single transduction.  The approach used required: a) the cloning of the 
shRNAmir30 sequence from Open Biosystems pTRIPZ vectors into a Gateway 
pENTR1a vector; b) the cloning of Invitrogen’s Gateway destination cassette 
into the BamHI site in pSLIEW.  These two vectors would then be recombined 
to produce the final pSLMIEW vectors. 
This work was performed by Simon Bomken (2.3.12.2, 2.3.12.3 and 2.3.12.6) 
with the assistance of two MRes students, Cara Hernon (2.3.12.2, 2.3.12.4 and 
2.3.12.6) and Nana Anim-Addo (2.3.12.5 and 2.3.12.6).  The strategy was 
designed by SB. 
2.3.12.2 PCR amplification of shRNAmir30 
The shRNAmir30 sequence to be cloned into the pENTR1a vector was 
amplified by PCR using primers designed to add SalI and EcoRV restriction 
sites to 5’ and 3’ ends respectively, see 2.2.5.4.  Additional 5’ GAGAGA 
sequences are required to allow efficient restriction digestion of the amplicon 
ends.  PCR amplification was performed using plasmid DNA of pTRIPZ 
constructs containing shMA6 (specific for MLL/AF4 fusion transcript), shAGF1 
(specific for RUNX1/RUNX1T1 fusion transcript) and the Open Biosystems non-
targeting control construct which contains an 18bp sequence in place of a 
hairpin. 
The amplification was pipetted on ice according to Table 2-6 and used a high 
fidelity polymerase, to reduce non-specific amplification and polymerisation 
errors.  The reaction was performed in 2 stages, Table 2-7.  The first 3 cycles 
used an annealing temperature specific for that portion of the primers which 
were complementary to the plasmid sequence, i.e. assuming the restriction site 
and 5’ GAGAGA sequences to be unbound.  The final 20 cycles used a higher 
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annealing temperature to ensure specific binding of the full primer sequence, 
now including the restriction sites and terminal GAGAGA bases. 
Amplification products were purified as described in 2.3.3.2, assessed by 
Nanodrop and restriction digested immediately. 
Table 2-6. Reaction mixture for PCR amplification of shRNAmir30 sequences 
Reagent Volume Final concentration 
ThermoPol buffer (10x) 5 µl 1x 
dNTPs (10 mM) 1 µl 200 µM 
Primer mix (10 µM) 1 µl 0.2 µM 
Plasmid DNA (20 ng) --- --- 
Vent polymerase (1:5 
dilution) 
1 µl 1 unit 
Nuclease free water --- --- 
Total volume 50 µl  
Table 2-7.  Reaction conditions for PCR amplification of shRNAmir30 sequences 
 Temperature Time Cycles 
 95oC 5 minutes  
Annealing of 
incompletely 
complementary 
primers 
95oC 30 seconds 
3 cycles 59oC 30 seconds 
72oC 30 seconds 
Annealing of 
complementary 
primers 
95oC 30 seconds 
20 cycles 64oC 30 seconds 
72oC 30 seconds 
 72oC 5 minutes  
 
2.3.12.3 Cloning of pENTR-shRNAmir30 
Purified shRNAmir30 amplicons from 2.3.12.2 and pENTR1a vector were 
restriction digested using SalI and EcoRV at 37oC for 2 hours to ensure 
complete digestion.  Reactions mixtures were as described in Table 2-8.  The 
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digestion products were again purified according to 2.3.3.2.  The pENTR1a 
digestion products were isolated by gel electrophoresis using a 1.25% w/v 
agarose/TBE gel, whilst the shRNAmir30 digestion products were separated 
using a 2% w/v agarose/TBE gel.  The appropriate bands excised and purified 
according to 2.3.3.3. 
Table 2-8.  Reaction mixture for restriction digest of shRNAmir30 amplicon and pENTR 
vector 
Reagent Quantity 
DNA     shRNAmir30 (500 ng) 
             pENTR         (1500 ng) 
--- 
--- 
SalI (10 units/ µl) 1 µl 
EcoRV (10 units/ µl) 2 µl 
Buffer O (10x) 2 µl 
Sterilised deionised water --- 
Total volume 20 µl 
 
Purified restriction digest products were ligated together in 1:1, 1:3 and 1:6 
ratios of vector to insert, at 16oC, overnight.  The reaction mixtures are shown in 
Table 2-9.  Ligated DNA, 2 µl, was transformed into competent DH5α cells as 
described in 2.3.7.2.  Transformations were plated onto culture plates 
containing 50 µg/ml kanamycin and cultured overnight.  Colonies were picked 
the following day and grown up in 5 ml LB medium supplemented with 50 µg/ml 
kanamycin.  Plasmid DNA was isolated from these pre-cultures as described in 
2.3.7.3 and sent for commercial sequencing by DBS Genomics, Durham, using 
the Entry vector reverse sequencing primer, 2.2.5.4. 
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Table 2-9.  Reaction mixture for ligation of shRNAmir30 and pENTR 
Reagent Volume 
DNA --- 
T4 ligase (5 units/µl dilution in SDW) 1 µl 
T4 ligase buffer (10x) 1 µl 
Sterilised deionised water --- 
Total volume 10 µl 
 
2.3.12.4 Cloning of ANGPT1 shRNA into pENTR-shRNAmir30 
To demonstrate the principle of cloning a new shRNA sequence into the 
pENTR-shRNAmir30 vector, the shRNA specific for ANGPT1 was excised from 
a commercially available pTRIPZ vector and ligated into the digested mir30 
sequence of the non-targeting pENTR-shRNAmir30 plasmid cloned in 2.3.12.3. 
The pTRIPZ and pENTRshRNAmir30 plasmids were digested using XhoI and  
EcoRI according to Table 2-10 .  The reaction was performed for 90 minutes at 
30oC and terminated by heating to 80oC for 20 minutes.  Digestion products 
were purified by gel electrophoresis as described in 2.3.12.3.  Ligations 
reactions were performed using 1:1 and 1:3 ratios of vector to insert as 
described in Table 2-9. 
Table 2-10.  Reaction mixture for restriction digest to clone shANGPT1 hairpin into 
pENTR-shRNAmir30 
Reagent Quantity 
Plasmid DNA (1 µg) --- 
XhoI (10 units/ µl) 1 µl 
EcoRI (10 units/ µl) 2 µl 
Buffer O (10x) 2 µl 
Sterilised deionised water --- 
Total volume 20 µl 
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Ligation products were transformed into competent DH5α cells, as described in 
2.3.7.2, cultured on culture plates containing kanamycin 50 µg/ml.  Colonies 
were picked, cultured overnight in LB medium containing kanamycin 50 µg/ml 
and plasmid DNA isolated, as described in 2.3.7.3.  A control digest was 
performed using SalI and EcoRI, as described in Table 2-8, and the resultant 
products analysed by gel electrophoresis using a 2% w/v agarose/TBE gel.  
Clones with the appropriate bands were sent for commercial sequencing by 
DBS Genomics using the Entry vector reverse sequencing primer, 2.2.5.4. 
2.3.12.5 Cloning of pSLIEW destination vector 
The Gateway conversion cassette, reading frame A, was cloned into the BamHI 
restriction site 5’ to fLuc and 3’ to IRES in pSLIEW.  pSLIEW was digested at 
37oC for 2 hours and heat inactivated at 80oC for 20 minutes.  The reaction 
mixture is described in Table 2-11.  The ends of the linearised plasmid were 
then blunted by a Klenow fill-in reaction, described in Table 2-12.  This was 
performed at 37oC for 10 minutes and heat inactivated at 75oC for 10 minutes. 
Table 2-11.  Reaction mixture for BamHI digest of pSLIEW 
Reagent Volume 
pSLIEW DNA (5 µg) 1.5 µl 
BamHI buffer (10x) 2 µl 
BamHI 1 µl 
Sterilised deionised water 15.5 µl 
Total volume 20 µl 
 
Chapter 2:  Materials & methods 
110 
 
Table 2-12.  Reaction mixture for Klenow fill-in of linear pSLIEW 
Reagent Volume 
Digested pSLIEW 20 µl 
dNTP mix (500 µM each) 20 µl 
Klenow reaction buffer (10x) 20 µl 
Klenow fragment 0.5 µl 
Sterilised deionised water 139.5 µl 
Final volume 200 µl 
 
The blunt-ended BamHI pSLIEW digest was purified as described in 2.3.3.2, 
and analysed using a Nanodrop.  A 5’ dephosphorylation reaction was 
performed using shrimp alkaline phosphatase at 37oC for 30 minutes, as 
described in Table 2-13.  The enzyme was heat inactivated at 65oC for 15 
minutes.  The DNA was again assessed by Nanodrop and adjusted to 20-50 
ng/µl with buffer TE, pH 8.0. 
Table 2-13.  Reaction mixture for 5’ dephosphorylation of linear pSLIEW  
Reagent Volume 
DNA (target 1 pmol of termini, actual 0.21 
pmol) 
17 µl 
SAP Reaction buffer (10x) 2 µl 
Shrimp Alkaline Phosphatase (1 unit/µl) 1 µl 
Total volume 20 µl 
 
The Gateway conversion cassette was then ligated into the dephosphorylated 
plasmid at 16oC overnight, as described in Table 2-14. 
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Table 2-14.  Reaction mixture for ligation of conversion cassette into linear pSLIEW  
Reagent Volume 
Linear plasmid (50 ng/µl) 0.5 µl 
50% PEG 4000 2 µl 
Gateway conversion cassette (5 ng/µl) 2 µl 
T4 DNA ligase buffer (10x) 1 µl 
T4 DNA ligase (5 units/µl) 1 µl 
Nuclease free water 12.5 µl 
 
The ligated pSLIEW-DEST plasmid was transformed into ccdB Survival 2T1R 
competent cells at 0.2 µl, 1 µl, 2 µl per 25 µl cells as described in 2.3.7.2.  
These bacteria have a mutation of DNA gyrase (gyrA462), which makes it 
resistant to interference caused by the CcdB protein product of the ccdB gene 
in the conversion cassette.  The chloramphenicol resistance gene on the 
conversion cassette allows negative selection of un-ligated plasmids, see 
Figure 2-1.  Transformed bacteria were spread on 1.5% w/v agar/LB plates with 
30 µg/ml chloramphenicol and incubated over 2 nights at 37oC.  Colonies were 
picked into 5 ml pre-cultures of LB medium with 30 µg/ml chloramphenicol and 
again grown overnight. 
Figure 2-1.  Gateway conversion cassette. attR – attachment sites R1 & R2, CmR – 
chloramphenicol resistance gene, ccdB – ccdB gene for negative selection. 
 
Plasmid DNA was extracted from positive cultures, as described in 2.3.7.3.  A 
control restriction digest was performed using PvuII according to the method in 
2.3.7.5.  In addition, four clones were sent for sequencing at DBS Genomics, 
using the Destination vector sequencing primers 1 and 2, see 2.2.5.4.    
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2.3.12.6 Recombination of vectors to produce pSLMIEW 
Each of the four pENTR-shRNAmir plasmids (shMA6, shAGF1, shANGPT1 and 
the non-targeting sequence) were recombined with pSLIEW-DEST to give 
completed Gateway expression vectors, known as pSLMIEW.  This process 
uses a proprietary enzyme mix from Invitrogen, LR Clonase II enzyme mix.  The 
reaction was incubated overnight at 16oC.  The reaction was stopped by 
addition of 2 µg Proteinase K and incubation at 37oC for 10 minutes.  Each 
reaction was transformed into competent DH5α cells as described in 2.3.7.2, 
which were spread onto culture plates containing 100 µg/ml ampicillin and 
cultured overnight.  Colonies were picked and cultured overnight in 5 ml LB 
medium containing 100 µg/ml ampicillin.  Plasmid DNA was extracted according 
to 2.3.7.3 and analysed by restriction digest using PvuII.  Successfully 
recombined clones were expanded in LB medium supplemented with 100 µg/ml 
ampicillin.  Plasmid DNA was extracted according to 2.3.7.4 and used for 
lentiviral production according to 2.3.9. 
 
  
 
Chapter 3 
Expression and function of the 
candidate stemness gene 
PIWIL2 in normal and malignant 
lymphoid populations 
  
Chapter 3:  PIWIL2 in normal and malignant lymphoid populations 
114 
 
3.1 Introduction 
Previous studies in both Drosophila and mice, have demonstrated a critical role 
for PIWI clade proteins in the maintenance of germline stem cells.  Due to the 
specificity of their small RNA partners, the PIWI interacting RNAs (piRNAs), for 
retrotransposons, it was presumed that their role is to silence mobile genetic 
elements by post translational degradation of mRNA, preventing insertional 
mutagenesis.  This is especially important during the period of global 
demethylation at the end of foetal development during which retrotransposons 
would otherwise be freely transcribed 
More recent studies, however, have suggested a wider role for PIWI/piRNA 
complexes as they have been shown to be essential for the de novo 
methylation of germline DNA which occurs during foetal development 
(Kuramochi-Miyagawa, Watanabe et al. 2008).  In addition, PIWI/piRNA 
sequence directed methylation of the CREB2 promoter modified its expression 
in Aplysia (Sea Hare) neurones, mediating the role of this transcription factor in 
response to serotonin (Rajasethupathy, Antonov et al. 2012). 
Following the identification of the expression of PIWIL2 in malignancy (Lee, 
Schutte et al. 2006), this project aimed to investigate the expression and 
function of PIWIL2 in acute lymphoblastic leukaemia.  Given the stem cell 
specific nature of its expression, this project particularly intended to investigate 
its role in the biology of ALL self-renewal/propagation.  Preliminary experiments 
within the laboratory (conducted by Svetlana Myssina) demonstrated the 
expression of PIWIL2 in a small cohort of presentation bone marrow specimens 
from children with acute lymphoblastic leukaemia (Figure 3-1).  Furthermore, 
paired samples taken at the end of remission induction showed loss of 
expression in all but one case.  This project aimed to further define the 
expression and function of PIWI-Like genes in childhood ALL. 
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3.2 Aims of the project 
 
The aims of this project were: 
1. To investigate the expression pattern of PIWI-Like genes in childhood 
acute lymphoblastic leukaemia; 
2. To determine the functional significance of PIWI-Like genes in ALL by 
serial electroporation and siRNA mediated gene knockdown 
 
During the course of this project, peripheral blood lymphocytes (PBLs) from 
healthy donors were used to provide normal control RNA.  Unexpectedly, 
expression of PIWIL2 was identified in unfractionated PBLs.  This led to a 
further project aim being developed. 
3. To determine the expression of PIWI-Like genes in fractionated 
peripheral blood lymphocytes  
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Figure 3-1.  Expression of PIWIL2, assessed by RT PCR.  Top panel – Presentation 
samples.  Bottom panel – Paired remission samples.  NTC – Non-target control.  833K – 
Positive control cell line.  Patient details are recorded in Appendix A. 
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3.3 Results 
3.3.1 Optimising the qRT PCR 
Primers suitable for quantitative RT PCR were designed to span exon-exon 
boundaries and therefore be specific for mRNA transcript.  A number of primer 
pairs were designed for each of the PIWI-Like genes, PIWIL1-4.  qRT PCR was 
performed using the testicular seminoma cell line 833K as a positive control.  
The final primer pairs to be used were chosen to ensure: 
 
1. A uniform melting curve during qRT PCR 
2. Primer efficiency close to 2, ensuring accurate quantitation by the 
ΔΔCt method 
3. The appropriate amplicon length, as determined by gel 
electrophoresis 
 
Using SDS 2.0, the melting curve was assessed.  Each of the primer sets was 
analysed and found to have a single peak, representing a single amplicon 
without the formation of primer dimers.  This analysis was performed following 
each individual qRT PCR run. 
Analysis of the primer efficiency was performed by pipetting serial dilutions of 
cDNA into the reaction as follows - 1:1, 1:10, 1:100, 1:1000 and 1:10000.  A line 
of best fit was plotted on a graph of ΔCt against cDNA dilution and the efficiency 
calculated by: 
    ( | ) 
where E is the primer efficiency and b describes the gradient of the line of best 
fit.  Acceptable primer efficiencies of 1.9-2.2 were achieved with each of the 
primers chosen for subsequent experiments. 
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Amplicon sizes were predicted from the known transcript sequences.  Following 
qRT PCR, amplicons were analysed by electrophoresis using an 8% 
polyacrylamide gel, stained with ethidium bromide.  This analysis demonstrated 
a single amplicon of the expected size for each of the primer pairs which had 
been selected following melting curve and efficiency analysis (Figure 3-2). 
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Figure 3-2.  Analysis of PIWI-Like amplicons by gel electrophoresis.  The predicted 
amplicon length in base pairs is displayed beneath the gel.  Marker sizes  (base pairs) are 
displayed beside the gel, Fermentas UltraLow ladder. 
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3.3.2 Confirmation of amplicon specificity by sequencing 
Following the unexpected finding of PIWIL2 expression in normal peripheral 
blood lymphocytes, see 3.3.4, the specificity of the qRT PCR primers was 
confirmed by sequencing of the amplicons.  This was performed by DBS 
Genomics, Durham, following the TA cloning of PCR amplicons into the pGEM-
T Easy vector.  The sequences generated demonstrate >98% sequence 
homology for the predicted amplicons of PIWIL1-3 (Figure 3-3, Appendix B).  
Despite repeated attempts, it was not possible to clone the amplicons of PIWIL4 
and GAPDH into the pGEM-T Easy vector and so these amplicons were 
sequenced in two directions using the qRT PCR primers.  By combining the 
sequences derived in 3’ and 5’ directions it was possible to determine the 
complete sequence homology of the amplicons.  These sequences also showed 
>98% homology to the predicted amplicon (Appendix B). 
Overall, this sequencing data gave a high degree of confidence in the novel 
finding that PIWIL2 and PIWIL4 were expressed in normal PBLs from healthy 
control donors. 
Chapter 3:  PIWIL2 in normal and malignant lymphoid populations 
121 
 
Figure 3-3.  Sequencing of PIWIL2 amplicon.  A) Raw sequencing data generated following 
TA cloning of qRT PCR amplicons into the pGEM-T Easy vector and sequencing by DBS 
Genomics. 
A 
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Figure 3-3. B) Sequence alignment of clones 1 and 6 performed using ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) demonstrates homology to the predicted PIWIL2 
sequence 
 
B 
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3.3.3 Expression of PIWI-Like genes in acute leukaemia 
The expression of PIWI-Like genes was initially analysed in a panel of acute 
leukaemia cell lines (Figure 3-4A).  Cells in stable culture were harvested and 
RNA extracted.  cDNA was prepared and the expression of all 4 PIWI-Like 
genes analysed relative to their expression in the testicular seminoma cell line 
833K.  There was substantial variation between cell lines and between PIWI-
Like genes.  PIWIL1 was not expressed in either ALL or AML cell lines.  PIWIL2 
was expressed in all ALL and MLL rearranged AML cell lines, but not in AML 
cell lines with the RUNX1-RUNX1T1 translocation.  Expression was 1-10% of 
that seen in 833K.  Expression of PIWIL3 was more variable between cell lines, 
showing no correlation with ALL versus AML or with MLL rearrangement.  
PIWIL4 was expressed in all cell lines.  In all but NALM-6, PIWIL4 expression 
was substantially higher than in 833K cells. 
Expression of PIWI-Like genes was then analysed in a panel of patient-derived 
(details in Appendix A) acute lymphoblastic leukaemias (Figure 3-4B).  RNA 
was extracted from stored viable bone marrow cells.  RNA samples RT636, 
RT929, RT1587 and RT3230 were kindly donated by Ronald Stam, Rotterdam.  
As with the derived cell line analyses, PIWIL1 was not expressed.  PIWIL2 was 
expressed in all patient-derived samples, at levels comparable to those seen in 
the ALL and MLL rearranged AML cell lines, (Figure 3-4A).  PIWIL3 expression 
was not consistent across samples, whilst PIWIL4 expression was again found 
to be 10-1000 times that seen in 833K cells. 
These analyses, together with the non-quantitative preliminary data in Figure 
3-1, demonstrate the consistent expression of PIWIL2 in childhood B precursor 
ALL.  Expression of PIWIL4, which is believed to be ubiquitous, was both 
substantially higher than PIWIL2 expression and higher than expression of 
PIWIL4 in 833K cells which were chosen as a positive control cell line due to 
their robust expression of PIWI-Like genes.  PIWIL1 was not found to be 
expressed, whilst PIWIL3 expression showed substantial variation.  
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Figure 3-4.  Expression of PIWI-Like genes in acute leukaemia.  A)  Derived cell line 
expression: NALM-6, 697, REH – B precursor ALL; SEM, RS4;11 – MLL rearranged B 
precursor ALL; MV4;11, THP-1 – MLL rearranged AML; SKNO-1, Kasumi-1 – 
RUNX1/RUNX1T1 translocated AML.  B)  Patient-derived B-precursor ALL samples – L880, 
L826, L876, RT636, RT929, RT1587, RT3230 have rearrangement of MLL. 
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3.3.4 Expression of PIWIL2 in sorted lymphoid populations 
Normal mononuclear cells had been isolated from the peripheral blood of 
healthy volunteers to provide a negative control for the analysis of PIWI-Like 
gene expression detailed in 3.3.3.  Unexpectedly, repeated qRT PCR on five 
different volunteer samples consistently demonstrated expression of PIWIL2 
and PIWIL4.  PIWIL1 and PIWIL3 were not expressed. 
In order to identify the peripheral blood leukocyte population responsible for the 
unexpected expression, CD19+ B lymphocyte, CD3+ T lymphocytes, CD14+ 
monocytes and CD15+ granulocytes were isolated from five further peripheral 
blood samples donated by healthy volunteers.  Isolation was performed by 
immunomagnetic bead sorting with Macs Microbeads (Miltenyi) directed against 
CD19, CD3, CD14 or CD15.  Purified cells were labelled with the respective 
fluorochrome labelled antibody and analysed by flow cytometry.  This 
demonstrated a high degree of cell purity (mean; range): CD19+ - 92.2%, 91.3-
93.1%; CD3+ - 92.7%, 89.5-97.7%; CD14 – 93.6%, 89.6-97.4%; CD15+ - 
99.9%, 99.6-100% (Figure 3-5A). 
End point analysis following qRT PCR demonstrated expression of PIWIL4 in all 
populations, but expression of PIWIL2 only in CD19/CD3+ lymphocytes and 
CD14+ monocytes, Figure 3-5B.  Quantitative analyses were compared using 
one way analysis of variance with Bonferroni correction for multiple testing.  
This demonstrated significantly lower expression of PIWIL2 in monocytes 
compared with both CD19+ B lymphocytes and CD3+ T lymphocytes (p<0.05) 
(Figure 3-5C).  As the monocyte fraction is derived from the mononuclear cell 
layer formed by density gradient centrifugation it is likely that the expression 
seen in the CD14+ monocyte fraction is consistent with 3-10% lymphocyte 
contamination present in isolated CD14+ populations.  Further purification was 
not attempted due to the limited cell numbers, but pooling samples and 
performing serial sorts, as described in 3.3.5, could identify the origin of this low 
level expression.  Expression in B and T cells was comparable with that seen in 
patient-derived ALL specimens (MLL rearranged specimens from Figure 3-4B 
presented for comparison) (Figure 3-5C). 
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This analysis shows that, in contrast to previous reports, PIWIL2 expression in 
healthy controls is found outside of the germline stem cell compartment.  
Restriction of expression to lymphocytes is consistent with a role in “self-
renewal”, as lymphocytes, unlike myeloid lineage cells, retain the ability to 
clonally expand in response to either successful B cell receptor rearrangement 
or antigenic stimulation.  Importantly, this capacity is not lost with terminal 
differentiation.  As patient-derived leukaemias express similar levels of PIWIL2 
to normal lymphocytes, it is possible that leukaemic blasts may access the 
clonal expansion programme of normal lymphoid cells to facilitate leukaemic 
expansion/propagation. 
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Figure 3-5.  Expression of PIWIL2 and PIWIL4 in normal peripheral blood leukocytes.  A)  
Purity of isolated leukocyte populations by flow cytometry (mean + standard error of the mean, 
s.e.m).  B)  End-point analysis of PIWIL2 and PIWIL4 expression by RT PCR.  Expression is 
shown in B and T lymphocytes and monocytes, but PIWIL2 expression is absent from 
granulocytes.  C)  Quantitative analysis of PIWIL2 expression shows significantly higher 
expression in B (p<0.01) and T (p<0.001) lymphocytes compared with either myeloid lineage 
(mean + s.e.m).  Expression is comparable with that seen in leukaemic populations.  
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3.3.5 Expression of PIWIL2 in CD34+ umbilical cord blood cells 
Following the unexpected finding of PIWIL2 expression in mature peripheral 
lymphocytes, the expression of PIWI-Like genes was assessed in CD34+ 
haematopoietic progenitor cells to investigate a wider role for these genes 
during haematopoiesis.  Stored umbilical cord blood cells were thawed, labelled 
with CD34 Macs Microbeads and sequentially passaged down two Macs 
columns.  Aliquots were taken for assessment of CD34+ cell purity prior to 
isolation and after each column and demonstrated a final purity of greater than 
90% compared with <1% in un-purified cord blood (Figure 3-6A).  This analysis 
was not performed for the first specimen as there were insufficient cells. 
Expression of the PIWI-Like genes was compared with the flow-through from 
the Macs isolation columns, representing a source of CD34- cord blood cells.  
This analysis did not demonstrate enrichment for expression of PIWIL2, or any 
other PIWI-Like gene, in CD34+ umbilical cord blood progenitor cells (Figure 
3-6B).  This is in contrast to a previous report of a role for PIWIL1 in human 
CD34+ bone marrow progenitor cells (Sharma, Nelson et al. 2001).  The lack of 
enrichment in CD34+ cells may result from the presence of a substantial 
population of lymphocytes in the CD34- population.  As the expression of 
PIWIL2 was comparable with that seen in patient-derived leukaemias (Figure 
3-6C) and normal lymphocytes (Figure 3-5C), greater fractionation of umbilical 
cord blood, achieved by multicolour FACS sorting, would allow accurate 
assessment of the differential expression throughout haematopoiesis. 
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Figure 3-6.  Analysis of PIWI-Like gene expression in CD34+ umbilical cord blood 
progenitor cells.  A)  Analysis of purity of umbilical cord blood CD34+ cells by flow cytometry.  
Purity increases sequentially from <1% in both umbilical cord blood (UCB) 2 and 3 to greater 
than 90%.  UCB1 – insufficient cells for analysis.  B)  Expression of PIWI-Like genes in isolated 
CD34+ cells compared with CD34- umbilical cord blood cells.  C)  Expression of PIWIL2 in 
purified CD34+ cells compared with patient-derived leukaemic specimens. 
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3.3.6 Transient transfection with siRNA - confirmation of knockdown 
To investigate the functional significance of PIWIL2 in ALL, transient 
transfection of the childhood ALL cell line SEM was performed by 
electroporation in the presence of 500 nM siRNA.  Following electroporation, 
qRT PCR was used to assess the reduction in PIWIL2 mRNA levels, known as 
the knockdown.  The controls used were siMA6, specific for the MLL/AF4 
breakpoint present in SEM cells, siAGF1, specific for the RUNX1/RUNX1T1 
breakpoint found in Kasumi-1 cells and not present in SEM cells, and Mock in 
which no siRNA was used but cells were electroporated just as for all other 
experimental samples. 
Initially, the efficacy of a number of different siRNAs from different 
manufacturers was assessed at 24 and 48 hours post electroporation (Figure 
3-7A).  The two siRNAs found to have the greatest effect, siPIWIL2_c and 
siPIWIL2_5 (designed by two independent manufacturers) were subsequently 
identified as having the same sequence.   
As only modest knockdown (40-50%) was achieved with the most effective 
siRNA, siPIWIL2_5, the cellular localisation of PIWIL2 mRNA was investigated.  
As experimental knockdown occurs only in the cytoplasm (where siRNAs and 
RISC co-localise), a nuclear predominance of PIWIL2 transcript would mask 
potentially effective cytoplasmic knockdown in whole cell RNA preparations.  
Fractionation of cytoplasmic and nuclear mRNA was followed by qRT PCR, 
demonstrating a 2-3 fold higher level of mRNA in the nucleus than in the 
cytoplasm.  However, knockdown in the cytoplasm remained approximately 
50% (Figure 3-7B), whilst no knockdown was seen in the nuclear fraction 
(Figure 3-7C). 
A subsequent early time course experiment aimed to identify whether a very 
early peak knockdown had been missed by sampling at 24 hours.  This showed 
that the peak PIWIL2 knockdown of approximately 50% was achieved by 8 
hours and maintained thereafter (Figure 3-7D).  The positive control experiment 
demonstrates 75-80% knockdown of the MLL/AF4 fusion transcript by siMA6 as 
early as 4 hours post electroporation (Figure 3-7E). 
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As it was not possible to identify an experimental reason for the modest 
knockdown achieved, a further three commercially designed siRNAs were 
purchased.  The best amongst these, siPIWIL2_e, was found to have a similar 
efficacy to siPIWIL2_5.  These two siRNAs were used for subsequent 
experiments of the functional effect of PIWIL2 in SEM cells, see 3.3.8, either 
individually or in combination at 250 nM each (697 cells only). 
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Figure 3-7.  Knockdown of PIWIL2 electroporation with siRNAs.  A)  Knockdown 48 hours 
after transfection.  PIWIL2_c and PIWIL2_5 show the greatest knockdown.  (PIWIL2_4 result 
1.89, not shown in full).  Fractionation of cytoplasmic and nuclear mRNA - B)  Cytoplasmic 
knockdown remains approximately 50% whilst C) no nuclear knockdown is demonstrated.  D)  
Time course of PIWIL2 knockdown.  50% reduction in mRNA is achieved by 8 hours.  E)  
Positive control demonstrates ≥75% knockdown of MLL-AF4 by 4-8 hours.  Relative expression 
is ΔΔCt relative to Mock. 
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3.3.7 Analysis of knockdown of protein by Western blot 
In order to confirm the effect of mRNA knockdown on PIWIL2 protein levels, 
protein collected at the same time as mRNA was probed for PIWIL2 by Western 
immunoblotting.  Proteins were separated by gel electrophoresis using an 8% 
polyacrylamide gel and blotted onto PVDF membrane.  A number of 
commercially available antibodies were used to probe for PIWIL2 protein, as 
described below. 
Initially, a polyclonal antibody from Abnova was used.  An exposure for 10 
seconds produced a very clear band at 40 kDa (Figure 3-8A).  However, full 
length PIWIL2 protein is approximately 110 KDa.  In retrospect, the 
manufacturer’s website specified a 187 amino acid, 40 kDa target.  Analysis of 
the immunogenic sequence showed no homology to PIWIL2.  No further 
experiments were performed with this antibody. 
The next antibody to be tested was a polyclonal antibody from Santa Cruz.  An 
initial blot was performed using antibody dilutions between 1:100 and 1:500, as 
suggested by the manufacturer.  This produced multiple bands between 70 and 
>170 kDa, but with no band present at the correct size (Figure 3-8B).  In order 
to try and reduce non-specific background labelling, a repeat experiment used 
antibody dilutions of 1:1000-1:25000.  Up to 1:5000 dilution gave similar bands 
to the first trial, but with no clear band at 110 kDa. 
A trial blot of samples taken 24 hours following electroporation was performed 
with the Santa Cruz antibody.  There was no observable decrease in the size of 
any of the bands (Figure 3-8C), despite knockdown of mRNA (Figure 3-7D). 
A third antibody from AbCam was trialled in two separate experiments, but gave 
no signal on either occasion.  The loading control analysis of GAPDH gave 
clear bands of the appropriate size. 
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Following the failure to demonstrate a band of the correct size, or any band 
which was modulated by knockdown, using any of these three antibodies, and 
with no other commercial antibodies available, it was decided to monitor 
knockdown with qRT PCR alone and investigate whether any functional 
phenotype could be elicited.  
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Figure 3-8.  Western immunoblot analysis of PIWIL2.  A)  Abnova antibody demonstrates 40 
kDa protein of unknown identity.  B)  Initial dilutions of Santa Cruz antibody from 1:100-1:500 
demonstrated multiple bands, but no clear predominance at 100 kDa.  C)  Santa Cruz antibody 
following 48 hours of knockdown with siPIWIL2_c and siPIWIL2_5.  No difference is seen in any 
of the bands present.  833K – Positive control.  CD15+ - Granulocyte – Negative control.  
GAPDH – Loading control.  Marker sizes in kDa are recorded alongside each blot.  
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3.3.8 Functional assessment following PIWIL2 knockdown in SEM cells 
Having established a loss of function assay with electroporation and siRNA, an 
assessment of the functional significance of PIWIL2 was made using serial 
electroporation of both SEM (performed by SB) and 697 (performed by SB and 
Hesta McNeill) cells to provide sustained knockdown.  Electroporation was 
performed every 48-72 hours.  At each of these time points, cells were counted 
and an aliquot taken for re-electroporation.  Further aliquots were taken for RNA 
extraction, to confirm knockdown, and for analysis of cell cycle distribution.  For 
SEM cells, three independent experiments were performed over 6 (n=1) or 8 
(n=2) days.  For 697 cells, three independent experiments were performed over 
10 (n=2) or 14 (n=1) days. 
Serial cell counts were adjusted as described in 2.3.4.3.  These data were then 
plotted against time and an exponential trendline fitted.  From the equation 
describing the trendline,          doubling times were calculated as 
        .  Doubling times were analysed using one way analysis of variance 
with a Bonferroni correction for multiple testing, with each PIWIL2 specific 
siRNA being compared to each negative control.   
PIWIL2 knockdown resulted in decreased proliferation in both SEM (Figure 
3-9A) and 697 cells (Figure 3-9B).  This was quantified as a significant 
prolongation of doubling times in both SEM and 697 cells (Figure 3-9C and D).  
Cell cycle analysis of SEM cells demonstrated a significant, although not 
substantial, G1/G0 arrest, accompanied by a decreased proportion of cells in S 
phase, following PIWIL2 knockdown (Figure 3-9E).  Cell cycle analysis in 697 
cells did not show a consistent pattern of change of the distribution of cells 
within the cell cycle.  
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Figure 3-9.  PIWIL2 knockdown affects cell proliferation and cell cycle distribution.  A) 
Proliferation of electroporated SEM cells.  B) Proliferation of electroporated 697 cells.  
Electroporation performed with combination of 250 nM each of siPIWIL2_5 and siPIWIL2_e.  
Cell counts were performed 2 days after each electroporation.  A single representative 
experiment is shown in each of A and B.  Doubling times of electroporated C) SEM or D) 697 
cells.  Data are mean of three experiments, error bars show standard error of the mean.  E)  
Cell cycle analysis performed 2 days after each serial electroporation of SEM cells.  Cell cycle 
phases are compared against the same phase in Mock treated cells at the same time point.  
Data are mean values of three experiments, error bars show standard error of the mean.  For 
panels B-D, * p<0.05, ** p<0.01, *** p<0.001. 
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3.4 Discussion 
The importance of PIWIL2 in mammalian germline stem cells (Kuramochi-
Miyagawa, Kimura et al. 2004; Aravin, Hannon et al. 2007; Carmell, Girard et al. 
2007), combined with its expression in a wide range of human malignancies 
(Lee, Schutte et al. 2006; Feng, Peng et al. 2009; He, Chen et al. 2010; Lee, 
Jung et al. 2010; Yin, Li et al. 2011) suggested that PIWIL2 may play a critical 
role in the regulation of self-renewal, or alternative stem cell characteristics, in 
cancer.  This project was designed to investigate the role of PIWIL2 in 
childhood acute lymphoblastic leukaemia, particularly in the context of 
identifying genetic determinants of leukaemia propagating cell biology.   
Expression of PIWIL2 and PIWIL4 was demonstrated in childhood acute 
lymphoblastic leukaemia for the first time, using both derived cell lines 
representing a spectrum of cytogenetic backgrounds and patient derived 
specimens.  During the validation of the qRT PCR analysis of PIWI-Like 
expression, peripheral blood mononuclear cells were used as a source of 
negative control RNA.  Unexpectedly, expression of PIWIL2 was also identified 
in these control cells.  By fractionating the peripheral blood leukocytes it was 
possible to demonstrate that PIWIL2 was expressed in both B and T lymphoid 
cells, but not in myeloid lineage cells.  Furthermore, expression was not seen in 
either of two acute myeloid leukaemia cell lines harbouring the 
RUNX1/RUNX1T1 translocation.  These findings demonstrate that PIWIL2 
expression is a feature common to both normal and malignant lymphoid 
populations.  As the role of PIWIL2 in normal lymphocytes is not known, and the 
present study was unable to determine its role in acute leukaemia, it remains to 
be determined whether PIWIL2 is critical to cellular self-renewal, as it is in 
germline stem cells, or whether it has an alternative function in lymphoid 
malignancy.  Intriguingly, PIWIL2 may provide an example of a normal lymphoid 
derived genetic determinant of leukaemic biology.  It will be important to 
determine whether or not PIWIL2 represents one component of a clonal 
expansion programme which is shared by normal and malignant lymphoid 
populations. 
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Expression was also seen in the MLL rearranged AML cell lines MV4;11 and 
THP-1.  This may result directly from the powerful transforming potential of this 
translocation, although knockdown of MLL/AF4 in SEM cells did not affect 
PIWIL2 expression.  A broader analysis of AML samples is required to know 
whether expression is restricted to MLL rearranged AML or whether 
RUNX1/RUNX1T1 associated AML is unusual in its low expression.  As 
expression of the PIWI-Like genes in human umbilical cord blood stem cells 
was not clearly defined by the present study, it remains to be determined what 
impact the cell of origin might have on PIWIL2 expression. 
Modulating PIWIL2 expression in both SEM and 697 cells proved challenging, 
with 40-60% knockdown being the best achieved.  However, despite achieving 
only modest knockdown, a consistent phenotype was observed, initially in SEM 
cells.  Reduction in PIWIL2 expression in SEM cells resulted in a decrease in 
cellular proliferation which may be accompanied by a G1/G0 cell cycle arrest.  
Repeat experiments in 697 cells also demonstrated a significant decrease in 
cellular proliferation, but no consistent effect on cell cycle distribution was seen.  
This may again result from the modest degree of knockdown achieved, or may 
indicate an alternative causation for the reduced proliferation other than cell 
cycle arrest. 
To maintain a consistent degree of knockdown and accurate cell numbers over 
5-7 serial electroporations of 697 cells proved challenging.  Whilst it had been 
hoped that prolonged knockdown would allow the investigation of changes in 
promoter methylation in ALL cells, it was not possible to maintain consistent 
knockdown and rates of proliferation for long enough to be confident of 
identifying PIWI/piRNA methylation targets.  This analysis was therefore not 
performed. 
Following the departure of a collaborator, Professor Karim Nayernia, with 
substantial experience in PIWIL2 biology and with the difficulties experienced in: 
1) achieving strong knockdown; 2) the lack of a protein based assay for 
demonstrating knockdown; 3) maintaining consistency over a large number of 
serial electroporations, it was decided to end the PIWIL2 project.  An 
alternative, unbiased approach to identifying the genetic determinants of ALL 
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propagating cell biology was adopted.  This whole-genome RNAi screen is 
described in Chapter 5. 
To end the PIWIL2 project was a strategic decision and not based on the data 
produced.  Indeed, the finding of PIWIL2 expression in normal lymphoid 
populations is consistent with the hypothesis underlying this Fellowship, that 
“acute lymphoblastic leukaemic blasts derive an intrinsic propagating potential 
from their lymphoid cell of origin”.  Development of our understanding of PIWIL2 
biology has therefore remained interesting.  This interest has grown in the light 
of recent publications determining a sequence specific role for PIWI/piRNAs 
outside of the germline in both neuronal cells (Rajasethupathy, Antonov et al. 
2012) and especially in the lymphoid lineage derived NK cell (Cichocki, Lenvik 
et al. 2010).  Promoter methylation is the mechanism of action in both of these 
settings, and provides a feasible mechanism of PIWIL2 mediated control of self-
renewal/propagation in lymphoid cells.  In addition, the identification of piRNAs 
in murine lymphoid cells which, in contrast to repeat sequence specific piRNAs 
found in haematopoietic precursors and myeloid lineage cells, show specificity 
for 5’ UTRs, 3’ UTRs, coding and intronic regions (Yan, Hu et al. 2011), 
suggests a specific role for PIWI/piRNAs in lymphoid cells.  With our improved 
knowledge of PIWI/piRNA biology and with developments both in commercially 
available technology (improved methylation arrays, new antibodies) and 
particularly with the routine use of commercially available microRNA adapted 
shRNA lentivectors in our laboratory, there is now the opportunity to provide 
more consistent modulation of PIWIL2 in lymphoid malignancy, allowing 
assessment of the effect of PIWIL2 loss on promoter methylation.  In parallel, a 
new collaboration will allow the identification of lymphoid piRNAs, providing an 
additional source of information on potential PIWIL2 targets.  This project is 
described in greater detail in Chapter 9.
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1. Introduction 
In acute myeloid leukaemia, a clear hierarchy has been identified within which 
leukaemia stem cells with the greatest repopulating capacity sit at the apex and 
have a CD34+CD38- immunophenotype, mirroring normal haematopoiesis 
(Lapidot, Sirard et al. 1994; Bonnet and Dick 1997).  Leukaemia propagating 
capacity is now thought to be present in more diverse populations than was 
once believed, but it still appears that this capacity reduces as cells 
“differentiate” towards more mature immunophenotypes (Hope, Jin et al. 2004; 
Goardon, Marchi et al. 2011).  Recent identification of stemness signatures has 
demonstrated real differences between leukaemic populations in expression of 
genes associated with normal haematopoietic stem cells, suggesting that 
leukaemia stem cells utilise stemness programmes derived from normal stem 
cells, either embryonic (Somervaille, Matheny et al. 2009) or haematopoietic 
(Eppert, Takenaka et al. 2011). 
In contrast, leukaemia propagating cells in ALL are more frequent and present 
in a diverse range of immunophenotypic populations (Kong, Yoshida et al. 
2008; le Viseur, Hotfilder et al. 2008; Rehe, Wilson et al. 2012)(Appendix D).  
Sorting blasts for expression of CD34 has demonstrated a correlation between 
the loss of expression of CD34 and up-regulation of several B-precursor 
associated genes, including IRF4, MS4A1 (CD20), IgH constant region, and IgL 
κ and λ loci (le Viseur, Hotfilder et al. 2008).  Recent re-analysis of this data, 
comparing the most differentially expressed genes within sorted CD34+ and 
CD34- leukaemic blasts, has demonstrated the similarity of these populations to 
their respective normal stem/precursor populations.  CD34+ leukaemic blasts 
cluster with normal CD34+ haematopoietic stem cells.  Furthermore, applying 
the HSC/LSC signature generated by Eppert et al (Eppert, Takenaka et al. 
2011), CD34+ and CD34- ALL blasts cluster together and not in association 
with AML CD34+ cells or normal HSCs (Rehe, Wilson et al. 2012)(Appendix D), 
demonstrating that leukaemia propagating potential in ALL is not identified by 
this candidate LSC stemness signature. 
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This project aimed to analyse the expression of a number of candidate 
stemness related genes in sorted, patient-derived ALL specimens.  These 
genes were derived from published studies of the control of haematopoietic or 
leukaemic stemness. 
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2. Aims of the project 
 
The aims of this project were: 
1. To sort patient-derived leukaemic blasts according to surface 
expression of CD34 
2. To analyse expression of the candidate stemness genes BMI1, CD34, 
EZH2, HMGA2, MEIS1 and TERT in sorted leukaemic blasts and 
umbilical cord blood stem cells 
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3. Results 
4.1.1 Purity of sorted populations 
Patient-derived leukaemic blasts (see Appendix A for patient details) were 
retrieved from storage in liquid nitrogen, thawed and labelled with CD19 PE and 
CD34 FITC antibodies.  Primografted samples were also labelled with murine 
CD45 PECy7 and Ter119 PECy7 to exclude murine cells.  Samples were then 
sorted using a FACS Vantage cell sorter (Hesta McNeill).  For comparison, RNA 
was taken from umbilical cord blood cells sorted for expression of CD34, as 
described in 3.3.5. 
Post sorting purity of leukaemic blasts was assessed using the FACS Vantage.  
Except for sample 2510, purity was >85% in all populations (Table 4-1).  The 
purity of UCB1 was not assessed by flow cytometry as there were insufficient 
cells.  However, the substantial difference in CD34 expression indicates a 
substantially enriched population (Figure 4-1A).  UCB2 was labelled with CD34 
APC and analysed by flow cytometry as described in 3.3.5. 
Table 4-1.  Purity of sorted patient-derived leukaemic cells. 
Specimen CD34+ CD34- 
EMCR1 91.0% 98.5% 
L784 87.8% 97.7% 
L49101 96.8% 92.6% 
2510 88.9% 63.7% 
L4951 97.1% 95.6% 
L826 94.7% 91.8% 
Mean 92.7% 90.0% 
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4.1.2 Expression of candidate stemness genes 
Sorted populations were washed and RNA was extracted.  Quantitative RT 
PCR was performed with primers specific for the candidate stemness genes 
BMI1, CD34, EZH2, HMGA2, MEIS1 and TERT.  Expression was analysed by 
ΔCt using GAPDH as a reference gene.  Using Wilcoxon matched-pairs signed 
rank analysis, only CD34 expression differed significantly between sorted 
leukaemic populations, p=0.03, as it did for sorted umbilical cord blood 
specimens.   
Unexpectedly, the polycomb group genes BMI1 and EZH2 showed no 
consistent difference in expression between CD34+ and CD34- populations 
from either leukaemic or umbilical cord blood specimens.  However, expression 
of TERT, MEIS1 and HMGA2 showed substantially higher expression in CD34+ 
umbilical cord blood stem cells than in the corresponding CD34- population, as 
would be expected (Figure 4-1B-D).   
In contrast to sorted umbilical cord blood HSCs, expression of TERT was not 
different between sorted leukaemic populations and overall was higher than in 
either of the HSC populations, suggesting an important function across both 
populations of leukaemic blasts (Figure 4-1B).  Expression of MEIS1 and 
HMGA2 was more restricted.  Neither of these genes showed higher expression 
in CD34+ cells, except for the expression of HMGA2 in the Philadelphia 
chromosome positive ALL sample, L4951 (Figure 4-1C).  However, the two fold 
higher expression seen in CD34+ leukaemic cells from this sample was 
substantially lower than the 31-36 fold difference in expression seen in sorted 
HSC populations.  MEIS1 was characteristically highly expressed in the one 
MLL rearranged sample tested (Figure 4-1D).  Together, these findings argue 
against these candidate stemness genes having an important role in a CD34+ 
leukaemia stem cell population, consistent with the lack of a stem cell hierarchy 
in ALL. 
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Figure 4-1.  Expression of candidate stemness genes in CD34+ and CD34- leukaemic 
blasts.  A) CD34 expression is substantially higher in CD34+ cells (black bars) from both 
umbilical cord blood (UCB) and leukaemic blasts.  B)  TERT expression is substantially higher in 
CD34+ UCB cells than in CD34- cells (hashed bars).  In leukaemic blasts, no difference in 
TERT expression is seen.  The same pattern is seen in expression of both C) HMGA2 and D) 
MEIS1, although expression in leukaemic blasts is less consistent.  Relative expression is 2
-ΔCt
, 
reference gene GAPDH  
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4. Discussion 
As leukaemia propagating cells in ALL are present in both CD34+ and CD34- 
sorted populations (Kong, Yoshida et al. 2008; le Viseur, Hotfilder et al. 2008), 
both populations would be predicted to express genes required for extensive 
cellular proliferation.  This project aimed to assess the expression of a number 
of candidate stemness genes in sorted CD34+ and CD34- leukaemic blasts 
using qRT PCR.  A normal haematopoietic control was provided by two 
umbilical cord blood specimens, also sorted for expression of CD34.  The 
differential expression of the CD34 gene in all samples provided a control for 
the validity of this approach. 
The first candidate showing differential expression in umbilical cord blood stem 
cells is telomerase reverse transcriptase (TERT).  TERT encodes a key 
component of the telomerase complex, which functions to maintain telomere 
length and prevent cellular senescence.  As such it is an essential component 
of the self-renewal programme of normal and malignant stem cells.  In 
leukaemia, TERT expression is under the control of the leukaemic fusion genes 
MLL/AF4 and RUNX1/RUNX1T1 (Gessner, Thomas et al. 2010).  Down-
regulation resulted in reduced clonogenicity and induction of replicative 
senescence.  Baseline expression is however, too low for TERT expression to 
be reliably represented in expression array analyses and therefore it is not 
surprising that it does not appear in the stemness signature of Eppert et al 
(Eppert, Takenaka et al. 2011). 
MEIS1 is a homeobox protein implicated in the leukaemogenesis of MLL 
rearranged leukaemias and contained in the AML stemness signature defined 
by Eppert et al (Eppert, Takenaka et al. 2011).  MEIS1 is up-regulated by MLL 
fusion proteins, whilst knockdown of MEIS1 in MLL rearranged leukaemic cell 
lines impairs engraftment and proliferation in murine xenograft models (Kumar, 
Li et al. 2009; Orlovsky, Kalinkovich et al. 2011).  The present project 
demonstrated higher expression of MEIS1 in CD34+ cord blood HSCs, 
compared with CD34- HSCs.  Leukaemic expression was low in all samples 
other than L826, the only MLL rearranged leukaemia in the panel tested and 
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L4951, a Philadelphia chromosome positive ALL.  In both of these samples, 
however, expression was higher in the CD34- population. 
HMGA2 encodes the high mobility group protein A2 which is highly expressed 
during embryogenesis but is then down-regulated (Gattas, Quade et al. 1999).  
It functions to control growth and development, as evidenced by abnormal 
growth both in mutated mice (Zhou, Benson et al. 1995; Battista, Fidanza et al. 
1999) and in a child with constitutional mutation of this gene  (Ligon, Moore et 
al. 2005).  HMGA2 expression has been identified in haematopoietic stem cells 
as well as blasts from both acute and chronic myeloid leukaemias (Meyer, 
Krisponeit et al. 2007).  Expression in the present study was limited to four 
samples, although levels were substantially higher in sample L4951, positive for 
the Philadelphia chromosome.  Overall there was no evidence for higher 
expression in CD34+ leukaemic cells.  
The polycomb group proteins BMI1 and EZH2 were not differentially expressed 
in either sorted HSCs or leukaemic blasts.  This was a somewhat unexpected 
finding as both of these genes are essential to the maintenance of HSC self-
renewal capacity by generating bivalent chromatin domains (Konuma, Oguro et 
al. 2010) and control the proliferative potential of leukaemia stem cells (Lessard 
and Sauvageau 2003).  The reasons for the lack of differential expression in the 
present study are not clear.  It is possible that the single marker sorting strategy 
was insufficiently effective in isolating HSCs resulting in analysis of a mixed 
population. 
This project has shown that the candidate leukaemic stemness genes TERT, 
MEIS1 and HMGA2 are differentially expressed in sorted CD34+ and CD34- 
normal haematopoietic stem cells.  In contrast, expression in sorted leukaemic 
blasts showed no bias towards higher expression in CD34+ cells consistent with 
the lack of a stem cell hierarchy in acute lymphoblastic leukaemia (Rehe, 
Wilson et al. 2012)(Appendix D). 
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5.1 Introduction 
Following the decision to stop the candidate (PIWIL2) self-renewal gene project, 
the alternative strategy to investigate the cancer stem cell programme in 
childhood acute lymphoblastic leukaemia was to perform an unbiased, genome-
wide functional screen.  This project used a commercially available short hairpin 
RNA (shRNA) library, produced by Open Biosystems.  The Decode™ negative 
selection library contains approximately 70000 different lentiviral constructs, 
each coding for a unique shRNA.  This provides coverage of the entire genome 
with 2-3 constructs per gene.  The library is divided into 7 pools, each of which 
contains lentiviral particles produced from approximately 10000 individual 
constructs.  
The transfer vector used is the Open Biosystems pGIPZ vector, Figure 5-1.  
Here, expression of a single transcript is driven by the RNA polymerase II 
promoter CMV and codes for Turbo GFP (reporter gene), puromycin N-acetyl-
transferase (PAC, mammalian selection) and an shRNAmir30 construct (RNAi).  
Cloning the shRNA within a microRNA (mir30) sequence is believed to result in 
the transcript being cleaved by the normal microRNA processing pathway, 
namely Drosha within the nucleus, active transport into the cytoplasm via 
Exportin 5 and subsequent Dicer cleavage followed by active loading into the 
RNAi Induced Silencing Complex, RISC, see section 1.3.  This results in more 
effective loading of shRNA into RISC and improved degradation of target 
transcript – known as knockdown (Dickins, Hemann et al. 2005; Silva, Li et al. 
2005).  This is a critical feature in a pooled library screen as each target cell 
must be transduced with only a single viral particle to allow deconvolution of 
constructs at the end of the experiment.  That is, if cells were to contain multiple 
constructs, it would not be possible to determine which of those constructs were 
responsible for the altered phenotype of the cell.  Immediately 3’ to the 
shRNAmir construct is an approximately 60 nucleotide barcode sequence which 
is specific for the hairpin and is used to deconvolute the pools by microarray 
analysis following completion of the screen. 
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Figure 5-1. The Open Biosystems pGIPZ vector.  A single transcript codes for the turbo GFP, 
puromycin selection marker and short hairpin RNA which is sited within a larger sequence 
derived from microRNA30.  cPPT – Central polypurine tract, Zeo – zeomycin selection marker, 
CMV – CMV promoter, tGFP – Turbo GFP reporter, IRES – Internal Ribosomal Entry Site, Puro
r
 
– Puromycin-N-Acetyltransferase, shRNAmir – short hairpin construct in mir30 context, WRE – 
Woodchuck response element, sinLTR – self-inactivating 3’ long terminal repeat, pUC Ori – 
E.coli origin of replication, Amp
r
 – ampicillin resistance, 5’LTR – 5’ long terminal repeat (Image 
taken from www.openbiosystems.com/rnai/shrnamirlibraries/gipzlentiviralshrnamir). 
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5.2 Aim of the project 
This project sought to develop a genome-wide RNAi screen which would allow 
the identification of novel candidate genes important to the self-renewal of acute 
lymphoblastic leukaemia propagating cells.  These genes, or the pathways to 
which they belong, may offer novel therapeutic opportunities.  Specifically, the 
aims of this project were to: 
1. Optimise transduction of ALL cell lines using the pGIPZ lentiviral system to 
allow screening with the Decode shRNA library 
2. Investigate the potential for performing the screen using co-culture with bone 
marrow stromal feeder cells to simulate leukaemic-niche interactions 
3. Perform a trial screen using a single lentiviral pool 
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5.3 Results 
5.3.1 Optimisation of Decode screening methodologies 
5.3.1.1 Optimisation of lentiviral transduction 
Transduction was performed using a spinfection technique.  The initial work 
within this project involved optimising the spinfection to maximise the cell 
coverage available from each vial of titred virus provided with the library.  These 
experiments also allowed estimation of the transduction efficiency of leukaemic 
cells lines.  Comparison of transduction efficiency relative to HEK293T cells, 
within which the library had been titred by the manufacturer, allows a calculation 
of the volume of virus required to achieve a desired rate of transduction in a 
known number of cells.  This is known as the multiplicity of infection (MOI). 
The standard transduction protocol used within the laboratory involves 
suspending 106 cells in 1 ml medium supplemented with 8 µg/ml polybrene.  
Virus is added and 500 µl of suspended cells pipetted per well of a 48 well 
plate.  The plate is then centrifuged at 1500 x g for 2 hours at 32oC.  This 
protocol was initially modified by performing the spinfection in a 48 well plate, 
rather than 24 well.  This modification brought the cells closer together, 
increasing the likelihood contact with virus.  When compared to a previous 
experiment using the original 24 well protocol in the MLL rearranged cell line 
SEM (performed by Svetlana Myssina, post-doctoral researcher), the reduction 
in surface area was accompanied by an increase in the relative transduction 
efficiency from 14% to approximately 50% (Table 5-1). 
Additional factors were subsequently examined.  These were: 1) reduction in 
polybrene concentration from 8 µg/ml to 4 µg/ml; 2) use of protamine 5 µg/ml 
instead of polybrene; 3) use of serum free Optimem medium without 
polybrene/protamine; 4) reduction in transduction time from 18 hours to 6 hours 
to limit toxicity of exposure to polybrene.   
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The relative transduction efficiency was also determined for additional 
lymphoblastic leukaemic cell lines – 697 and REH, and t(8;21) AML cell lines 
Kasumi-1 and SKNO-1.  The results of the six test transductions performed to 
assess these variables are presented in Table 5-1. 
In parallel to assessments of transduction efficiency, cell proliferation and 
viability were assessed during transductions 2-5.  This demonstrated a 
proliferative advantage to those cells transduced in the presence of protamine 
as compared with polybrene (4 or 8 µg/ml), but due to the lower transduction 
efficiency this did not result in a greater number of viable transduced cells. 
Transductions 4-6 also investigated scaling up the transduction to a 6 well-plate 
format.  For this transduction, 5 x 106 cells were resuspended in 2 ml medium 
and pipetted into a 6 well plate.  A modification was made to the spinfection 
protocol, with a 20 minute, 50 x g spin performed to settle the cells evenly onto 
the plate surface, followed immediately by increasing the speed to the full rate 
of 1500 x g.  This prevented the cells layering along one edge of the well, as 
was seen to happen if the centrifuge was set initially to 1500 x g.  During these 
three test transductions, each of which was conducted with SEM cells and 
polybrene 8 µg/ml, the relative transduction efficiency was 81%, 101% and 
54%.  The third experiment (and the whole of transduction 6) was conducted 
with a new stock of SEM cells, bought fresh from DSMZ (Braunschweig, 
Germany), as these were the cells to be used for the final screen experiment. 
The multiple test transductions demonstrated that no alternative method offers 
an advantage over the standard protocol of polybrene 8 µg/ml, incubated in the 
presence of virus overnight.  Experiments to scale up the transduction produced 
similar outcomes to the initial transductions, although there was still a 
substantial variability between transductions of 54-101% relative transduction 
efficiency.  Therefore, this scaled up standard protocol was used for the trial 
screen described in 5.3.2.  
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Table 5-1.  Relative transduction efficiency determined in each of six test transductions 
using GIPZ non-target control virus particles.  Relative transduction efficiency is calculated 
relative to efficiency in HEK293T cells (viral titre data provided by manufacturer).  Transduction 
6 used new SEM cells purchased from DSMZ. 
  
Transduction Cell line Polybrene Polybrene Protamine Serum free
8 µg/ml 4 µg/ml 5 µg/ml
1 SEM 91 54
2 SEM 55
697 120
REH 120
Kasumi-1 8.2
3 SEM 44 15.5 6.5
697 7.3 3.7 2.8
REH 29 8.5 1.9
Kasumi-1 7.0 1.5 -
SKNO-1 9.0 2.8 -
4 SEM 53 21 8.5
REH 42 14 4.8
5 SEM -6 hrs 105 78 33
SEM -18 hrs 133 100 68
6 SEM 62 45
Maximum relative transduction efficiency (%)
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5.3.1.2 Determining puromycin toxicity 
Following transduction targeting an MOI of 0.3, transduced cells were to be 
selected by a period of culture in the presence of puromycin.  In order to 
determine the minimum concentration of puromycin effective for selection, two 
experiments cultured untransduced cells in the presence of increasing 
concentrations of puromycin from 0 – 4 µg/ml for up to 14 days.  Cells were 
monitored by performing cell counts and by using a WST-1 assay as a measure 
of metabolic activity. 
In the first experiment, both cell numbers and metabolic activity were affected 
by day 4, with cells grown in 0.5 µg/ml puromycin showing a substantial drop in 
numbers and loss of metabolic activity (Figure 5-2A-B).  This threshold did not 
change up to day 10 or 14 (Figure 5-2C-D).  As there was a substantial 
difference between 0.25 µg/ml and 0.5 µg/ml, a second experiment was 
conducted with further concentrations tested between 0 µg/ml and 0.5 µg/ml.  In 
this second experiment, three other cell lines were also tested, namely REH, 
697 and Kasumi-1.  This experiment confirmed that the minimum concentration 
required to negatively select untransduced SEM cells was 0.4 µg/ml (Figure 
5-2E).  The results varied in other cell lines, with both REH and 697 cells 
showing a clear threshold of 0.3 µg/ml.  Kasumi-1 cells gave a less clear result, 
with gradually increasing toxicity observed between 0 – 2 µg/ml. 
Initially 0.4 µg/ml puromycin was used to positively select transduced SEM-
GIPZ cells.  However, during the course of the test transductions described in 
5.3.1.1, trial selections demonstrated that 0.8 µg/ml puromycin could be used 
without excessive cell death and produced a more rapid positive selection 
(Figure 5-2F).  This became the standard concentration for positive selection of 
SEM-GIPZ cells.  
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Figure 5-2.  Assessment of puromycin toxicity.  A) Metabolic activity (assessed by WST-1 
assay) and B) cell counts in SEM cells at day 4 of puromycin treatment.  Metabolic activity in 
SEM cells at C) day 10 and D) day 14.  E) Metabolic activity at day 6 of puromycin treatment in 
697, REH, SEM and Kasumi-1 cells.  F) Positive selection of SEM-GIPZ cells with different 
concentrations of puromycin. 
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5.3.1.3 M2-10B4 feeder cell culture and growth arrest 
M2-10B4 murine bone marrow stromal cells were grown to confluence in 175 
cm2 dishes/flasks before being divided 1:5 every 3-4 days.  As they grow 
rapidly, two different approaches were taken to arrest their growth.  Initially, 
mitomycin C was used at concentrations between 2 - 20 µg/ml.  Cells were 
exposed for 2 ½ hours before being washed and fresh medium added.  
However, growth arrest was not achieved using this protocol.  Using an 
alternative approach, M2-10B4 cells were irradiated with 80 Gy as described in 
2.3.2.1 and seeded into fresh culture dishes/flasks at 5 x 106 cells/ml.  Using 
this approach, good growth arrest was achieved with very little cell death or 
formation of proliferative foci.  All experiments assessing feeder cell co-culture 
used these irradiated feeder cells. 
5.3.1.4 Leukaemic – feeder cell interactions 
In order to provide the greatest chance of identifying genes involved in 
leukaemic propagation in vivo, the standard suspension culture/outgrowth 
assay used in genome-wide RNAi screening was modified to involve a re-
plating assay.  Lymphoblastic leukaemic cell lines do not form colonies in 
standard colony formation assays, so co-culture on a bone marrow stromal cell 
derived feeder layer, M2-10B4, was investigated.  This offered not only the 
potential for an assay of colony formation from low cell density, but also 
provided the potential for leukaemic-niche interaction. 
Initially, the relevance of the feeder layer was investigated.  It was assumed that 
SEM cells seeded at a very low density of 104 cells/ml (standard density 5 x 105 
cells/ml), 50 ml per 175 cm2 dish/flask, would not proliferate.  However, when 
seeded onto a sub-confluent layer of irradiated feeder cells (5 dishes) in RPMI 
1640, 10% v/v FCS, GIPZ transduced SEM cells expanded from 2.5 x 106 cells 
to 1.7 x 108 cells, approximately 6 doublings, in 7 days.  In a second 
experiment, serial re-plating showed almost 4 doublings in 5 days, followed by 
more than 4 doublings in 4 days of the second plating and more than 2 
doublings in 3 days of the third replating.  During these replating steps Turbo 
GFP (tGFP) expression was also analysed.  Having been 88% prior to the first 
plating, tGFP expression dropped to 78% at the first harvest.  After the second 
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plating, tGFP remained stable at 78%, before reducing further to 66% after a 
third re-plating step.  As expression of shRNA and tGFP are driven by the same 
promoter, a drop in tGFP expression raises concerns over the expression of 
shRNA.  Maintaining the expression of tGFP by on-going puromycin selection 
pressure was therefore examined further and is described in 5.3.1.6. 
To look at the physical interactions of SEM and M2-10B4 cells, irradiated M2-
10B4 cells were seeded into a 7 cm2 glass culture dish to give a sub-confluent 
layer.  Once adherent, feeder cells were counter stained with Rhodamine B, 20 
ng/ml, for 30 minutes.  A total of 3 x 104 SEM-GIPZ cells were seeded onto the 
feeder cells and cultured for 6 days before being viewed using a confocal 
microscope.  This analysis demonstrated the growth of SEM-GIPZ cells in 
discrete colonies, supporting the use of this assay as a modified colony 
formation assay (Figure 5-3A).  Furthermore, 3-dimensional images, 
reconstructed by stacking multiple planar images taken along the Z-axis, 
demonstrated that SEM-GIPZ cells were growing down between the feeder 
cells, not simply growing adjacent to them (Figure 5-3B).  This is consistent with 
presence of physical leukaemic-niche interaction.  
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Figure 5-3.  Confocal imaging of SEM-GIPZ cells growing in colonies on M2-10B4 feeder 
cells.  A)  Planar image of SEM-GIPZ cells, expressing tGFP (green), growing in discrete 
colonies on M2-10B4 feeder cells, counterstained with Rhodamine B (red).  Scales show 100 
µm.  B) Z-stacked 3-dimensional images showing SEM-GIPZ cells growing down into M2-10B4 
feeder cells.  Left image is surface view.  Right image shows same z-stack rotated 180
o
 about 
the Z axis so that the underside of the feeder monolayer (red) is now seen.  This demonstrates 
SEM-GIPZ cells growing down through the feeder cell layer. 
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During validation of the assay, an experiment was performed to demonstrate 
that SEM cells would not grow when seeded at 104 cells/ml in the absence of 
feeder cells.  In the first experiment, SEM-GIPZ cells were plated out in 
standard medium (RPMI 1640, 10% v/v FCS) at 104 cells/ml, 50 ml in a 175 cm2 
culture dish.  Unexpectedly the cells proliferated well, undergoing more than 5 
doublings in 7 days, a rate consistent with standard culture conditions. 
It was hypothesised that decreasing the concentration of FCS in the culture 
medium would make the leukaemic cells reliant on niche support.  Two 
independent experiments were performed to identify the concentration of FCS 
required to support the growth of SEM cells, at low seeding density (104 cells/ml 
in 50 ml) in the absence of feeder cells.  Cells were plated out in 175 cm2 
dishes with concentrations of FCS from 0-10% v/v and cell counts performed 7 
days later.  These two experiments confirmed that, in the presence of 10% v/v 
FCS, SEM cells were able to undergo more than 5 doublings in 7 days (Figure 
5-4).  The growth rate decreased as the concentration of FCS decreased, until 
no growth was seen with 1% v/v FCS. 
One further experiment seeded SEM-GIPZ cells at 104 cells/ml, 50 ml per dish 
in medium with 1% v/v FCS either with or without feeder cells.  This again 
showed no growth in the cells grown in the absence of feeder cells, whilst those 
cells grown on feeder cells underwent approximately 4 doublings in 7 days (final 
cell count 7.8 x 106 cells in total).  It was therefore decided that during the 
screen, SEM-GIPZ cells would be re-plated with irradiated M2-10B4 feeder cells 
(5 x 106 cells/175cm2) in RPMI 1640, 1% v/v FCS.  
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Figure 5-4.  Proliferation of SEM cells at low seeding density with decreasing 
concentrations of fetal calf serum.  SEM cells proliferated normally in 7.5-10% FCS but failed 
to proliferate in 1% or 0%.  Graph shows mean of two independent experiments with bars 
indicating standard error of the mean. 
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5.3.1.5 Expression of tGFP during culture on feeder cells 
Having established a standard culture condition for SEM-GIPZ cells on 
irradiated M2-10B4 feeder cells (104 cells/ml RPMI1640, 1% v/v FCS, 50 ml per 
175 cm2 culture dish/flask), the maintenance of tGFP expression was 
examined.  This followed an early re-plating experiment, conducted with 10% 
v/v FCS, in which expression of tGFP was seen to reduce from 88% prior to 
plating to 78%, 78% and then 66% following each of 3 serial re-plating steps, 
described in 5.3.1.4.  As tGFP and the shRNAmir construct are expressed from 
the same promoter, a reduction in expression of tGFP is likely to be 
accompanied by a reduction in expression of shRNA.  An attempt was therefore 
made to co-culture SEM-GIPZ cells on M2-10B4 feeder cells in the presence of 
puromycin. 
SEM-GIPZ cells were seeded onto two plates of feeder cells using the standard 
conditions described above.  In addition, puromycin 1 µg/ml was included.  
Feeder cells were resuspended by trypsinisation on day 5 (one plate) and day 
11 (second plate).  Cells trypsinised on day 5 were reseeded in standard 
conditions with the addition of either 1 µg/ml or 0.4 µg/ml puromycin and re-
trypsinised 6 days later.  For the first plating, analysis at day 5 showed a total of 
7.5 x 105 cells (less than one doubling), with expression of tGFP >98%.  
Analysis of the second plate at day 11 showed 1.4 x 106 cells (less than 2 
doublings).  Expression of tGFP remained high, >99%.  For the SEM-GIPZ cells 
re-plated after 5 days on feeder cells, analysis on day 6 showed that with 1 
µg/ml puromycin no increase in cell numbers had occurred, whilst with 0.4 
µg/ml puromycin the total cell count was 1.25 x 106 cells (less than 2 doublings).  
Expression of tGFP was >98% in both samples. 
These experiments demonstrated that tGFP expression can be maintained 
during feeder cell co-culture by the addition of 0.4 µg/ml puromycin, but even at 
this concentration, the growth of SEM-GIPZ cells is substantially reduced as a 
result of feeder cell toxicity.  M2-10B4 feeder cells were therefore stably 
transfected with pPAC, a plasmid encoding puromycin N-acetyltransferase. 
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5.3.1.6 Puromycin resistant feeder cells 
In order to allow the on-going selective pressure of culture with puromycin 
during the co-culture assay, M2-10B4 feeder cells were stably transfected with 
pPAC.  Initially, transfection was attempted using calcium phosphate 
precipitation, as described for transfection of 293T cells with lentiviral plasmids.  
This approach was not successful, with all M2-10B4 cells dying under 
puromycin selection on two occasions.  An alternative approach was taken 
using Lipofectamine LTX.  M2-10B4 cells were grown to sub-confluence in 6 
well plates and then incubated with pPAC plasmid and varying concentrations 
of Lipofectamine LTX.  Having allowed 72 hours for expression of the plasmid, 
puromycin was added at 1 µg/ml and then increased to 2 µg/ml the following 
day.  A small number of surviving colonies were isolated and expanded under 
continued selection with 2 µg/ml puromycin. 
To test whether M2-10B4-PAC cells were able to support the growth of SEM-
GIPZ cells with on-going puromycin selection pressure, 5 x 105 SEM-GIPZ cells 
were seeded onto irradiated M2-10B4-PAC feeder cells in 50 ml RPMI 1640, 
1% v/v FCS and 0.4 µg/ml puromycin.  After 4 days the feeder cells were 
trypsinised, counted and analysed by flow cytometry.  This confirmed that SEM-
GIPZ cells had expanded 3 fold and that expression of tGFP was maintained at 
95%.  
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5.3.2 First trial screen 
Through the protocol optimisation described in 5.3.1 an experimental design 
was developed which would allow the screening of individual pools of lentiviral 
constructs in leukaemic cell lines.  Initial transduction would be followed by a 
short period of positive selection to achieve >85% expression of tGFP.  
Transduced leukaemic cells would then be serially re-plated on bone marrow 
stromal cells to recreate leukaemic propagation in a bone marrow niche micro 
environment. 
This protocol, however, represents a substantially more complex experiment 
than the standard outgrowth assay used most frequently in RNAi screens.  As 
such, it was important to demonstrate both the relevance and feasibility of this 
approach by performing a trial screen (Figure 5-5).  Having completed this, a 
replicate trial was performed using the same virus pool to assess the 
reproducibility of the protocol.  In order to determine the number of re-plating 
steps necessary, trial samples were taken at baseline (required to provide a 
comparator), following puromycin selection (to achieve >85% selection), 
following a period of suspension culture equivalent to 11-12 doublings in total 
and following the first and second re-plating steps.  Comparison of the results 
derived from each of these time points would allow determination of the final 
experimental protocol to be used for the complete screen.  Trial screens were 
performed using pool 7 from the decode library as this pool had the highest viral 
titre.  
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Figure 5-5.  Experimental design for trial screens.  Transduced cells undergo positive 
selection with puromycin prior to being split into two parallel arms.  The first arm is plated twice 
at low density onto puromycin resistant bone marrow stromal feeder cells.  The second arm is 
maintained using a “standard” suspension culture approach.  
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5.3.2.1 Transduction 
Transductions were performed in 6 well plates, 5 x 106 cells per well in 2 ml 
medium.  The standard transduction medium was used (RPMI 1640, 10% v/v 
FCS, polybrene 8 µg/ml) and standard spinfection protocol (1500 x g, 2 hours, 
32oC).  For the first trial experiment, an estimate of the number of cells required 
was made as follows: the desired coverage for the 10,000 construct pool was 
1000 fold (this is equivalent to 95% probability of achieving a 100 fold coverage, 
see section 2.3.10.3); the desired MOI was 0.3; cell survival following 
transduction would be 90% (as seen in test transductions using 6 well plate). 
    
         
                    
If the relative transduction efficiency was 90% then this transduction would 
require 12.9 µl virus from pool 7 (9.56 x 108 TU/ml).  In order to use the entire 
25 µl vial of virus, the number of cells was scaled up to 7.5 x 107 cells.  If the 
actual relative transduction efficiency was closer to the lower estimate 
generated in 5.3.1.1, approximately 50%, the total number of transduced cells 
would be 1.2 x 107, still sufficient to achieve a 1000 fold coverage. 
The day following transduction, cells were resuspended, pooled into two 
aliquots (14 ml) and centrifuged 300 x g, 10 minutes.  Seven millilitres of 
supernatant was removed from each aliquot to reduce the polybrene 
concentration and then cells resuspended with addition of a further 30ml 
medium to give a final cell concentration of 106 cells/ml and pooled.  
Resuspended cells were divided into one of two 75 cm2 flasks. 
5.3.2.2 Analysis of transduction 
Analysis of tGFP expression on day 4 following transduction demonstrated only 
7.7% of cells expressing tGFP (Figure 5-6A).  From a starting number of 75 x 
106 cells, this equated to a total number of 5.8 x 106 transduced cells, although 
an increase in the cell number meant that by day 4 there were 190 x 106 total 
cells and 14.6 x 106 transduced cells.  With such a low proportion of cells 
containing an integrated construct, the baseline DNA sample would significantly 
under-represent integrations, failing to maintain the fold coverage into the array 
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analysis.  Transduced cells were therefore enriched by overnight culture in 
puromycin. 
5.3.2.3 Density centrifugation of viable cells 
Selection with 1 µg/ml puromycin was performed overnight using one third of 
the total number of cells in culture – 4.7 x 106 transduced cells.  The following 
day, day 5, expression of tGFP was 17% of viable cells (Figure 5-6A).  Viable 
cells were enriched by density gradient centrifugation, from which a total of 28 x 
106 cells were retrieved to provide the baseline sample.  Expression of tGFP in 
the enriched population was stable at 15%.  This equated to 4.2 x 106 tGFP 
positive cells retrieved, 450 fold coverage.  On-going culture was performed 
with 0.8 µg/ml puromycin. 
5.3.2.4 Monitoring of positive selection 
The expression of tGFP was monitored by flow cytometry throughout the period 
of initial selection.  This showed an increase in expression to >95% in the first 7 
days of selection (day 11 post transduction) (Figure 5-6A).  However, 
throughout this period there was no increase in viable cell numbers (Figure 
5-6B).  Large numbers of apoptotic cells were present.  On day 14 following 
transduction a further enrichment of viable cells was performed using density 
gradient centrifugation.  This recovered a total of 4 x 106 cells.  Following this 
enrichment SEM-GIPZ cells again proliferated, doubling approximately 3.7 
times between days 14 and 23.  This gave sufficient leukaemic cells for seeding 
onto feeder cells (5 x 106 cells), continuing suspension culture (32 x 106 cells) 
and harvesting for DNA (107 cells).  Cells for DNA were washed with PBS and 
stored as a cell pellet at -20oC. 
Cells maintained in suspension culture (puromycin 0.8 µg/ml) were passaged 
three times per week until day 35 when they were harvested for DNA.  Cells 
harvested for DNA were washed with PBS and stored as a cell pellet at -20oC. 
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5.3.2.5 Re-plating steps 
SEM-GIPZ cells were seeded onto 10 plates of M2-10B4 feeder cells at a 
concentration of 104 cells/ml, 50 ml per plate.  The medium used was RPMI 
1640 with 1% v/v FCS and 0.4 µg/ml puromycin.  Cells were harvested by 
trypsinisation after 7 days.  At this time, 5 of the plates, all seeded with the 
same batch of feeder cells, showed a marked difference to the other 5 plates 
which had received a different batch of feeder cells.  The total cell count in the 
first 5 plates was 21.8 x 106 cells whilst in the second 5 plates the count was 
just 5 x 106 cells.  The decision was taken to carry forward only cells from the 
first 5 plates, which had doubled 3 times since seeding.  The expression of 
tGFP in cells from the selected dishes had dropped slightly to 84% (Figure 
5-6A). 
SEM-GIPZ cells were either harvested for DNA (5 x 106 cells), re-seeded onto a 
further 11 plates of feeder cells (5.5 x 106 cells) or stored as back-up in liquid 
nitrogen (11.5 x 106 cells).  The second plating of SEM-GIPZ cells was 
harvested after 7 days.  Cells were recovered both from the supernatant (1.1 x 
106 cells) and following trypsinisation of adherent SEM-GIPZ/feeder cells (2.2 x 
106 cells).  A total yield of only 3.3 x 106 cells demonstrated almost no 
expansion in cell numbers over the period of co-culture. 
The feeder cells used in the second plating had, unlike the first plating, been 
irradiated and then stored ready for use in liquid nitrogen.  When seeded out 
prior to the plating, a substantial number of these cells had failed to adhere to 
the dish and the morphology of those which did was unusual, being elongated 
and spindle-like.  A repeat re-plating was therefore performed using feeder cells 
which were irradiated and then seeded out immediately into culture dishes.  
SEM-GIPZ cells stored in liquid nitrogen after the first plating were thawed and 
cultured in standard medium with 0.4 µg/ml puromycin.  After 72 hours SEM-
GIPZ cells were seeded out onto 8 dishes of fresh feeder cells and cultured for 
7 days.  Having observed a drop in expression of tGFP over the first plating, the 
concentration of puromycin was increased to 0.6 µg/ml for the second plating.  
Four of these dishes developed fungal infection, leaving four dishes to be 
harvested (total cell number seeded out 2 x 106).  Harvesting these plates 
yielded 13.2 x 106 cells, representing between 2 and 3 doublings.  Of these 6 x 
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106 cells were enriched by CD133 MACS sorting, which in turn yielded 2 x 106 
cells for immediate isolation of DNA.  Analysis of this sorted population showed 
that with the higher concentration of puromycin, expression of tGFP was 
maintained at 92% (Figure 5-6A).  
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Figure 5-6.  Selection and growth of SEM-GIPZ cells – first trial RNAi screen.  A) 
Expression of tGFP rises rapidly following overnight puromycin selection and density gradient 
centrifugation (day 4 to day 5) and then continues to rise with on-going puromycin selection.  
There is a drop in tGFP expression following the first plating on feeder cells (Feeder 1, 
puromycin 0.4 µg/ml) but the second plating results in a return to higher expression (Feeder 2, 
puromycin 0.6 µg/ml).  B) Adjusted transduced cell numbers during suspension culture in the 
presence of puromycin 0.8 µg/ml.  No growth is seen prior to eradication of apoptotic cells.  
Growth afterwards shows an appropriate doubling time of approximately 50 hours.  
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5.3.3 Second trial screen 
The initial trial screen had been subject to a number of difficulties.  These 
included: 
1. A low rate of transduction 
2. Poor growth of transduced cells during early positive selection 
3. Fungal infection of feeder cells 
4. Drop in tGFP expression during first plating on feeder cells 
5. Poor attachment of feeder cells which had been stored in liquid nitrogen 
6. Poor growth on feeder cells 
Whilst the second trial was intended to assess the reproducibility of the 
protocol, a number of modifications were made to address the problems 
encountered during the first trial. 
1. Fewer SEM cells were used to reduce the number of untransduced cells 
subject to puromycin selection (assumed relative transduction efficiency of 
0.6, therefore used 4.7 x 107 cells) 
2. Second density gradient centrifugation was performed early (day 8 post 
transduction) to reduce the period without leukaemic cell growth 
3. 175 cm2 flasks used instead of culture dishes to reduce airborne 
contamination by fungus 
4. Puromycin in plating assays used at 0.8 µg/ml to maintain tGFP 
expression 
5. Feeder cells irradiated and seeded straight into flasks without freezing  
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5.3.3.1 Summary of results of second trial 
The expression of tGFP on day 4 following transduction was 9.8% (Figure 5-7), 
giving a total of 4.7 x 106 transduced cells.  Puromycin was again applied at 1 
µg/ml overnight and density gradient centrifugation performed to enrich for 
viable cells.  The expression of tGFP following enrichment on day 5 was 26% 
(Figure 5-7).  A total of 5.4 x 106 transduced cells were recovered from the 
enrichment to provide the baseline sample.  By day 8 post transduction (day 4 
of positive selection), there had been no increase in viable cell numbers.  A 
second density gradient centrifugation enrichment was performed on day 8, 
returning 6.6 x 106 viable cells with 96% expressing tGFP (Figure 5-7). 
Following the earlier enrichment, cell growth was rapid with 3.7 doublings 
(equivalent to that seen between days 14 and 23 during trial screen 1) being 
completed by day 14.  Transduced cells were seeded out at this point into 10 
flasks of feeder cells (5 x 105 cells per flask at a concentration of 104 cells/ml, 
50 ml per flask).  The medium used was RPMI 1640 with 1% v/v FCS and 0.8 
µg/ml puromycin.  Cells were harvested after 7 days, at which time they had 
undergone exactly 3 doublings (as during plating 1 of trial screen 1).  SEM cells 
were purified by CD133 MACS sorting.  Expression of tGFP in these sorted 
cells was 78% (Figure 5-7).  Samples were taken for DNA and back-up cells 
frozen and stored in liquid nitrogen.   
A second plating was performed into 10 flasks of M2-10B4 feeder cells, as for 
the first plating.  After 7 days the cells did not look as densely grown as after the 
first plating.  Flasks were trypsinised, giving a total of 17 x 106 cells, equivalent 
to just 1.8 doublings.  SEM cells were isolated from feeder cells by CD133 
MACS sorting.  However, only 106 cells were recovered from this sort.  The 
second plating was therefore repeated using SEM cells frozen after 
trypsinisation of the first plating.  SEM were plated into 10 flasks of freshly 
irradiated feeder cells as described for the first plating.  After seven days the 
cell density did not look sufficiently high so half of the medium was aspirated off, 
the cellular content centrifuged out at 300 x g, 10 minutes and then 
resuspended in an equal volume of fresh complete medium which was returned 
to the flasks.  Flasks were then harvested after a total of 10 days of culture, at 
which point a total of 4 x 107 SEM were recovered, representing 3 doublings, 
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similar to that achieved for the second plating in the first trial screen.  
Expression of tGFP in recovered SEM cells was 79% (Figure 5-7). 
The suspension culture, maintained in parallel to the two re-plating steps was 
harvested on day 24 after 10.7 doublings, equivalent to the 10 doublings 
achieved in the first trial screen.  
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Figure 5-7.  Selection and growth of SEM-GIPZ cells – second trial RNAi screen.  
Expression of tGFP rises rapidly following overnight puromycin selection and densit y gradient 
centrifugation (day 4 to day 5) and then continues to rise with on-going puromycin selection.  
There is a drop in tGFP expression following the first plating on feeder cells but this level of 
expression is maintained through the second plating (both platings with puromycin at 0.8 µg/ml). 
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5.3.4 Sample processing and data analysis 
5.3.4.1 Amplification and purification of barcodes for pool deconvolution 
DNA was extracted from freshly harvested or frozen SEM-GIPZ cells stored as 
cell pellets at -20oC.  Viral barcode sequences were amplified using the 
negative selection primers contained within the Decode library kit.  Between 4 
and 22 individual PCR reactions, each containing 850 ng of DNA, were 
performed for samples taken at each time point.  The variation in number of 
reactions performed results from the varying proportions of transduced cells in 
the population, that is varying quantities of template, as well as the varying 
requirements for the arrays - 6 µg of DNA for the baseline sample which 
provided the comparator for the other time points, each of which required 1.5 
µg.  The PCR products were analysed by gel electrophoresis to ensure an 
appropriate 250 bp product was present in each reaction.  Reactions were then 
pooled and purified by gel electrophoresis.  DNA concentration was analysed by 
spectrophotometry before being sent to the Functional Genomics and 
Proteomics Facility, Birmingham University, who performed the labelling, 
hybridisation and scanning of the custom microarrays provided with the Decode 
library kit.  
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5.3.4.2 Data analysis 
Data analysis was performed commercially through the Functional Genomics 
and Proteomics Facility, Birmingham University.  For the first trial screen this 
analysis demonstrated a low signal intensity and high signal to noise ratio, 
presumed to result from the use of only one of seven viral pools, and therefore 
only 1 in 7 array probes being hybridised.  The distribution of Cy3 and Cy5 
signals was appropriate (Figure 5-8A).  For the second screen, the signal to 
noise ratio was again high.  However, in addition three of the four arrays 
demonstrated a technical problem, with the hybridisation giving an uneven 
distribution of signal (Figure 5-8B).  The second trial screen has therefore not 
been included in further analysis and the amplification and array analysis will be 
repeated. 
The baseline sample was competitively hybridised with each of the other four 
time points – day 23, day 35, replating 1 and replating 2, allowing comparison 
between these four later time points.  Using day 23 as an early point during 
stable culture, comparison was made to day 35 (10 doublings) as well as to 
feeder cell replating 1 (F1) and feeder cell replating 2 (F2).  Hairpins showing 
greater than a 2.5 fold change in abundance were identified (Figure 5-9).  This 
analysis identified: 24 constructs showing >2.5 fold decrease and 38 showing 
>2.5 fold increase between day 23 and day 35; 58 constructs showing >2.5 fold 
decrease and 42 showing a >2.5 fold increase between day 23 and F1; 18 
constructs showing >2.5 fold decrease and 9 showing a >2.5 fold increase 
between day 23 and F2.  
Chapter 5:  Genome-wide RNAi screen 
179 
Figure 5-8.  Example spatial distributions of positive (red) and negative (green) log ratios.  
A)  First trial screen.  B)  Second trial screen. 
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Figure 5-9.  Candidate constructs showing >2.5 change in abundance between day 23 
and subsequent time points.  A)  Candidates showing a >2.5 fold reduction in abundance.  B)  
Candidates showing a >2.5 fold increase in abundance. 
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A substantial overlap was identified between the constructs demonstrating a 
change at each of these time points.  In total, eight constructs decreased >2.5 
fold in all of the three later time points (Figure 5-10A).  A further eight constructs 
showed a >2.5 fold decrease in each of the feeder replating steps, but not the 
suspension culture (day 35) suggesting that these may represent genes critical 
for the colony formation assay/niche interaction provided by the feeder cell co-
culture (Figure 5-10A). 
In contrast, less commonality was seen in constructs demonstrating an increase 
in abundance.  Only 3 constructs were common to all time points, with a single 
additional construct common only to the two replating steps (Figure 5-10B). 
Amongst all of these candidates, one stood out as being of immediate interest, 
ANGPT1 (Figure 5-9A).  ANGPT1 encodes the secreted protein Angiopoietin 1 
which is the activating ligand for the vascular endothelial and haematopoietic 
progenitor cell surface receptor, TEK/Tie2.  Previous work from our laboratory 
has identified ANGPT1 as being highly expressed in MLL rearranged 
leukaemias with down-regulation being seen in response to MLL/AF4 
knockdown both in the SEM cell line and patient-derived leukaemic blasts 
(GarridoCastro, Bomken et al.).  This target was therefore carried forward to the 
in vivo analysis project described in Chapter 7 for further investigation.  
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Figure 5-10.  Candidate genes identified by the first trial RNAi screen in SEM cells.   A)  
Overlap of candidates demonstrating >2.5 fold decrease in abundance between day 23 and 
later time points.  Those genes common to all later time points (top right panel) and those 
common to the two feeder replating steps are detailed (lower right panel).  B)  Overlap of 
candidates demonstrating >2.5 fold increase in abundance between day 23 and later time 
points. 
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5.4 Discussion 
The optimisation of the screening protocol was intended not only to develop 
understanding of this new methodology within the Northern Institute for Cancer 
Research, but also to ensure that efficient transduction would be performed.  
This was important given the limited volume of virus within each library.  
Balanced against this was the risk of multiple integrations per cell, which was 
minimised by determining the viral titre required to achieve a multiplicity of 
infection of 0.3.  Despite the optimisation performed, during both trial screens 
the rate of transduction was substantially lower than had been predicted.  The 
reasons for this remain unclear.  During the first trial screen a number of 
researchers within the NICR had cell lines which were growing very slowly or 
even dying.  This problem was investigated at an Institute level and was felt 
most likely to be the result of a poor quality batch of fetal calf serum.  This was 
replaced half way through the first trial screen, ahead of the repeat attempt of 
the second plating step.  This would not, however, explain the poor, although 
slightly improved, rate of transduction in the second trial screen.  Loss of viral 
titre in the pools used is one possibility, although investigating this would be 
difficult.  It is possible that the storage of these vials over the preceding three 
years (somewhat longer than the suggested shelf life) resulted in a decrease in 
titre. 
The other principle aim of the preparatory work during this project was to 
investigate the potential for, and relevance of, performing a co-culture assay.  
The aim of this approach was to provide leukaemic-niche interactions to 
maximise the chance of identifying targets relevant to the in vivo 
microenvironment.  Unexpectedly, under standard culture conditions SEM cells 
seeded at low density (104 cells/ml) were able to grow in the absence of feeder 
cells.  However, when the concentration of fetal calf serum was reduced from 
10% to 1%, co-culture with feeder cells was required to maintain proliferation.  
In keeping with this finding, SEM-GIPZ cells seeded onto M2-10B4 feeder cells 
grew in distinct colonies with individual cells growing through and underneath 
the feeder cell layer.  Whilst an absolute need for physical interaction between 
leukaemic and feeder cells has not been demonstrated here, these two pieces 
of evidence suggest a genuine role for this in vitro modelled bone marrow niche 
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environment in the present project.  In addition to the eight constructs whose 
abundance showed >2.5 fold reduction at all final time points, a further subset 
of eight targets was identified as being important for cell 
survival/proliferation/maintenance during feeder cell co-culture in the first trial 
screen.  These candidates will need to be validated by the repeat hybridisation 
of the second trial screen.  The result of this second analysis will inform the 
decision on whether to complete the full screen using a co-culture assay based 
approach. 
Despite the potential benefits of performing the full screen using re-plating steps 
on feeder cell layers, this approach does add a substantial degree of complexity 
to the experiment.  Feeder cells need to be expanded and irradiated to be 
available at the right time for plating steps.  Leukaemic cells need to be re-
isolated from feeder cells at the end of a plating step.  Leukaemic cell 
proliferation during re-plating has twice been lower than during the initial plating 
step, a situation complicated by not being able to accurately assess leukaemic 
cell numbers without trypsinising the feeder/leukaemic culture flasks.  Finally 
the length of time required to perform the screen will vary substantially between 
the two approaches.  In order to be able to respond to changes and difficulties 
experienced with the more complex re-plating approach, it is reasonable to 
expect that only a single pool can be assayed at any one time.  In contrast, 
suspension culture could reasonably be performed in sequence, transducing 
the next pool as soon as the previous pool is in a period of exponential growth.  
It is therefore important to decide whether the potential benefits offered by the 
re-plating approach justify the delay in generating the data.  Whilst the co-
culture end-points provided eight candidate genes not identified by the 
suspension culture, there was also a subset of genes identified at all three time 
points.  Amongst this subset was the single strongest candidate identified by the 
trial screen, ANGPT1.  This gene has previously been identified within our 
laboratory as being highly expressed in MLL rearranged ALL, and is regulated 
by MLL fusion oncogenes (GarridoCastro, Bomken et al.).  Whilst this provides 
some validation for the screen described in this project, it also suggests that key 
genes contributing to leukaemic development/maintenance can be identified 
using a standard suspension culture approach. 
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The final decision on how to conduct the screen will require the information 
gained from the repeat amplification and hybridisation of DNA obtained from the 
second screen.  With these data it will be possible to make a statistical 
assessment of the strength of the candidates identified by the suspension 
culture versus the co-culture assay.  If there is reasonable evidence that co-
culture is likely to identify candidates important to leukaemic-niche interactions 
that would not be identified by suspension culture then it will be worthwhile 
investing the additional resources required to complete this more complex 
experiment.  If not, the relative simplicity of the suspension culture assay will 
make it preferable. 
However the screen is conducted, it will be critical to both identify and validate 
individual candidate targets.  Validation will initially involve generating an 
shRNA library with a much lower complexity than the genome-wide library 
described here – perhaps just 1000 candidates.  shRNAmir constructs specific 
for candidates identified by the genome-wide screen will be purchased and 
pooled.  A more limited screen will then be performed either in vitro or in vivo 
using additional leukaemic cell lines.  Candidates which are again identified 
during this screen will then be validated using patient-derived leukaemic blasts 
in vivo.  To prepare for this final validation step, two further projects conducted 
within the present Fellowship aimed to develop techniques and technologies 
required for in vivo candidate analysis.  Firstly, a protocol was developed for the 
lentiviral transduction of patient-derived leukaemic blasts.  Secondly, a novel 
vector allowing the in vitro and in vivo tracking of leukaemia, combined with an 
shRNAmir construct to allow the modulation of candidate genes, was designed, 
cloned and validated.  These two projects are described in Chapter 6 and 
Chapter 7.
  
 
 
Chapter 6  
Development of a protocol for 
the lentiviral transduction of 
patient-derived leukaemic blasts 
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6.1 Introduction 
Candidate elements of the leukaemia stem cell/propagation programme derived 
from the whole-genome RNAi screen described in Chapter 6 will initially be 
validated in vitro, as described in section 6.4.  However, a subsequent 
validation step will involve modulation of novel candidates using patient-derived 
leukaemic blasts.  Due to the limited viability of patient-derived blasts in vitro 
this approach will require the use of xenograft assays.  As substantial 
differences have been seen between targets identified using in vitro and in vivo 
screening approaches (Meacham, Ho et al. 2009), this final validation will also 
serve to confirm the relevance of targets to the in vivo, albeit murine, 
microenvironment. 
The use of lentiviral transduction of patient-derived leukaemic cells will allow for 
the delivery of a short hairpin construct into cells with a low proliferative 
capacity.  Such an approach is essential in patient-derived blasts which do not 
divide well in vitro.  Introduction of shRNAs will allow the modulation of 
candidate genes throughout prolonged xenograft assays and potentially through 
serial engraftment, validating their role in leukaemic propagation.  However, 
successful lentiviral transduction of patient-derived leukaemic cells offers a 
wider potential.  Viral integration site analysis can be used for studying clonal 
complexity.  Competitive transplantation of differentially labelled populations will 
examine fitness in engraftment.  Tracking of cells labelled with Luciferase 
constructs will allow the real-time in vivo analysis of the effects of novel agents 
on disease progression with potential to look at specific sites of disease, such 
as the central nervous system. 
This project used the pSLIEW transfer vector, Appendix B.  This vector encodes 
both firefly Luciferase (fLuc) and enhanced green fluorescent protein (EGFP), 
separated by an internal ribosomal entry site (IRES) sequence, allowing 
translation of either gene from a single mRNA transcript.  The expression of 
both of these genes is driven by the spleen focus forming virus (SFFV) 
promoter, as this promoter is subject to minimal silencing in haematopoietic 
cells. 
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The process of optimising the lentiviral transduction protocol involved two, 
occasionally opposing, objectives.  Firstly, as patient-derived material is difficult 
to transduce it is important to maximise the efficiency of transduction.  
Secondly, however, maintaining viability of the patient-derived material in vitro is 
important so that viable cells are available to be transplanted at a suitable time 
point.  As a number of the options available for increasing rates of transduction 
can affect viability, achieving a balance between them was critical. 
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6.2 Aims of the project 
The aims of this project were to: 
1. Develop a protocol for the lentiviral transduction of patient-derived 
leukaemic cells followed by the safe transplantation into NSG mice 
2. Demonstrate successful transduction of the leukaemia propagating 
compartment by serial engraftment of NSG mice 
3. Investigate the potential for in vivo tracking of leukaemic progression 
using a firefly Luciferase expressing vector 
 
The approach taken was a step-wise modification to an existing spinfection 
protocol used for the lentiviral transduction of derived cell lines.  Spinfection 
involves suspending target cells in the presence of infectious virus and then 
centrifuging the suspension to bring the cells and virus into apposition on the 
surface of the culture plate.  Virus is then taken up by the cell, its RNA genome 
reverse transcribed into DNA which is then integrated into the target cell’s 
genome by the viral protein Integrase. 
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6.3 Results 
6.3.1 Optimising the transduction protocol 
The standard spinfection protocol and the final modified patient-derived material 
protocol are shown in Figure 6-1.  The following sections describe the stepwise 
modification from the standard to the modified protocol.  The details of each of 
the nine transductions performed during this project are presented in Table 6-1.  
The details of patients are recorded in Appendix A. 
6.3.1.1 Spinfection surface area 
This standard protocol involved spinfection of cells in a 24 well plate.  The first 
modification which was made was to switch to using a 48 well plate.  The 
reduction in the surface area of the well from 1.9 cm2 to 0.95 cm2 brought the 
cells closer together, increasing the likelihood of viral particles making contact 
with a cell.  Having blasts in greater proximity may also help improve viability by 
providing cell surface contact signals.  The validity of these assumptions was 
not tested experimentally however.  
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Figure 6-1.  Spinfection protocol.  A)  Standard spinfection protocol for transduction of derived 
cell lines.  RPMI 1640 – Roswell Park Memorial Institute medium.  FCS – Fetal calf serum.  B)  
Modified spinfection protocol for the lentiviral transduction of patient derived material, 
elimination of residual infectious virus and intrafemoral transplantation.  SFEM – Serum free 
expansion medium.  IL - Interleukin 
 
 
  
 
Table 6-1.  Details of nine transductions using patient-derived leukaemic blasts.  PB – Peripheral blood.  BM – Bone marrow.  T – Tumour (xenograft).  
αMEM – Alpha modified minimum essential medium.  SFEM – Serum free expansion medium.  SCF – Stem cell factor.  IL- Interleukin.  HS – Horse serum.  HS-
5 CM – Medium conditioned using HS-5 cells.  EGFP – Enhanced green fluorescent protein. 
 
Transduction Sample ID PB/BM/T Cytogenetic subtype Source Medium Adjunct Growth factors %EGFP
1 L826 PB t(4;11)(q23;q21) Primary SCF 19.6
SCF/IL-7 24.0
SCF/IL-7/IL-3 23.3
Optimem - SCF/IL-7/IL-3 17.8
2 L826 BM t(4;11)(q23;q21) Primary SCF/IL-7 16.0
SCF/IL-7/IL-3 10.4
SCF/IL-7 18.8
SCF/IL-7/IL-3 18.6
Optimem - SCF/IL-7/IL-3 19.0
3 L4951 BM t(9;22) Primograft Polybrene 8 μg/ml SCF/IL-7 40.2
Protamine 5 μg/ml SCF/IL-7 50.0
4 L578 T High Hyperdiploidy Primograft - 15.0
HS-5 CM/HS 20.4
5 L826 PB t(4;11)(q23;q21) Primary SFEM Polybrene 8 μg/ml HS 27.5
Polybrene 8 μg/ml SCF/IL-7 35.6
Polybrene 4 μg/ml HS 26.2
Polybrene 4 μg/ml SCF/IL-7 31.9
Protamine 5 μg/ml HS 14.6
Protamine 5 μg/ml SCF/IL-7 19.7
6 L826 BM t(4;11)(q23;q21) Primograft SFEM Polybrene 4 μg/ml SCF/IL-7 9.1
7 L880 t(4;11)(q23;q21) Primary SFEM SCF 3.4
IL-7 8.2
SCF/IL-7 6.4
8 L826 BM t(4;11)(q23;q21) Primary SFEM Polybrene 4 μg/ml IL-7/IL-3 14.0
9 L839 BM t(2;10)(q2?1;q2?2) Primary SFEM Polybrene 4 μg/ml IL-7/IL-3 41.8
αMEM Polybrene 8 μg/ml
Polybrene 8 μg/ml
Protamine 5 μg/ml
Polybrene 8 μg/ml
Polybrene 4 μg/ml
SFEM
αMEM
αMEM
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6.3.1.2 Transduction medium 
Transduction of derived cell lines used the standard culture medium for those 
cells, typically RPMI 1640 with 10% fetal calf serum.  In order to maximise the 
viability of patient derived material in vitro, a more enriched medium, alpha 
modified minimal essential medium Eagle (αMEM), was initially used in 
comparison with a serum free approach using Optimem.  The potential benefits 
of using Optimem were: 1) that in some circumstances the absence of serum 
may improve rates of transduction; 2) transduction without serum can be 
performed without the need for polybrene which is toxic to most mammalian 
cells.  αMEM was supplemented with 20% v/v fetal calf serum plus a further 
20% v/v horse serum which provides a rich source of growth factors.  RPMI 
1640 which had been conditioned with HS-5 feeder cells for 72 hours was 
added to 10% v/v.  Finally, cytokines were added as described in 6.3.1.4 and 
polybrene was used at 8 µg/ml.  This medium was compared with a serum free 
alternative Optimem, supplemented with 20% v/v Optimem conditioned with 
HS-5 feeder cells as described for αMEM.  This comparison was performed in 
transductions 1 and 2 (Table 6-1).   
In the first of these experiments, the rate of transduction with αMEM was 23.3% 
whilst with Optimem it was 17.8%.  In the second experiment the rate of 
transduction was 10.4% with αMEM but 19.0% with Optimem.  Whilst this was 
inconclusive, the results of the transduction of cells lines were consistently 
showing a substantial advantage to using complete medium with fetal calf 
serum and polybrene (Table 5-1).  At the same time, the basic medium was 
switched to be Serum Free Expansion Medium (SFEM), a medium specially 
formulated for the maintenance of haematopoietic stem and progenitor cells. 
A comparison of the effect of different concentrations of horse serum (0%, 5%, 
7.5% or 10% v/v) and HS-5 conditioned medium (0 or 10% v/v) on cell viability 
in vitro was made.  The material used was primografted L578, harvested from a 
thigh tumour.  The tumour was disaggregated through a 40 µm cell strainer and 
resuspended in SFEM/10% v/v FCS.  Cells were plated into a 24 well plate at 
106 cells/ml, 1 ml per well and incubated at 37oC, 5% CO2.  Counts of viable 
and non-viable cells (by trypan blue exclusion) were made each day between 
days 1 and 9.  This showed that freshly harvested cells initially expanded in 
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vitro in all media.  When grown in SFEM/10% v/v FCS, there was no difference 
in viable cell counts between samples incubated without (Figure 6-2A) or with 
(Figure 6-2B) 10% v/v HS-5 conditioned medium.  Neither did the viable cell 
count vary with different concentrations of horse serum between 0-10% v/v 
(Figure 6-2).  The standard transduction medium used thereafter was therefore 
SFEM with 10% v/v FCS. 
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Figure 6-2.  Proliferation and survival of primografted L578 in vitro.  A) Viable cell numbers 
in SFEM/10% v/v FCS without conditioned medium but with the addition of 0-10% v/v horse 
serum.  B)  Viable cell numbers in SFEM/10% v/v FCS with the addition of 10% v/v HS-5 
conditioned medium and 0-10% v/v horse serum. 
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6.3.1.3 Cationic transduction adjuncts – polybrene and protamine 
The cationic polymer polybrene is commonly used to facilitate viral 
transductions.  The positive charge binds to, and neutralises, negatively 
charged cell surface glycoproteins, facilitating binding of negatively charged 
viral particles.  However, polybrene is toxic to eukaryotic cells.  A three way 
comparison was made between polybrene at a standard concentration of 8 
µg/ml, polybrene at a reduced concentration of 4 µg/ml and an alternative 
cation, protamine sulphate, which may offer a lower degree of toxicity.  Three 
transductions (2, 3 and 5, see Table 6-1) were performed comparing polybrene 
(8 µg/ml) with protamine (5 µg/ml).  Of these, transduction 5 also compared 
these adjuncts with polybrene 4 µg/ml. 
The relative efficacy of polybrene 8 µg/ml compared to protamine 5 µg/ml was 
inconsistent between transductions 2 and 3, performed in parallel, and 
transduction 5 (Figure 6-3).  However, as with use of Optimem described in 
6.3.1.2, repeated transductions with cell lines demonstrated the superiority of 
polybrene over protamine (Table 5-1).  This was confirmed in transduction 5 
(polybrene 8 µg/ml 35.6%, protamine 5 µg/ml 19.7%, Figure 6-3).  As the 
relative efficacy of polybrene 8 µg/ml and polybrene 4 µg/ml were very similar 
(35.6% compared to 31.9%), it was decided to use polybrene 4 µg/ml to limit the 
associated toxicity.  
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Figure 6-3.  Transduction efficiency using different cationic adjuncts.  The efficiency of 
lentiviral transduction, determined by flow cytometry of %EGFP expression.  Three experiments 
are shown, L826 (transduction 2, left bars), L4951 (transduction 3, middle bars) and L826 
(transduction 5, right bars). 
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6.3.1.4 Recombinant cytokine adjuncts 
The recombinant human cytokines stem cell factor (SCF), interleukin (IL) 7 and 
IL-3 were used to support the viability of patient-derived leukaemic blasts in 
vitro.  This combination had been successfully used to maintain the growth of 
leukaemic blasts in vitro (Cox, Evely et al. 2004).  In order to identify which of 
the three cytokines were most important to leukaemic survival and efficiency of 
lentiviral transduction, comparisons were made of the effect of individual 
cytokines versus combinations, where the number of available blasts and 
quantity of virus allowed. 
Three individual transductions (1, 2 polybrene and 2 protamine) compared 
SCF/IL-7 versus SCF/IL-7/IL-3 and three transductions (1 αMEM, 5 and 7) 
compared SCF versus SCF/IL-7.  The last of these, transduction 7, also 
compared SCF alone versus IL-7 alone versus the combination of both. 
Three comparisons of SCF/IL-7 versus SCF/IL-7/IL-3 demonstrated no 
improvement in transduction efficiency with the addition of IL-3.  This cytokine 
was therefore withdrawn from subsequent transductions.  It was, however, 
reintroduced for transductions 8 and 9 due to the potential offered to support 
leukaemic survival and growth in vitro (Uckun, Gesner et al. 1989; Eder, 
Ottmann et al. 1990; Brown, Nosaka et al. 1999).  No experiments were 
performed to validate this. 
In the three transductions comparing IL-7 with medium not containing IL-7 
(transductions 1, 5 and 7), there was a significantly higher rate of transduction 
in IL-7 containing experiments, range 4.4-8.1% (p=0.03, Wilcoxon matched-
pairs signed rank test) (Figure 6-4).  Transduction 7 confirmed not only that IL-7 
produces a higher rate of transduction, but combination of SCF and IL-7 did not 
give a higher rate of transduction than IL-7 alone, 6.4% versus 8.3% 
respectively (Table 6-1).  SCF was therefore withdrawn from the final protocol. 
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Figure 6-4.  Effect of IL-7 on rates of transduction.  Three protocols (performed as part of 
transductions 1, 5 and 7) examining IL-7 demonstrate a significantly higher rate of transduction 
than those without IL-7, p=0.03. 
  
Chapter 6:  Lentiviral transduction of patient-derived blasts 
 200 
 
6.3.1.5 Spinfection protocol 
As the standard spinfection protocol involves centrifugation at high speed (1500 
x g) for a prolonged period (2 hours) a modification was made to reduce these 
parameters to limit the resultant cell damage.  A new spinfection protocol of 900 
x g for 50 minutes was initially trialled in SEM cells in direct comparison to the 
standard protocol and a third plate which was not centrifuged but immediately 
placed into a cell culture incubator.  In this setting, there was a 1.8-2.6% lower 
rate of transduction at the slower speed, and a 3.3-21.9% lower rate of 
transduction with no centrifuge step (Figure 6-5A). 
The slower spinfection protocol was trialled in two patient-derived specimens 
(transductions 8 and 9).  Here, both transduction efficiency and cell viability 
were assessed.  This confirmed that there was no loss of transduction efficiency 
(Figure 6-5B).  However, all populations in the slow spin plate showed improved 
cell viability on day 4 post transduction, range 19-51% p=0.048, compared with 
the standard spin plate (Figure 6-5C). 
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Figure 6-5.  Effect of modified spinfection protocol.  The modified, slow spinfection protocol 
does not substantially reduce the rate of transduction in either A) SEM or B) 2 patient derived 
specimens.  C)  The modified protocol does result in a significantly higher cell viability on Day 4 
post transduction, p=0.048. 
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6.3.1.6 Relative transduction efficiency 
For the two final transductions, 8 and 9, the complete modified protocol was 
used along with viral suspensions which had been titred in SEM cells using the 
standard spinfection protocol.  This allowed estimation of the relative 
transduction efficiency of these two patient-derived samples compared with 
SEM cells.  The titration in SEM cells had been repeated on two occasions, 
giving titres of 5.6 x 107 TU/ml and 1.2 x 108 TU/ml respectively.  The functional 
titre in sample L826 was 7.0 x 105-1.6 x 106 TU/ml, resulting in a relative 
transduction efficiency compared to SEM cells of 0.6-3.4%.  For sample L839 
the functional titre was 1.9-5.3 x 106 TU/ml, giving a relative transduction 
efficiency of 1.6-11%. 
This result gives a broad idea of the titre of virus required to transduce patient-
derived cells.  However, it also shows that different patient specimens will need 
different viral titres applied, and that for accurate rates of transduction the 
relative transduction efficiency will need to be determined in advance for each 
specimen.  
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6.3.2 Serial transplantation and in vivo monitoring of transduced 
patient derived material 
In order to assess the functional potential of transducing patient-derived 
leukaemic cells, three samples were transplanted intrafemorally into highly 
immunocompromised NSG mice.  The first two samples came from 
transductions 2 and 3 and were transplanted by Klaus Rehe, who also 
performed the bone marrow punctures.  The third sample was transduced and 
transplanted by Lars Buechler, but monitored, harvested and the second 
generation experiments conducted by SB.  The second generation transplants 
of this third sample, L578, were performed by Frida Ponthan. 
6.3.2.1 Transplantation of transduced L826 and L4951 cells 
On day 1 following transduction, L826 and L4951 cells were washed twice with 
complete αMEM and resuspended at approximately 8 x 104 cells (L826) or 1 x 
105 cells (L4951) per 30 µl transplant aliquot.  This aliquot was injected into the 
right femur of each of three female NSG mice per sample: L826 – mice 1-3; 
L4951 – mice 4-6.  Cells from the initial transduction which had not been used 
for transplantation were analysed by flow cytometry on day 4 post transduction 
to provide a baseline for the rate of transduction.  This analysis demonstrated 
that sample L826 was transplanted with 16% expression of EGFP (Figure 6-6A) 
and L4951 transplanted with 40% expression of EGFP. 
Engraftment was monitored using a Spectrum IVIS bioluminescent camera from 
week 2 onwards, every 1-3 weeks.  Bone marrow punctures were performed at 
weeks 4, 8 and 13.  At harvest, cells were recovered from femurs/tibias and 
spleens.  Expression of EGFP was assessed by multicolour flow cytometry and 
cells were either stored viable in liquid nitrogen or re-transplanted fresh into a 
second generation of mice (L4951 only, bone marrow and spleen). 
For sample L826, bioluminescent imaging demonstrated a moderate strength 
signal from the right femur of all three mice, present from week 3 (Figure 6-6B).  
The signal remained at the same intensity throughout the experiment.  
Furthermore, there was no evidence of disease dissemination over this period.  
Bone marrow punctures demonstrated engraftment of CD19+ cells, but <2% of 
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these expressed EGFP.  At harvest, analysis of bone marrow from mouse 1 
showed only 1.2% of CD19+ cells expressed EGFP, despite a persistent right 
femoral signal (Figure 6-6C).  Mouse 2, which has lost the right femoral 
luciferase signal showed good engraftment but <0.1% of CD19+ cells 
expressed EGFP (Figure 6-6D).  Mouse 3, also demonstrating a persistent right 
femoral signal, showed good engraftment but with only 0.7% CD19+ cells 
expressing EGFP.  These low rates of EGFP expression in the presence of 
persistent femoral Luciferase signal, especially in mouse 1, raised concerns that 
murine tissue may have been transduced by SLIEW virus which had not been 
removed by standard cell washing procedures.  No cells from this sample were 
re-transplanted. 
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Figure 6-6.  Transplantation of L826-SLIEW.  A)  L826 was transplanted on day 1 following 
transduction with 16% of cells expressing EGFP.  B)  Serial bioluminescent monitoring 
demonstrated a signal from the right femoral injection site at week 3 (left panel) but showed no 
evidence of dissemination or local increase in signal intensity.  Mouse 2 (centre mouse, right 
panel) lost the femoral signal by week 19.  Bone marrow analysed at harvest showed very low 
expression of EGFP:  C) Mouse 1 showed only poor engraftment (1 x 10
6
 cells analysed);  D) 
Mouse 2 showed strong engraftment but <0.1% of CD19+ cells expressed EGFP (1.5 x 10
5
 
cells analysed);  E)  Mouse 3 showed good engraftment and 0.7% of CD19+ cells expressed 
EGFP (2.5 x 10
5
 cells analysed). 
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For sample L4951, both serial bone marrow punctures (Figure 6-7A) and 
bioluminescent imaging (Figure 6-7B) demonstrated the on-going expression of 
EGFP and imaging demonstrated the dissemination of transduced leukaemic 
cells to the contralateral femur, spleen, vertebrae and skull/meninges/brain.  At 
the third bone marrow puncture, EGFP expression was found to have fallen 
from 40% at transplantation, to 8-17% in the three mice.  At harvest this had 
fallen further in both spleen and bone marrow, being 5.3-10%.  However, 
transduction was still seen equally within each of the immunophenotypic 
populations present (Figure 6-7A).  Signal intensity increased exponentially as 
engraftment progressed (Figure 6-7C). 
Twelve secondary recipient mice each received a total of 1 x 105 cells from 
either the bone marrow (n=3) or spleen (n=3) from either mouse 4 or mouse 6.  
Eleven out of twelve mice showed engraftment by bioluminescent imaging.  For 
the recipients of cells harvested from mouse 4, 2 of 3 bone marrow and 3 of 3 
spleen recipients engrafted.  The pattern of dissemination did not vary between 
cells of different origin.  At harvest, the expression of EGFP had dropped further 
to 0.2-1.8%. 
All six recipients of cells harvested from mouse 6 engrafted.  Again, the pattern 
of dissemination of cells from bone marrow and spleen did not differ.  
Surprisingly, however, expression of EGFP in CD19+ cells at harvest had 
increased in all mice from 7.3% (bone marrow) or 8.0% (spleen) to between 17 
and 42% of CD19+ cells.  Again, there was no bias in the populations 
expressing EGFP (Figure 6-7A). 
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Figure 6-7.  Serial monitoring of engrafted L4951-SLIEW.  A)  Multicolour flow cytometry 
following bone marrow puncture of (top panels) and harvest (middle panels) of mouse 6 and 
harvest of mouse 14 (bottom panels).  B) Serial monitoring of primary recipient mouse 6 (left 
panels) and secondary recipient mouse 14 (right panels).  Mouse 14 received 1 x 10
5
 bone 
marrow cells from mouse 6.  Images show progressive dissemination to contralateral femur, 
spleen, liver and vertebrae.  Analysis of bioluminescence from each C) primary or D) secondary 
recipient showing exponential increase in signal intensity during the period of engraftment.  
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6.3.2.2 Monitoring and re-transplantation of L578 
Leukaemic sample L578 had been transduced in a separate experiment.  
Expression of EGFP was substantially lower in this sample, being 2%.  A total 
of 1 x 106 cells was transplanted on day 4 post transduction.  As the initial 
experiment was discontinued, this mouse was brought into the present project 
and imaging continued by SB.  This mouse showed widespread leukaemic 
dissemination by bioluminescent imaging.  At harvest, expression of EGFP 
remained relatively stable at 1.6% (bone marrow) and 1.9% (spleen). 
Bone marrow was re-transplanted into three recipients at a total dose of 1 x 105 
cells per mouse.  Serial bioluminescent imaging demonstrated disease 
dissemination (Figure 6-8A), which could be localised further by 3-dimensional 
reconstructions.  These show that in this sample with a low rate of transduction, 
early engraftment is seen in discrete areas of skeleton and spleen (Figure 6-8B-
C).  These three mice were harvested at week 17, at which point the expression 
of EGFP in bone marrow was 0.3-2.9%.  Flow cytometric analysis of cells 
isolated from peripheral blood, bone marrow, spleen, liver and kidney showed 
no difference in expression of EGFP between these tissues (Figure 6-8D).  
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Figure 6-8.  Bioluminescent monitoring of L578-SLIEW.  A)  In vivo monitoring 
demonstrating disease progression from week 14 (left panel) to week 17 (right panel).  3-
dimensional reconstructions of mouse 35 (centre mouse in A) at B) week 12 and C) week 14, 
showing focal engraftment of vertebrae, increase in splenic signal and appearance of right 
femoral signal.  Scales are photons/second.  The skeleton is projected for orientation and not 
derived from imaging of this animal.  D) Organ specific engraftment with EGFP+ blasts.  
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To further validate the model, brain, spleen, liver and kidneys harvested from 
the primary recipient of L578-SLIEW were stained with haematoxylin and eosin 
and immunolabelled with antibodies specific for CD19, CD10, CD79a and TdT 
(Figure 6-9).  This showed a diffuse infiltrate of lymphoblasts expressing these 
characteristic B-precursor proteins.  Whilst the bioluminescent imaging had 
been unable to differentiate between infiltration of the skull vault and the 
brain/meninges, histology confirmed meningeal infiltration (Figure 6-9H-L). 
The presence of EGFP positive cells amongst the engrafting blasts was 
demonstrated by fluorescence microscopy, even in this sample with low rates of 
transduction (Figure 6-9M-O).  This analysis confirmed the presence of EGFP 
positive cells within the meninges (Figure 6-9P). 
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Figure 6-9.  Engraftment of primary recipient of L578-SLIEW.  Engrafted L578 leukaemic 
cells showed typical lymphoblastic morphology (a) and expressed characteristic proteins CD19 
(b), CD10 (c) and TdT (d). There was widespread dissemination to multiple sites including 
spleen (e, i, m), kidney (f, j, n), liver (g, k, o) and meninges (h, l, p) as illustrated by staining with 
H&E (e-h) and for CD79a (i-l). EGFP positive cells are seen sparsely throughout the organs (m-
p), consistent with the low levels of transduction in this experiment.  
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6.3.3 Ensuring safety prior to xenotransplantation 
During the primary transplantations with specimens L826 and L4951, medium 
was taken from the cells prior to transplantation and put onto 293T cells growing 
in 24 well plates.  These cells were incubated overnight before replacing the 
supernatant with standard complete DMEM.  These cells were viewed with a 
fluorescent microscope at day 4 following transduction and seen to express 
EGFP strongly.  This unexpected finding, along with the persistent luciferase 
signal from the site of injection in mice 1-3, suggested the persistence of 
infectious viral particles not only 24 hours post transduction but also following 
two washes of the cells prior to transplantation.  An alternative protocol was 
therefore developed to ensure the removal of infectious virus prior to 
transplantation.  This is essential to prevent transduction of murine cells (and 
false positive imaging results) as well as to protect the transplanter who uses 
sharp needles to perform the transplant. 
A modified washing procedure was devised, as detailed in section 2.3.11.3.  In 
three separate experiments, supernatant was taken from cells which had been 
stringently washed daily since day one post transduction and control cells which 
had not.  Supernatant was again incubated with 293T cells overnight and then 
washed off the following morning.  Supernatant from the unwashed cells was 
shown to have a high titre of infectious virus as long as four days post 
transduction (Figure 6-10A-B).  However, virus was effectively removed by just 
two stringent washes, making it safe to transplant on day 2 post transduction 
(Figure 6-10C). 
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Figure 6-10.  Persistence of infectious SLIEW virus following transduction of patient-
derived material. 293T cells were assessed for transduction by expression of EGFP both by A) 
fluorescence microscopy - supernatant taken day 3 post transduction, and B) flow cytometry - 
supernatant was taken at either day 3 (n=3) or day 4 (n=2) (mean + standard deviation) from 
transduced but unwashed leukaemic blasts.  Both demonstrate high residual transduction 
capacity.  C) Effect of washing protocol - by day 2, washing transduced leukaemic blasts has 
effectively removed residual transduction capacity from the supernatant, whilst the supernatant 
from unwashed blasts retains a high viral titre. 
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6.4 Discussion 
This project has developed a protocol for the transduction of patient-derived 
leukaemic blasts using a lentiviral construct expressing EGFP and firefly 
luciferase.  This has allowed the in vivo tracking of disease progression using 
an NSG xenotransplantation model.  Successful engraftment of two generations 
of mice with low doses of transduced cells (as low as 2 x 104 followed by 1.6 x 
103) has confirmed the transduction of the leukaemia propagating cell 
compartment.  However, the reasons for the substantial changes in EGFP 
expression remain unclear.  Whilst in some samples (L826 primary transplant 
and L4951 mouse 4 secondary transplants) expression of EGFP was either lost 
or substantially reduced, in others it was stable (L578) or even increased 
(L4951 mouse 6 secondary transplant).  Work is currently on-going within the 
laboratory to elucidate the changes seen in clonal complexity with serial 
transplantation, using ligation mediated PCR analysis of lentiviral integration 
sites.  This work should define how many cells contribute to disease 
engraftment and may explain the variation in EGFP expression seen in the 
present project.  However, initial results have demonstrated that oligoclonal 
outgrowth does not explain the increase in EGFP expression seen in secondary 
recipients of mouse 6 bone marrow, mice 13 and 14 (Bomken, Buechler et al. 
2012), Appendix D , as persistence of stable polyclonal engraftment has been 
demonstrated. 
Further improvements to the transduction protocol should allow both the 
reduction in the titre of virus required as well as improvements in cell viability.  
The use of additional or alternative cytokines may support cell growth, survival 
and consequently transduction.  Co-culture with a feeder cell layer to support 
leukaemic viability was considered but not investigated here.  The concern with 
using feeder cells is the almost certain transduction and subsequent 
transplantation of the feeder cell line.  Whilst it may be possible to sort blasts 
from feeders by FACS, preliminary trials of sorting patient-derived blasts, post-
transduction, have demonstrated extremely poor viability post-sorting.  
Immunomagnetic bead sorting may provide an alternative, but would not allow 
concurrent sorting using EGFP expression. 
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Whilst the xeno-transplantation studies described here have only sought to 
track disease progression in vivo, many more potential uses exist for this 
protocol.  Examples include: 
 using shRNA containing constructs to modulate the expression of genes 
of interest – the development of such a vector is described in Chapter 7; 
 monitoring disease progression during testing of novel therapies/drug 
combinations – an early experiment using a novel therapy is currently in 
progress using FACS sorted tertiary transplants of L4951 harvested from 
the spleen of mouse 14; 
 transplantation with blasts transduced with vectors containing different 
fluorescent/luminescent markers to examine fitness to engraft in a 
competitive situation. 
The on-going development of this protocol will allow for these experiments to be 
developed both in leukaemic cells and, potentially, in other malignancies as 
well.
  
Chapter 7 
Development of a single 
lentiviral vector for the 
transduction of primary material 
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7.1 Introduction 
This project was designed to modify the existing pSLIEW lentivector to include a 
shRNA sequence in addition to the existing firefly luciferase and EGFP genes 
(Appendix B).  The purpose behind the cloning of a single vector capable of in 
vitro monitoring/cell sorting, in vivo bioluminescent monitoring and RNAi was to 
create a tool for the transduction and modulation of patient-derived leukaemic 
blasts for xenotransplantation assays.  Existing commercial vectors would only 
allow two of the three functions.  Therefore, to achieve all three functions would 
require multiple transductions of primary blasts.  The limited viability of ALL 
blasts in vitro makes it highly unlikely that this could be performed successfully.   
The requirements for the strategy were: 
1) To clone into the single remaining unique restriction site within the 
transcribed region of the provirus - BamHI, 3’ of fLuc, 5’ of the IRES 
2) To allow easy, repeated cloning of different shRNA constructs 
 
The approach taken was to develop two vectors derived from the Gateway 
recombination system from Invitrogen.  Conventional restriction cloning was 
used to produce a Destination vector and an Entry vector.  Employing a system 
developed from lambda bacteriophage recombination, these two vectors are 
then recombined at complementary attachment (att) sites, switching the 
sequence contained between att sites on one vector with that contained 
between the att sites of the other vector.  For the current project, that meant 
cloning the Gateway Destination cassette into the BamHI site of pSLIEW (to 
give pSLIEW-DEST) (Figure 7-1A) and the shRNA sequence into a commercial 
Gateway Entry vector (to give pENTR-shRNAmir) (Figure 7-1B).  A 
recombination reaction would then clone the shRNA sequence between fLuc 
and the IRES site of the resultant pSLMIEW (Figure 7-1C). 
In order to maximise the efficiency of knockdown in hard to transduce patient 
derived cells, a microRNA adapted shRNA sequence was used, as described in 
Chapter 5.  This sequence has unique XhoI and EcoRI restriction sites within 
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the microRNA backbone, allowing new shRNAs to be inserted into the 
backbone by conventional restriction cloning.  The Entry vector cloning strategy 
was designed to exploit this potential by excising XhoI and EcoRI sites from the 
multiple cloning site of pENTR1a (Figure 7-1B). 
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Figure 7-1.  Cloning strategy to create pSLMIEW.  A)  The Gateway Destination cassette was 
to be cloned into the BamHI site between the fLuc and IRES of pSLIEW to produce pSLIEW-
DEST.  B)  The microRNA adapted short hairpin sequences produced by PCR amplification 
from existing pTRIPZ/pGIPZ vectors were cloned into pENTR using SalI and EcoRV restriction 
sites, thereby excising EcoRI and XhoI restriction sites from the residual multiple cloning site of 
pENTR-shRNAmir.  The remaining XhoI and EcoRI sites within the shRNAmir sequence were 
therefore unique, allowing repeated cloning of new shRNA sequences into the microRNA 
backbone of pENTR-shRNAmir.  C)  Lambda recombination of complementary attL and attR 
sites would then insert the shRNAmir30 sequence into the pSLIEW vector to create a new 
pSLMIEW transfer vector. 
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7.2 Aims of the project 
The aims of this project were to: 
1. Clone the Gateway Destination cassette into the BamHI site in the open 
reading frame of pSLIEW 
2. Clone an shRNAmir30 construct into the multiple cloning site of pENTR 
3. Clone a novel shRNA construct into the microRNA backbone sited in 
pENTR (proof of principle) 
4. Recombine the new pSLIEW-Destination vector and pENTR-shRNAmir 
vector to produce a single vector expressing fLuc, shRNAmir30 and 
EGFP – pSLMIEW 
5. Functionally validate this vector by: 
a. Producing infectious virus 
b. Analysing shRNA production, target knockdown and phenotype 
c. Validating residual fLuc expression 
6. Perform a preliminary in vivo assessment of the vector following 
xenotransplantation 
 
The cloning component of this project was completed as part of the supervision 
of two BSc students, Nana Anim-Addo who cloned the pSLIEW-DEST vector 
(7.3.1) and performed the initial recombination reactions (7.3.4) and Cara 
Hernon who cloned the shANGPT1 construct into the existing pENTR-
shRNAmir vector (7.3.3) and performed the respective recombination reaction 
(7.3.4).  The cloning strategy was designed by SB.  All lentiviral work was 
completed by SB. 
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7.3 Results 
7.3.1 Cloning of pSLIEW-Destination vector 
pSLIEW was digested using BamHI and the resultant 5’ overhang filled in with a 
Klenow reaction.  In order to stop the linearised vector from re-ligating, 5’ 
phosphate groups were removed with calf intestinal alkaline phosphatase.  The 
Gateway destination cassette, reading frame A, was then ligated in using T4 
DNA ligase.  The initial trial of this protocol did not produce any colonies from 
transformed bacteria, so the protocol was modified to use Shrimp alkaline 
phosphatase which is more efficiently heat inactivated.  With this modification, 
24 colonies were produced from transformed ccdB Survival 2T1R competent 
cells.  Ten colonies were grown overnight and plasmid DNA extracted.  A 
control digest was performed using PvuII which was able to determine the 
orientation of the destination cassette.  In 7/10 clones this digest produced 
bands at 2850bp, 3066bp, 3364bp and 4296bp as would be expected for 
cassette insertion in the correct orientation.  In the remaining 3/10 clones it 
demonstrated bands at 2355bp, 2850bp, 3066bp and 5305bp as would be 
expected for reverse insertion of the cassette (Figure 7-2). 
Clones 2, 4, 6 and 10 were sequenced commercially using the Destination 
vector sequencing primers 1 and 2 (DBS Genomics).  This confirmed the 
insertion of the correct sequence at the BamHI site with fLuc 5’, and IRES 3’, to 
the cassette.  Clone 2 was expanded and plasmid DNA extracted for use in 
recombination experiments (sequence and plasmid map are detailed in 
Appendix B).  
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Figure 7-2.  Restriction digest of pSLIEW-Destination vector.  PvuII digest showing the 
bands expected of a correctly orientated Gateway destination cassette (2850bp, 3066bp, 
3364bp and 4296bp) in clones 1-4, 7-9).  The bands expected of a reverse orientated cassette 
(2355bp, 2850bp, 3066bp and 5305bp) are seen in clones 5, 6 and 10).  Marker – Fermentas 
1kb DNA marker. 
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7.3.2  Cloning of pENTR-shRNAmir constructs 
Three shRNAmir30 sequences were amplified by PCR from existing Open 
Biosystems vectors.  These vectors contained shRNAs specific for the MLL/AF4 
fusion transcript (variant found in SEM cells), the RUNX1/RUNX1T1 fusion 
transcript (found in Kasumi-1 and SKNO-1 cells) and a non-targeting sequence 
provided by Open Biosystems as a negative control.  Primers were designed to 
add SalI and EcoRV restriction sites at the 5’ and 3’ ends respectively.  The 
PCR products were restriction digested using SalI and EcoRV, as was the 
pENTR vector.  Gel purification of the digested pENTR vector prevented 
reincorporation of the excised multiple cloning site. 
Digested shRNAmir30 sequences and pENTR were ligated to give the three 
pENTR-shRNAmir constructs.  The ligated plasmids were transformed into 
DH5α cells, cultured overnight and colonies picked and expanded over a 
second night.  Plasmid DNA was extracted from successful cultures.  In view of 
the PCR step, all clones were sequenced commercially (DBS Genomics) using 
the pENTR reverse sequencing primer to demonstrate the accuracy of the 
shRNAmir sequence.  One correctly sequenced clone for each construct was 
expanded and plasmid DNA isolated for recombination experiments (sequences 
and plasmid map are detailed in Appendix B). 
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7.3.3 Cloning of the novel shANGPT1 hairpin into pENTR-shRNAmir 
In order to demonstrate the principle of cloning a new shRNA sequence into the 
newly developed pSLMIEW/pENTR-shRNAmir30 system, an shRNA sequence 
specific for ANGPT1 was excised from a commercially available pTRIPZ vector 
using XhoI and EcoRI.  The existing non-targeting sequence was excised from 
the control pENTR-shRNAmir construct described in 7.3.2.  After gel purification 
of the digested pENTR-shRNAmir vector, the shANGPT1 sequence was ligated 
in using T4 DNA ligase and transformed into DH5α cells.  Colonies were picked, 
expanded overnight and plasmid DNA extracted from successful cultures. 
Double restriction digests using EcoRI and SalI failed to give the predicted 
bands of 382bp for the non-targeting control vector and 468bp for the 
successfully clones shANGPT1 vector (Figure 7-3).  However, as clones 3-6 
gave a band approximately 80-90bp longer than the non-targeting vector 
(included as a negative control), it was presumed that these clones now had the 
alternative shANGPT1 construct.  All six clones were sequenced using the 
pENTR reverse sequencing primer (DBS Genomics).  This demonstrated that 
the 4 clones giving the larger bands (clones 3-6) had the correct sequence for 
the shANGPT1 construct (sequences and plasmid map are detailed in Appendix 
B). 
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Figure 7-3.  Restriction digest of pENTR-shANGPT1.  EcoRI/SalI double restriction digest to 
excise the shRNAmir30 sequence including the new shANGPT1 sequence.  The control digest 
of pENTR-non-targeting control (pENTR-NTC, far right lane) shows a band larger than the 
predicted 382bp, but equal to the bands from clones 1 and 2.  Clones 3-6 have a larger band 
(predicted to be 86bp larger).  Marker is Fermentas 100-3000bp marker. 
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7.3.4 Recombination of pSLIEW-Destination and pENTR-shRNAmir 
Successfully sequenced vectors were recombined with pSLIEW-DEST cloned 
in 7.3.1.  Recombination products were transformed into DH5α cells and 
incubated overnight.  Colonies were picked and grown further overnight.  
Plasmid DNA was extracted from overnight cultures and digested using PvuII.  
Successful recombination removed the PvuII restriction site within the Gateway 
destination cassette so that the digest pattern returns to approximately that 
seen in the native pSLIEW vector (Figure 7-4). 
Successfully recombined clones were expanded and used for production of 
lentivirus for subsequent validation experiments. 
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Figure 7-4.  Restriction digests of recombined pSLMIEW vectors.   PvuII digests showing 
the same pattern of bands in pSLIEW and successfully recombined clones (expected bands at 
2849bp, 3064bp and 6532bp) of: A) Non-target control (NTC) clones 1-4 and shMLL/AF4 clone 
1.  NTC clone 5 shows an incorrect digest pattern; B) shMLL/AF4 clones 2-5 and 
RUNX1/RUNX1T1 clones 1-3. 
  
Chapter 7:  Single lentiviral vector for patient-derived transduction 
 228 
 
7.3.5 Validation of pSLMIEW function in vitro 
Virus was produced using the four pSLMIEW vectors described above.  SEM 
and Kasumi-1 cells were transduced with each of the four viruses, resulting in 
expression of EGFP.  The functional effect of knockdown was assessed in vitro 
using a competitive proliferation assay.   
SEM (n=2) and Kasumi-1 (n=1) cells were transduced with each of the 
constructs at approximately equal rates.  Cells were then maintained in 
suspension culture without sorting.  The proportion of cells expressing EGFP 
was monitored by serial flow cytometric measurements.  Knockdown of the 
relevant fusion transcript (MLL/AF4 in SEM cells, RUNX1/RUNX1T1 in Kasumi-
1 cells) resulted in a reduction in the expression of EGFP (Figure 7-5), 
demonstrating a proliferative disadvantage for transduced cells and confirming 
the on-going importance of the fusion oncogene to leukaemic maintenance in 
vitro.  In the first experiment, the expression of EGFP appeared to stabilise in 
SEM-shMLL/AF4 cells between 20-30% after approximately 40 days (Figure 
7-5A).  The same plateau was not seen in Kasumi-1-shRUNX1/RUNX1T1 cells 
(Figure 7-5C). 
Kasumi-1 cells transduced with shANGPT1 also showed a proliferative 
disadvantage compared with control cells, but this was not as marked as in the 
Kasumi-1 cells transduced with shRUNX1/RUNX1T1 (Figure 7-5C).  
Surprisingly, given that ANGPT1 is up-regulated by the MLL/AF4 fusion product 
(Figure 7-6C), SEM cells transduced with shANGPT1 did not show a 
proliferative disadvantage (Figure 7-5A-B).  The reason for this remains unclear 
but is the subject of on-going experiments within the laboratory.  
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Figure 7-5. Functional assessment of SLMIEW constructs in vitro.  A-B)  Two independent 
transductions of SEM cells demonstrate a proliferative disadvantage to shMLL/AF4 transduced 
cells.  C)  Transduction of Kasumi-1 cells shows proliferative disadvantage to 
shRUNX1/RUNX1T1 and shANGPT1 transduced cells.   
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Production of shRNA and target gene knockdown over time were confirmed by 
qRT PCR.  Expression of the hairpin constructs was directly assessed by qRT 
PCR 13 days following transduction.  Strong expression of both 
shRUNX1/RUNX1T1 and shANGPT1 was seen in SEM and Kasumi-1 cells 
(Figure 7-6A).  In contrast, shMLL/AF4 was expressed at a substantially lower, 
although easily detectable, level (Figure 7-6A). 
Despite differential expression of shRNA, effective knockdown was achieved for 
each of the three target transcripts.  MLL/AF4 knockdown, assessed in SEM 
cells, showed a maximal knockdown on day 6 (Figure 7-6B).  At this time point 
a knockdown of 48% was seen in a mixed population with 68% EGFP+ cells.  
The knockdown, adjusted for the rate of transduction, was therefore 71%.  As 
the proportion of transduced cells decreases throughout the experiment, so the 
measured knockdown is seen to reduce (Figure 7-6B). 
shRUNX1/RUNX1T1 produced a slightly weaker knockdown, as assessed in 
Kasumi-1 cells (Figure 7-6D).  Here, a maximal knockdown of 40% was again 
seen at day 6.  As only 69% of the population expressed EGFP on this day, the 
knockdown was adjusted to 58% for the rate of transduction.  As described for 
SEM cells, transduction of Kasumi-1 cells with the relevant fusion specific 
shRNA construct (shRUNX1/RUNX1T1) resulted in a proliferative disadvantage 
and so the knockdown is seen to decrease as the proportion of transduced cells 
decreases (Figure 7-6D). 
Finally, ANGPT1 knockdown was assessed in both SEM (Figure 7-6C) and 
Kasumi-1 (Figure 7-6E) cells and peaked on day 6 in Kasumi-1, consistent with 
the proliferative disadvantage in this population.  As SEM cells showed no 
proliferative disadvantage, knockdown continued to increase through to the end 
of the experiment on day 43.  In 79% (Kasumi-1) and 81% (SEM) transduced 
populations, knockdown was 74% and 64% respectively, adjusting to 94% 
knockdown in Kasumi-1 cells and 79% in SEM cells. 
Analysis of ANGPT1 also identified the reduction of expression of this transcript 
associated with knockdown of the respective fusion oncogene.  In both SEM 
cells transduced with shMLL/AF4 (Figure 7-6C) and Kasumi-1 cells transduced 
with shRUNX1RUNX1T1 (Figure 7-6E), expression of ANGPT1 reduces initially 
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(Day 6-13) before rising again as the proportion of transduced cells in each of 
these populations decreases.  This is in keeping with other studies within our 
laboratory which have demonstrated the control of ANGPT1 expression by the 
MLL/AF4 and RUNX1/RUNX1T1 fusion oncogenes.  
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Figure 7-6.  In vitro expression and knockdown by SLMIEW constructs.   A)  Expression of 
shRNA by SEM cells (left panel) and Kasumi-1 cells (right panel).  Expression is presented as 2
-
ΔCt
, relative to the control small nuclear RNA, RNU6-2.  Groups along the X-axis represent the 
transduced SLMIEW construct.  Minor columns adjacent to the column of shRNA expression 
expected from an individual construct represent non-specific background signal.  B)  
Knockdown of MLL/AF4 in SEM cells.  C)  Knockdown of ANGPT1 in SEM cells.  D)  
Knockdown of RUNX1/RUNX1T1 in Kasumi-1 cells.  E)  Knockdown of ANGPT1 in Kasumi-1 
cells.  Relative expression is ΔΔCt using GAPDH as the reference transcript and normalising 
against expression in shRUNX1/RUNX1T1 transduced cells (B-C) or shMLL/AF4 transduced 
cells (D-E).  
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The final element of in vitro validation was to analyse the luciferase activity from 
each of the constructs.  As the shRNA construct is sited immediately 3’ to the 
Luciferase gene, processing of the single transcript by endogenous RNAi 
pathway proteins (Drosha/Dicer) would reduce the proportion of transcript 
available for translation into Luciferase protein.  As some shRNA constructs 
may be more efficiently processed than others, it was important to investigate 
how this affected Luciferase activity. 
Transduced SEM and Kasumi-1 cells were adjusted for the percentage 
expression of EGFP and 105 EGFP positive cells pipetted into triplicate wells.  
The total volume was made up to 175 µl.  D-Luciferin, 0.075 µg in 25 µl, was 
added to each well and the plate analysed using a Fluostar Omega 
fluorescence plate reader, 1 second per well, at different time intervals. 
Within each of the two cells lines tested, luciferase activity demonstrated a 
moderate variation.  This did not change with the interval time to reading, three 
minutes giving the highest counts.  In SEM cells, the non-target control 
construct had 25% higher luciferase activity than the lowest activity construct, 
shANGPT1 (Figure 7-7A).  Adjusting the luciferase activity for the geometric 
mean of EGFP expression, used as a measure of expression intensity, resulted 
in a small reduction in this difference to 16% (Figure 7-7A). 
In Kasumi-1 cells, the greatest luciferase activity was again in the non-target 
control construct (Figure 7-7B).  There was a 46% difference between the non-
target construct and the shMLL/AF4 construct which showed the lowest 
luciferase activity.  In Kasumi-1 cells, these differences showed a more marked 
correction with adjustment for the geometric mean of EGFP expression. 
Most strikingly however, was the difference between SEM cells and Kasumi-1 
cells.  In Kasumi-1 cells the luciferase activity of the non-target construct was 
over 4 times that in SEM cells.  Even having adjusted for the EGFP geometric 
mean, the activity in Kasumi-1 cells was still 2.5 fold that in SEM cells. 
These preliminary results suggest that the luciferase activity will need to be 
assessed for any new shRNA constructs created and, potentially, adjustments 
made accordingly to data derived from in vivo imaging studies.  
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Figure 7-7.  Luciferase activity of SLMIEW constructs in vivo.  The raw and adjusted 
(normalising data by comparing the geometric mean of individual cells/constructs against the 
geometric mean of Kasumi-1 –shNTC) luciferase activity for A) SEM and B) Kasumi-1 cells. 
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7.3.6 Xenotransplantation of SEM-SLMIEW constructs 
In order to test the effectiveness of the single vector in a xenotransplantation 
experiment, SEM cells were transduced with SLMIEW virus containing either 
shMLL/AF4, shRUNX1/RUNX1T1 (negative control) or shANGTP1 constructs.  
The shANGPT1 construct was chosen as data from the laboratory have shown 
high expression of ANGPT1 in MLL rearranged leukaemias as well as control of 
the expression by the MLL/AF4 fusion product (Figure 7-6C). 
An estimation of the volume of inoculum required to give an MOI of 0.8 was 
made by putting a line of best fit onto the standard curves produced from a viral 
titration experiment.  SEM cells were transduced using the standard 
transduction protocol and washed on subsequent days using the stringent 
washing procedure described in 2.3.11.3.  On day 4 following transduction 
SEM-SLMIEW cells were FACS sorted at the Newcastle University Flow 
Cytometry Core Facility, Centre for Life.  Cell sorts achieved a 94% efficiency.  
Cells were incubated overnight in RPMI1640, 20% v/v FCS and 1% v/v 
penicillin/streptomycin mixture.  The following day, cells were counted and 
resuspended.  This showed that a substantial proportion of cells were no longer 
viable.  However, 3 x 104 viable cells were injected into each of six mice (3 
female, 3 male) per construct.  Engraftment was monitored by serial 
bioluminescent imaging. 
Unfortunately, the mouse colony suffered from a problem (presumed to be an 
undiagnosed infection) during this experiment, with a large number of both 
transplanted and stock mice developing distended abdomens and dying.  In 
total this problem killed 4 shRUNX1/RUNX1T1 negative control mice and 2 
shANGPT1 mice.  None of the shMLL/AF4 mice were affected. 
In the shMLL/AF4 arm, 3/6 mice engrafted (mice 51, 52 and 53).  Engraftment 
of transduced cells showed a delayed dissemination away from the right 
femoral site of injection and a weaker overall engraftment, even at week 8 
(Figure 7-8A, Figure 7-9A), one week after most other mice were killed.  The 
two surviving shRUNX1/RUNX1T1 negative control mice showed different 
degrees of engraftment, with mouse 62 showing a stronger luciferase signal 
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than mouse 60.  However, both of these mice showed widespread 
dissemination to the contralateral femur, vertebrae, spleen and skull/meninges 
(Figure 7-8B, Figure 7-9B).  Mice transplanted with SEM-SLMIEW cells 
containing the shANGPT1 construct also showed incomplete engraftment.  Of 
the 4 surviving mice, engraftment was seen in 3 (mice 64, 65 and 66).  Mouse 
63 also engrafted but then died during week 5.  The 3 surviving engrafted mice 
also showed widespread dissemination, similar to the negative control group 
(Figure 7-8C, Figure 7-9C).  
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Figure 7-8.  In vivo bioluminescent imaging of NSG mice transplanted with SLMIEW 
transduced SEM cells.  A)  shMLL/AF4 mice (week 8) show reduced dissemination and lower 
engraftment of transduced cells compared to B) negative control shRUNX1/RUNX1T1 (week 7) 
mice or C) shANGPT1 mice (week 7).  Signal scales are in photons/s/cm
2
/sr. 
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Figure 7-9.  In vivo bioluminescent imaging of NSG mice transplanted with SLMIEW 
transduced SEM cells.  Mice are demonstrated in the same order as in Figure 7-8 but with all 
images taken at week 7 and identical scales provided for comparison.  A)  shMLL/AF4 mice.  B) 
negative control shRUNX1/RUNX1T1 mice or C) shANGPT1 mice.  Signal scales are in 
photons/s/cm
2
/sr. 
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Analysis of the total luminescence of each mouse demonstrated a reduced 
signal in the shMLL/AF4 group compared with either the negative control or 
shANGPT1 group (Figure 7-10A), consistent with the images seen in Figure 
7-8.  There was no difference between the shANGTP1 group and the negative 
control shRUNX1/RUNX1T1 group (Figure 7-8, Figure 7-9). 
Mice were killed and harvested on week 7 (shRUNX1/RUNX1T2 mouse 62 and 
shANGPT1 mice 64, 65, 66 and 68) or week 8 (shMLL/AF4 mice 51-56 and 
shRUNX1/RUNX1T1 mouse 60).  The details of engrafted mice are contained in 
Table 7-1.  Bone marrow and splenic material was harvested from all engrafted 
mice and analysed by multicolour flow cytometry.  There was a close correlation 
between the expression of EGFP in the bone marrow and that in the spleen 
(Figure 7-10B).  SEM cells were isolated from bone marrow by CD133 
MacsBead sorting and analysed for expression of MLL/AF4 and ANGPT1. 
Two of three mice engrafted with shMLL/AF4 transduced SEM cells had the 
lowest expression of EGFP, demonstrating a proliferative disadvantage to these 
cells.  The third mouse in this group, mouse 52, showed higher proportions of 
EGFP expression (bone marrow 86%, spleen 67%).  Overall, the expression of 
EGFP in harvested samples correlates well with the intensity of the 
bioluminescent signal produced with in vivo monitoring (Figure 7-10C).   
The proliferative disadvantage of shMLL/AF4 transduced SEM cells is 
corroborated by the absence of MLL/AF4 knockdown in re-isolated SEM cells 
(Figure 7-11A).  In contrast, knockdown of ANGPT1 persisted in re-isolated 
shANGPT1 transduced cells, albeit with some variation (Figure 7-11B).  
shRNAmir expression (Figure 7-11C) is similar to that seen in vitro (Figure 
7-6A).  
Chapter 7:  Single lentiviral vector for patient-derived transduction 
 240 
 
Figure 7-10.  Analysis of luminescence of engrafted mice.  A) Total luminescence from mice 
surviving in each of the three groups.  Negative control (shRUNX1/RUNX1T1) and experimental 
(shANGPT1) groups show more rapid and greater engraftment of transduced cells than the 
positive control group (shMLL/AF4).  B) Bone marrow and splenic expression of EGFP correlate 
closely.  C) End-point total luminescence correlates with expression of EGFP in the bone 
marrow at harvest. Arrow shows samples from mouse 52  
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Table 7-1.  Details of mice transplanted with SLMIEW transduced SEM cells.   BM – bone 
marrow.  EGFP – Enhanced green fluorescent protein.  %EGFP expression is percentage of 
CD19+ cells expressing EGFP.  Mice marked – in the engraftment column died before 
demonstrating engraftment.  Mouse 63 engrafted but was found dead on week 5.  
  
Mouse Engrafted BM EGFP Spleen (g) Spleen EGFP
51 Y 5.8% 0.06 8.8%
52 Y 86% 0.05 67%
53 Y 9.7% 0.08 9.4%
54 N - 0.04 -
55 N - 0.04 -
56 N - 0.05 -
57 - - - -
58 - - - -
59 - - - -
60 Y 40% 0.16 34%
61 - - - -
62 Y 85% 0.13 86%
63 Y - - -
64 Y 82% 0.29 79%
65 Y 67% 0.5 67%
66 Y 98% 0.05 98%
67 - - - -
68 N -
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Figure 7-11.  Knockdown and expression of shRNAmir30 constructs in SEM cells re -
isolated from murine bone marrow.  A) Expression of MLL/AF4.  B) Expression of ANGPT1.  
Columns represent mean and standard error of the mean of mice transplanted with SEM cells 
transduced with the each of the three shRNAmir constructs.  Relative expression is ΔΔCt 
compared to mouse 62 (shRUNX1/RUNX1T1) using GAPDH as the reference transcript.   C) 
Expression of shRNAmir constructs in re-isolated SEM cells.  Expression is 2
-ΔCt
 using RNU6-2 
as a reference transcript. 
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7.4 Discussion 
The aim of this project was to construct a lentiviral transfer vector which would 
allow in vitro analysis/sorting, in vivo monitoring and modulation of target genes 
in a single transduction.  Such a vector would allow for functional analysis of 
candidate genes using patient-derived material in xenotransplantation assays.  
The cloning strategy was designed to allow new short hairpin constructs to be 
easily cloned into a microRNA backbone which could then be inserted into a 
transfer vector.  This concept has been proven to work using an shRNA 
construct specific for ANGTP1. 
Both of the original shRNAmir constructs derived from pGIPZ/pTRIPZ vectors 
(shMLL/AF4, shRUNX1/RUNX1T1) and the newly cloned shANGPT1 construct 
have been shown to express shRNA and produce effective knockdown.  There 
was some variation in the knockdown efficacy, but this would be expected in 
any experimental RNAi context and represents a sequence specific 
phenomenon.  Due to the restrictions placed on the design of fusion transcript 
specific hairpins by the very limited sequence availability, it is not surprising that 
these two constructs gave the weakest knockdown, whilst the shANGPT1 
construct achieved the best knockdown at 79-94%.  The variation seen in 
knockdown was not as great as the variation seen in shRNA expression, 
suggesting that perhaps the shRNA qRT PCR was subject to sequence specific 
differences, giving a falsely low analysis of shMLL/AF4 expression. 
Having successfully demonstrated the knockdown achieved by the new 
constructs, the continued functioning of the original reporter genes was 
assessed, as it was possible that processing of the miRNA transcripts might 
differentially affect translation of either the fLuc or EGFP transcripts.  As the 
basic measure used to quantitate the efficiency of transduction, EGFP 
expression has been preserved.  Further validation of the efficiency of EGFP 
expression is difficult, as any analysis would be dependent on the rate of 
transduction.  Luciferase activity, however, can easily be compared between 
populations with known rates of transduction, assuming constant EGFP 
expression.  Analysis of luciferase activity demonstrated variation between 
constructs in vitro.  However, there was a good correlation between the 
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proportion of EGFP positive cells and the luciferase signal obtained by in vivo 
bioluminescent imaging of mice engrafted with SEM cells transduced with the 
three SLMIEW constructs.  Whilst new constructs will need to be analysed to 
determine Luciferase activity, in principle the in vitro validation of the new vector 
system was successful. 
In an initial experiment to demonstrate the value of the single vector in 
xenograft assays, the cell line SEM was transduced with three SLMIEW 
constructs – shMLL/AF4, shANGPT1 and shRUNX1/RUNX1T1 (negative 
control).  Unfortunately, this experiment was significantly disrupted by a 
presumed infection within the NSG colony and insufficient time was available to 
repeat it within this Fellowship.  Despite this, SEM cells transduced with the 
shMLL/AF4 construct demonstrated substantially slower and less extensive 
engraftment than control cells (shRUNX1/RUNX1T1).  This, combined with the 
substantial drop in EGFP expression in 2/3 engrafted populations and the loss 
of MLL/AF4 knockdown in re-isolated SEM cells demonstrates for the first time 
the role MLL/AF4 expression in leukaemic maintenance in vivo.  This result is 
consistent with the importance of on-going expression of MLL/AF4 in leukaemic 
cells in vitro demonstrated both in the present study and in previous work from 
our laboratory (Thomas, Gessner et al. 2005).  Furthermore, this result not only 
demonstrates the effectiveness of bioluminescent monitoring in this assay, but 
also supports the value of tracking proportional EGFP expression as an 
experimental endpoint. 
The rapid engraftment of the two surviving mice in the shRUNX1/RUNX1T1 
negative control group again demonstrates the effectiveness of this approach.  
Optimising the consistency within this negative control group will be important.  
It is hoped that this can be achieved by improving the viability of cells at 
transplantation. 
Despite the up-regulation of ANGPT1 by the MLL/AF4 fusion product present in 
SEM cells, the shANGTP1 construct did not produce a consistent phenotype in 
this xenotransplantation experiment.  Expression of the shANGPT1 construct 
remained strong following re-isolation.  Whilst the ANGPT1 knockdown data 
showed some variation, when combined with the strong shANGPT1 expression 
it seems unlikely that poor knockdown was the cause of this result.  One 
Chapter 7:  Single lentiviral vector for patient-derived transduction 
 245 
 
alternative was that the experimental design itself may be the cause of the 
negative finding.  It is possible that whatever the function of ANGPT1 in primary 
leukaemias, it is not required in the context of a derived cell line or within a 
murine microenvironment.  Repeating the experiment using patient-derived 
material would investigate the first possibility but addressing the second would 
require a substantially different approach.  An alternative explanation is that any 
advantage offered by ANGPT1 may only be uncovered in a competitive 
situation.  This possibility would be addressed by moving to a lower multiplicity 
of infection and transplanting without FACS sorting.  Finally, it is possible, 
especially given the lack of effect from ANGPT1 knockdown in vitro that this is a 
true negative finding. 
In addition to demonstrating the importance of MLL/AF4 in leukaemic 
engraftment/maintenance in vivo, this experiment also provided a substantial 
amount of information on the functioning of this vector and potential 
improvements to methodological design.  Sorting the transduced cells resulted 
in substantial cell death which presumably reduced the engrafting cell dose 
below that which was transplanted.  Any difference in cell viabi lity between 
populations would provide a source of bias to the timing or likelihood of 
engraftment.  A preferable approach would be to transduce all populations to a 
known/predicted rate, based on lentiviral titration, and then monitor the change 
in EGFP expression as one outcome.  This has the added advantage of 
providing a competitive situation, which may demonstrate more subtle 
differences in engraftment potential than engraftment of a sorted population. 
In summary, this project has successfully produced a novel vector offering three 
functions from a single transduction.  In combination with the modified 
transduction protocol described in Chapter 6, this will offer the opportunity to 
perform in vivo tracking of gene modulation studies using patient-derived 
material.  When considering the difficulties experienced during the 
xenotransplantation experiment described in 7.3.6, in combination with 
published concerns regarding the toxicity associated with high levels of 
exogenous shRNA (Grimm, Streetz et al. 2006; Pan, de Ruiter et al. 2011), 
moving towards an approach with a lower multiplicity of infection (e.g. 0.3-0.4) 
would offer a number of advantages.  Firstly, it would reduce potential toxicity 
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from high levels of shRNA.  Secondly, transplanting unsorted populations will 
improve cell viability and consistency between populations.  Finally, introducing 
a competitive element to the experiment may identify more subtle advantages 
than are seen in a straightforward engraftment situation.  These changes will be 
introduced with the next experiments using this vector system.
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The identification of leukaemia propagating cells in ALL has been complicated 
by the influence of xenograft assay variables (mouse strain, route of injection, 
antibodies used for cell sorting and mouse gender) on the engraftment of 
patient-derived blasts (Vormoor 2009; McDermott, Eppert et al. 2010; Taussig, 
Vargaftig et al. 2010).  Recent studies using the most permissive models have 
shown engraftment with low numbers of primary or primografted lymphoblasts 
(Morisot, Wayne et al. 2010; Schmitz, Breithaupt et al. 2011), without 
enrichment being identified in any specific immunophenotypic population (Kong, 
Yoshida et al. 2008; le Viseur, Hotfilder et al. 2008).  Remaining questions in 
the determination of LPC identity in lymphoblastic leukaemia have recently 
been addressed by our own laboratory, in the most comprehensive study to 
date, transplanting sorted primary blasts at limiting dilution (Rehe, Wilson et al. 
2012)(Appendix D).  Together, these data demonstrate that leukaemia 
propagation in lymphoblastic leukaemia cannot be enriched for by 
immunophenotypic sorting of B-cell precursor markers and is best described by 
a stochastic model. 
Whilst cancer stem cells have been enriched from a number of malignancies, 
examples exist where tumour propagating capacity is common and cannot be 
enriched, notably melanoma (Quintana, Shackleton et al. 2008; Quintana, 
Shackleton et al. 2010) and lymphoma (Kelly, Dakic et al. 2007).  Melanoma 
excepted, in the majority of malignancies investigated, a primitive looking 
population has been identified which contains the bulk of the tumour 
propagating capacity.  The unusually diverse nature of propagating cells in B 
precursor ALL (Kong, Yoshida et al. 2008; le Viseur, Hotfilder et al. 2008) led us 
to consider what might underlie this feature of lymphoid malignancy.   
Lymphoid cells are, perhaps, the only lineage of cells in which maturation is not 
associated with a loss of proliferative capacity.  Indeed, it is a central feature of 
lymphoid development that both B cell precursors and germinal centre B cells 
are required to clonally expand.  For B cell precursors a round of clonal 
expansion occurs following successful rearrangement of the B cell receptor 
heavy chain, producing a clone able to rearrange the light chain genes in the 
hope of creating a functional B cell receptor.  In the germinal centre, somatic 
hypermutation and consequent affinity based selection are accompanied by 
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several rounds of clonal expansion to produce both high affinity antibody 
producing plasma cells and memory B cells (Victora and Nussenzweig 2012).  
Subsequent re-exposure to antigen is accompanied by further clonal expansion 
of memory B cells and further rounds of affinity maturation.  It therefore seems 
plausible that the unusually broad capacity for the propagation of both 
leukaemias (Kong, Yoshida et al. 2008; le Viseur, Hotfilder et al. 2008; Morisot, 
Wayne et al. 2010; Schmitz, Breithaupt et al. 2011) and lymphomas (Kelly, 
Dakic et al. 2007) may reflect a property inherent to the originating cell lineage. 
The aim of this project was to investigate the genetic programmes underlying 
the leukaemia propagating capacity of childhood ALL.  The hypothesis was that 
“acute lymphoblastic leukaemic blasts derive an intrinsic propagating potential 
from their lymphoid cell of origin”.  However, little is known about the genetics 
driving lymphoid clonal expansion.  The best studied element is the 
transcriptional repressor BCL6 which is characteristically expressed in germinal 
centre B cells (Victora and Nussenzweig 2012).  BCL6 is also expressed 
following successful VH-DJH rearrangement, in response to preB receptor 
signalling, where the repression of Arf and p53 prevents apoptosis in response 
to Ig light chain gene single strand breaks (Duy, Yu et al. 2010).  In ALL, BCL6 
has been seen to be highly expressed in Down syndrome associated ALL 
(Hertzberg, Vendramini et al. 2010) and is regulated by the BCR/ABL1 fusion 
product where experimental BCL6 inhibition results in re-sensitisation of 
previously resistant leukaemia propagating cells to tyrosine kinase inhibitors 
(Duy, Hurtz et al. 2011). 
Given the relatively limited understanding of the control of lymphoid clonal 
expansion, this PhD took two new approaches to identifying genes relevant to 
leukaemic propagation.  Firstly, a candidate approach was designed to 
investigate the role of the germline stem cell maintenance associated gene, 
PIWIL2, which had previously been identified in a number of malignancies 
including leukaemias.  Secondly, an unbiased approach was developed using a 
genome-wide functional RNAi screen.  The third aim was to develop techniques 
and technologies required for the in vivo validation of candidates identified in 
the earlier components of this PhD. 
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The first project within this PhD was able to confirm the expression of PIWIL2 in 
childhood acute lymphoblastic leukaemia.  This was accompanied by the 
unexpected finding of PIWIL2 expression in lymphoid populations from healthy 
donor peripheral blood.  This project was further able to demonstrate the 
functional relevance of PIWIL2 in two ALL cell lines, SEM (MLL/AF4) and 697 
(E2A/PBX1).  However, it was not possible to demonstrate PIWIL2 by Western 
blot.  Serial electroporation, an approach which had been highly successful over 
a limited number of repetitions (Gessner, Thomas et al. 2010), proved 
extremely challenging given the duration of PIWIL2 depletion required to 
demonstrate a phenotype.  Finally, the departure of the project collaborator 
resulted in the strategic decision to stop this project and shift the focus of the 
PhD towards the functional RNAi screen.  Since this decision, further 
publications have demonstrated a potential role for this novel pathway in normal 
and malignant lymphoid cells.  Firstly, the demonstration of PIWI/piRNA control 
of DNA methylation (Aravin, Sachidanandam et al. 2008; Watanabe, Tomizawa 
et al. 2011; Rajasethupathy, Antonov et al. 2012), a mechanism of action which 
might plausibly function in the control of lymphoid clonal expansion.  Secondly, 
identification of a bias of piRNA sequence specificities in lymphoid cells away 
from intergenic/repeat sequences and towards coding regions, introns and 
untranslated regions (UTRs) (Yan, Hu et al. 2011), makes a role in the control 
of gene expression feasible.  This project will therefore be restarted, employing 
techniques recently available both within our laboratory (microRNA adapted 
shRNA knockdown) and commercially (improved antibodies, improved 
methylation arrays) and will look to identify DNA methylation events targeted in 
a sequence specific manner by PIWI/piRNA complexes (Chapter 9). 
Having stopped the candidate based approach, the focus of this PhD became 
the unbiased screen for pathways involved in leukaemic propagation.  The 
project was aimed at developing this new technique within the Northern Institute 
for Cancer Research, as well as investigating the potential for performing a 
genome-wide screen using a feeder cell co-culture assay.  Early work both 
optimised the transduction procedure and determined the functional relevance 
of feeder cells to the t(4;11) acute lymphoblastic leukaemic cell line SEM.  A 
trial screen was then devised to further validate the use of feeder cell co-culture 
Chapter 8:  General discussion 
 251 
 
by comparing the results of negative selection screening with and without co-
culture replating steps. 
Despite relatively consistent results during test transductions, the rate of 
transduction achieved during the trial screens was approximately half that 
predicted.  This led to the need for an additional early puromycin selection step 
prior to taking the baseline sample and subsequently for an additional density 
gradient centrifugation step as the presence of substantial amounts of apoptotic 
cells resulted in minimal expansion of the remaining viable cells.  The reason for 
the poor transduction is not clear, but comparison of the same protocol using a 
newly purchased aliquot of pooled viral constructs may help determine whether 
there has been a loss of titre in the original library virus 
Analysis of the first trial screen identified eight candidate genes common to both 
suspension culture and feeder cell co-culture approaches.  Within this 
“common” group of candidates was ANGPT1.  This gene has previously been 
identified within our laboratory, not only as being highly expressed in MLL 
rearranged lymphoblastic leukaemias, but also as being down-regulated 
following MLL/AF4 knockdown.  There was, however, a group of 41 up-
regulated constructs only identified using the feeder cell co-culture approach.  
Re-analysis of the second trial screen, aimed at achieving successful array 
hybridisation, will allow analysis of the strength of each of these candidates.  
This information will then inform the decision on whether the complete screen is 
conducted using suspension culture or feeder cell co-culture.  If there is not 
strong evidence of a likely benefit to using co-culture then the pragmatic 
approach, given the experimental difficulties experienced during the trial 
screens, may be to simplify the screen.  This approach may involve use of the 
more limited “Annotated gene” library containing only 3 pools of 10000 
constructs and/or use of suspension culture only, rather than co-culture.  The 
feeder cell co-culture approach could be re-applied during a later, more limited, 
validation screen. 
The final aim of this PhD was to develop techniques necessary for the in vivo 
validation of candidate genes identified by the in vitro RNAi screen.  This aim 
had two focuses: firstly, developing a protocol for the lentiviral transduction of 
patient-derived leukaemic blasts; secondly, cloning of a single vector capable of 
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in vitro analysis/ cell sorting (EGFP), in vivo tracking (Luciferase) and candidate 
gene modulation (shRNA).  Developing the transduction protocol adopted a 
pragmatic approach.  This was necessary both because of the limited 
availability of patient-derived material and the high titres of virus required to 
achieve good rates of transduction.  The final protocol represents a functioning, 
practical approach which balances rates of transduction against maintenance of 
cell viability.  Unexpectedly, the persistence of infectious virus up to four days 
after transduction required a further protocol for the removal of residual virus 
following transduction in order to both prevent direct transduction of murine 
tissues and to remove the risk posed by needle stick injury to an experimental 
operator.  This was achieved using a stringent washing procedure.  The utility of 
the transduction protocol has already been demonstrated in preliminary 
experiments investigating the clonal complexity of engrafting populations 
(Bomken, Buechler et al. 2012).  On-going work on this is being performed 
within the laboratory by Dr Alex Elder.  In addition, one leukaemic sample 
transduced during this project (L4951) has been transplanted in a further 
experiment which is using bioluminescent monitoring to determine the efficacy 
of a novel therapeutic agent.  Despite these early applications, further 
improvements to the protocol will be possible.  These may include the use of 
Retronectin coated plates to reduce spinfection speeds/times further or the trial 
of additional/alternative supportive cytokines to improve cell viability. 
The design and successful cloning of a novel vector allowing in vitro analysis, in 
vivo tracking and RNAi from a single transduction will allow the use of patient-
derived material for this critical in vivo validation step.  The design of the vector 
allows repeated cloning of novel hairpin sequences into the “companion” 
pENTR-shRNAmir vector, which can then be recombined into the pSLIEW-
Destination construct to create a new pSLMIEW vector.  This system allows the 
simple screening of multiple hairpins against a candidate, as well as the 
validation of multiple candidate genes.  Whilst the pSLMIEW vector is equally 
suitable for derived cell-line transductions, the constitutive expression of the 
miRNA adapted shRNA will mean that for some experiments it will be preferable 
to dual transduce – once with a vector allowing sorting/tracking and once with a 
vector allowing sorting/inducible RNAi. 
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The aim of this PhD was to determine genetic programmes responsible for the 
propagation of acute lymphoblastic leukaemia.  Whilst this aim has not been 
fully realised, many of the techniques required to achieve it have now been 
developed within our laboratory.  Furthermore, through the PIWIL2 project, a 
potential novel component of the clonal expansion programme of normal 
lymphoid cells has been identified as being functionally relevant in malignant 
lymphoid cells also.  Having developed substantial experience with lentiviral 
approaches to RNAi and with the publication of several lines of evidence which 
suggest a lymphoid specific role for PIWI/piRNAs, the PIWIL2 project will now 
recommence.  The on-going validation and final screening using the Decode 
RNAi library will provide additional leukaemia propagation candidates to 
investigate further. 
In summary, this PhD has functionally validated a novel component of 
malignant lymphoid cells, PIWIL2, which in addition was identified in normal 
lymphoid cells for the first time.  Further candidate elements of the leukaemic 
propagation programme are yet to be identified by a genome-wide functional 
RNAi screen.  Candidates which are identified by this screen, as well as further 
elements identified by on-going work into the pathways affected by 
PIWI/piRNAs, can be validated in vivo, with patient-derived material, using the 
transduction protocol and lentiviral vector described here.  Successfully 
validated candidates can then be assessed for their suitability as novel 
therapeutic targets.  The hope is that drugs specific for targets critical to 
leukaemic propagation will offer improved rates of cure for resistant or relapsed 
disease whilst reducing the side-effects associated with current, less well 
targeted therapies.
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9.1 Understanding the mechanism of action of PIWIL2 in 
lymphoblastic leukaemia propagating cells 
Following the strategic decision to stop the PIWIL2 project detailed in Chapter 
3, further published work has developed our understanding of potential 
mechanisms of action for PIWI-Like genes in leukaemia.  As a result of these 
publications I have developed a succession project to investigate further the 
role of PIWIL2 in ALL.  In particular this concentrates on the mechanism of 
action of PIWIL2 and piRNAs in ALL.  I will be Principle Investigator for this 
project and have led on both finance applications and appointing a research 
assistant who is due to start the study on 1st January 2013.   
In the medium term, a successful outcome to this project will prompt a parallel 
study in B cell non-Hodgkin lymphoma, my intended future research and clinical 
sub-specialty.  This transition is based on the hypothesis that the clonal 
expansion programme which is expressed by ALL blasts is common to all B 
lineage cells able to clonally expand, including peripheral/germinal centre B 
cells which are believed to be the cell of origin in B cell non-Hodgkin lymphoma. 
9.1.1 Novel data relating to PIWI/piRNA function in mammals 
The first study which further developed our understanding of the function of 
PIWI/piRNAs outside of the genome was a study by Tom Tuschl and Eric 
Kandel’s labs (Rajasethupathy, Antonov et al. 2012).  They incidentally found 
piRNAs in small RNA libraries prepared from Aplysia (Sea Hare) neurones.  
They demonstrated that PIWI/piRNA complexes directed CpG methylation, in a 
sequence specific manner, to the promoter region of the transcriptional 
regulator CREB2, in response to the neuronal modulator serotonin.  This was 
the first demonstration of PIWI/piRNA directed DNA methylation outside of 
germline cells.  This potential mechanism of action was particularly interesting 
as DNA methylation is important in both B-cell precursor development (Challen, 
Sun et al. 2012) and in germinal centre B cells (Shaknovich, Cerchietti et al. 
2011). 
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As the project developed, three more studies provided evidence to support 
further investigation of the mechanism of PIWIL2 action in ALL/lymphocytes.  
Firstly, the demonstration of piRNA expression in murine lymphocytes (Kuchen, 
Resch et al. 2010) and secondly a re-analysis of the same data to show that, 
unlike other cell types, lymphoid piRNAs showed a high degree of sequence 
specificity for 5’UTRs, coding regions, introns and 3’UTRs (Yan, Hu et al. 2011).  
This is in dramatic contrast to piRNAs from murine myeloid lineage cells, which 
are largely specific for unannotated regions of the genome and piRNAs from 
Drosophila, which show almost exclusive homology to repeat sequences.  This 
change in the balance of piRNA sequences is suggestive of a specific role in 
lymphoid lineage cells, and therefore potentially in lymphoid malignancies. 
Finally, a fourth study demonstrated the production of an antisense transcript 
from the proximal promoter of KIR3DLI, which codes for one of the killer Ig-like 
receptors (KIR) expressed on the surface of NK cells, a cell closely related to 
the lymphoid lineage (Cichocki, Lenvik et al. 2010).  This antisense transcript 
was processed to produce a single piRNA-like small RNA which was 
responsible for directing CpG methylation of the promoter and suppressing 
expression of the sense transcript. 
Together these studies have: 1) demonstrated a role for PIWI-Like genes and 
piRNAs in methylation of promoters outside the germline; 2) demonstrated a 
bias, specifically in lymphoid expressed piRNAs, for sequence homology for 
promoter and coding regions, rather than repeat sequences; 3) provided an 
example of a lymphoid related cell using a single piRNA to regulate the 
methylation and subsequent expression of a key gene. 
The project will use a lentiviral approach to knockdown both PIWIL2 and 
PIWIL4 (a ubiquitously expressed PIWI family member capable of histone 
modification (Sugimoto, Kage et al. 2007)) expression in childhood ALL cell 
lines, combined with array based analysis of transcriptome and DNA 
methylation changes.  Alongside this, a collaboration with Tom Tuschl, 
Rockefeller University (New York, USA), will generate piRNA libraries which will 
be sequenced to identify potential promoter homologies.  The intersect of these 
approaches will provide candidate genes for validation and investigation as 
potential therapeutic targets. 
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9.2 Completion of a genome-wide functional RNAi screen in ALL 
Following the unsuccessful hybridisation of the second trial screen, barcode 
sequences will be re-amplified and a repeat hybridisation performed.  If 
successful, this will provide the opportunity to analyse the reproducibility of the 
screening approaches detailed in Chapter 5, as well as assess the probability 
that any candidates identified are genuine.  This information will assist in the 
critical decision making around how the final screen is performed.  If 
reproducibility and a substantial benefit (in terms of quality of candidate 
identified) can be demonstrated using the co-culture approach, then this will be 
used for the final screen.  In this case it may be necessary to reduce the screen 
to use only pools targeting annotated genes to reduce the complexity of the 
experimental process (total of 3 pools rather than 7).  If sufficient benefit is not 
demonstrated then use of a suspension culture approach will greatly simplify 
the screen and the genome-wide library can be used. 
Candidates derived from the final screen will be validated using a custom library 
containing 3-5 constructs targeting each candidate.  As approximately 1000 
constructs are expected to be returned, the complexity of this validation screen 
requires that it will be conducted in vitro.  In order to identify candidates with 
global importance in childhood ALL, the cell lines REH/t(12;21) and 697/t(1;19) 
will be used in place of SEM/t(4;11).  If the actual number of candidates 
returned by the initial screen is substantially lower (e.g. 300), this additional in 
vitro step may be omitted and validation proceed immediately to the in vivo 
stage.  In vivo validation will consist of ALL cell line clones which have been 
transduced with the pSLIEW vector being further transduced with the relevant 
inducible pTRIPZ constructs and engrafted in an immunocompromised mouse 
assay.  This will allow in vivo disease tracking alongside candidate gene 
knockdown.  In order to select therapeutic candidates which are not critical to 
normal haematopoiesis, retained hits from the sequential screening process will 
be analysed for function using haematopoietic precursor cells derived from 
umbilical cord blood.  Candidates which are found to have relevance across the 
childhood ALL subtypes described, but found not to have a role in normal 
haematopoiesis will be considered as potential targets for novel drug 
development.  Additional targets may be derived based on known function, e.g. 
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involvement in B cell receptor signalling pathway.  Each of these candidates will 
be further investigated using patient-derived material transduced with the 
pSLIEW vector (see Chapter 6) allowing in vivo tracking during trials of novel 
therapeutic agents, combined with a complementary shRNA approach using the 
pSLMIEW vector (see Chapter 7).  This represents a substantial amount of 
work and will be conducted as part of a wider programme of ALL propagating 
cell research within the Leukaemia Stem Cell laboratory. 
Chapter 9:  Future work 
260 
 
9.3 Summary 
The two pieces of on-going work described here will generate new information 
about the genetic control of malignant lymphoid propagation.  Both projects are 
capable of identifying targets and pathways critical to this process, and 
potentially identifying targets for novel therapeutic agents designed specifically 
to reduce the clonal expansion of malignant B lineage cells.  These targets may 
be specific to B-precursor ALL, to mature B cell lymphomas or have therapeutic 
benefit in both.  Ultimately this work is intended to result in improved treatment, 
with fewer side effects, for children and young people affected by leukaemia or 
non-Hodgkin lymphoma.
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